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Synthesising nucleoside analogues for imaging proliferation in cancer and 
other biomedical applications      
Andreas M. Doepner 
Abstract 
 
Rapidly proliferating cells, such as cancerous cells, show increased reliance on deoxyribonucleic 
acid (DNA) salvage pathways for producing nucleotides required for DNA synthesis.  As such 
targeting these salvage pathways using radiolabelled nucleosides can provide a means of imaging 
the extent of proliferation within a tissue using positron emission tomography (PET).  This 
permits the detection of malignant growths.  Thiothymidine and 2’-deoxy-2’,2’-difluoro 
nucleoside analogues are currently being evaluated for theoretically superior properties in 
comparison to 3’-deoxy-3’-[18F]-fluorothymidine (FLT), the current standard PET proliferation 
marker.  Investigations towards the design and synthesis of radiolabelled analogues of these 
nucleosides for evaluation as PET tracers were carried out.  
 
Synthesis and radiosynthesis of the 2’,2’-difluoro nucleoside analogue i was completed using a 
Stille coupling to introduce the carbon-11 radiolabel.  The synthesis of ii, a precursor to a carbon-
11 methylated gemcitabine analogue and iii, an intermediate in the synthesis of thiothymidine 
nucleosides are also reported. 
 
 
 
Based on the synthetic route developed for accessing iv an analogue of ii suitable for 
radiolabelling with fluorine-18, a series of difluoro nucleoside analogues with potential uses in 
PET, HIV therapy and fluorescent imaging were also synthesised v-viii.   
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INTRODUCTION 
 
 
 
1.0   Background 
 
 
Cancer, or malignant neoplasm, is a set of mammalian diseases in which groups of affected cells 
show uncontrolled growth and proliferation causing damage to nearby tissues.
 1
  In later stages of 
the disease cells gain the ability to spread to other areas of the body (metastasize), creating 
multiple tumours which can ultimately lead to death.
1
  The disease occurs as the result of genetic 
mutations which can be caused by a number of factors including: exposure to chemical 
pollutants, radiation, specific infections, lifestyle choices and hereditary factors, or indeed, a 
combination of many of these.
2
     
 
Cancer is a leading cause of death in the world, and was responsible for approximately 7.6 
million deaths in 2008, contributing to 13% of all deaths worldwide.
3
  The incidence of cancer 
has been shown to increase with age.
4
  Therefore, as the result of a growing, aging population the 
occurrence of cancer is projected to increase dramatically within the next 20 years with an 
estimated 22.2 million new cases predicted for 2030 in comparison to 12.7 million cases reported 
in 2008.
5
 
 
Due to the enormous number of people affected by cancer and subsequent mortality rates, it is 
imperative to continue research into discovering new treatments for this set of diseases and 
improved methods for its detection. 
 
1.0.1  The Hallmarks of Cancer 
 
In 2000 Hanahan and Weinberg published their seminal paper proposing six specific cellular 
traits or “Hallmarks” common to cancerous cells that differentiate them from normal healthy 
cells.  These were: self-production of growth signals, indefinite division, insensitivity to anti-
growth signals, avoidance of cell death (apoptosis), metastasis and the acquisition of sustained 
angiogenesis (Figure 1).
6
  More recently the authors have published an updated review outlining 
the emergence of two new hallmarks: reprogramming of cellular energetics and avoiding immune 
destruction.
7
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Figure 1- The hallmarks of cancer.
6
 
 
Self-Production of Growth Signals 
 
In general, a cell can only enter a state of proliferation when activated by exogenous growth 
factors.  Growth factors are proteins and hormones which bind to specific trans-membrane 
receptors.  These receptors then relay signals into the cell, and the cell nucleus, inducing growth 
and cellular division.
8
  Cancerous cells have the ability to synthesise their own growth factors as 
well as expressing the corresponding receptors for binding them.  As such, they show a decreased 
dependence on external growth signals.
9
 
 
Insensitivity to Anti-Growth Signals 
 
In normal cells tumour suppressor genes act in conjunction with anti-proliferative signals (for 
example transforming growth factor-β (TGF-β)) to regulate cell growth and division within a 
tissue.  However, when these genes mutate causing disruption to the pathways governing cell 
growth, it can lead to insensitivity to anti-growth signals.  For example, in certain human cancers 
mutation of the tumour suppressor gene coding for the retinoblastoma associated protein (pRB) 
causes a down-regulation in the production of cell surface receptors for TGF-β.  The result is a 
loss of response to this anti-growth signal, allowing the cell to continue proliferation.
6,
 
8
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Indefinite Division 
 
It has been demonstrated that normal, healthy cells have a limited potential for replication. 
Generally a non-proliferative state, known as senescence, is attained after a certain number of 
cell divisions.
10
  Following each division DNA protecting the end of the chromosomes (the 
telomere) is shortened.  When the telomere is eroded to a critical point, fusion of chromosomes 
can occur.  This leads to the formation of dimeric chromosomes and unviable cells, resulting in 
mass cell death in a state known as crisis.  In malignant cells, up-regulation of the DNA 
polymerase enzyme, telomerase, prevents shortening of the telomere.  Found in around 90% of 
tumour cells, telomerase counteracts the effects of cell division by extending the end of telomeric 
DNA, granting limitless replicative ability.
11
  
 
Avoidance of Apoptosis 
 
Apoptosis, or programmed cell death, can be induced by detection of both intracellular (for 
example from DNA damage and hypoxia) and extracellular signals, such as the cytokine tumour 
necrosis factor (TNF).
12
  When these signals are detected, a cascade is initiated which ultimately 
leads to destruction of the affected cell at the hands of effector caspases.  In order for cancerous 
cells to avoid apoptosis they must either: disable receptors for apoptotic signals or disable their 
corresponding effectors.  A prime example, occurring in approximately 50% of human cancers, is 
mutation of the gene coding for the protein p53.
13
  The p53 protein is a key sensor for detecting 
abnormalities in DNA.  As a result of its inactivation malignant cells are able to ignore apoptotic 
signals.
7
  
 
Metastasis 
 
The arrangements of cells and maintenance of their quiescent state within tissues is governed by 
several classes of proteins, particularly cell-cell adhesion molecules (CAMs).   These proteins are 
deregulated as part of the invasion-metastasis cascade.  Malignant cells can then detach from the 
surrounding tissue and travel to other areas of the body, via the bloodstream and lymph, to create 
secondary tumours.
14
  Perhaps the most well studied example involves mutations to the epithelial 
cell protein E-cadherin.  E-cadherin transmits signals to maintain specific cellular assemblies and 
limit growth by forming cell to cell bridges; alterations to this protein prevent these interactions, 
leading to metastatic behaviour.
15
  
18 
 
Sustained Angiogenesis 
 
In order for a cell to function, it must be provided with oxygen and other specific nutrients which 
are delivered via blood vessels.  When a tissue is fully developed the ability to encourage growth 
of new blood vessels (angiogenesis) is carefully controlled by angiogenic inducing and inhibiting 
signals.  In tumours the balance of these signals is altered.  For example, by increasing the 
expression of the initiator vascular endothelial growth factor (VEGF), and decreasing the 
expression of the inhibitor β-interferon, the growth of new blood vessels to provide additional 
resources for the tumour is promoted.
16
 
 
Reprogramming Cellular Energetics and Avoiding Immune Destruction 
 
Reprogramming of cellular energetics is the adjustment of energy metabolism to support 
increased cell growth and proliferation.
7
  Cancerous cells alter the machinery of a cell so that 
anaerobic respiration is carried out even in the presence of oxygen, an effect first observed by 
Warburg.
17
  The mechanisms behind this process are examined in greater detail in Section 
1.3.1.1.  
 
It is well known that immunocompromised humans show greater susceptibility to certain 
opportunistic cancers although these generally arise as a result of viral infection.
18
  However, it 
has been shown in murine models that tumour cells from immunodeficient mice are generally 
unsuccessfully transplanted into immunocompetent mice whereas cancerous cells originating 
from healthy mice can effectively cause further tumours when transplanted.
19,
 
20
  This evidence 
suggests that only cancerous cells which have developed the ability to avoid destruction at the 
hands of the immune system develop into tumours.
7
 
 
It should be noted that both of these capabilities have yet to be completely validated. They are 
therefore classified as emerging hallmarks and required further investigation before they can be 
accepted alongside the other established hallmarks.
7
   
 
In these reviews Hanahan and Weinberg highlight the progress made in understanding the nature 
of cancer and the causes behind it.  However, there is still much to be learned and it is important 
to continue research into understanding this set of diseases.  In terms of therapeutic uses, these 
19 
 
characteristic differences between healthy and malignant cells provide targets for the 
development of new chemotherapeutic drugs and methods of detection.  
 
1.0.2  Detecting Cancer  
 
There are various methods available for detecting cancer including: endoscopies, biopsies, 
molecular diagnostics and imaging techniques.  Imaging techniques are not only useful in 
detecting cancer, but can be used in all aspects of treatment including: screening, evaluation of 
the success of therapy, planning for future therapies and providing guidance for palliation.  These 
modalities also have the advantage of being non-invasive and, in certain cases, are able to 
provide real time monitoring of a patient.
21
  There are a variety of imaging methods, including: 
magnetic resonance (MRI), single photon emission computed tomography (SPECT), positron 
emission tomography (PET), ultrasound, X-ray computerised tomography (CT) and optical 
imaging.
22
     
MRI takes advantage of the inherent magnetic moment of hydrogen atoms within the body which 
will produce a signal known as free induction decay (FID), when placed in an applied magnetic 
field.  The FID produced by these protons can be detected and analysed to give anatomical 
information on the area of the body being examined (Figure 2).
23, 24   
 
 
 
Figure 2- MRI of the brain, showing a metastatic tumour.
25
 
 
MRI is a powerful technique for providing high resolution (up to 10 μm) images of the body and 
detecting cancers.  However, it is a relatively costly modality and has fairly long scanning times 
(minutes to hours).
22
  
 
20 
 
Ultrasound is defined as sound with a frequency greater than 20 kHz.  However, for 
medical imaging purposes sound between the frequencies of 2-10 MHz are generally 
used.
26
  Diagnostic ultrasound imaging involves directing a pulse of ultrasound into the 
body, detecting its reflections/echoes and converting these signals into an image (Figure 3).
 
27
  
 
 
 
Figure 3- A pancreatic tumour visualised using ultrasound.
27
 
 
Compared to other imaging modalities, ultrasound is cheap and portable and can also offer 
high resolutions (50 μm) and real time imaging.  However, it does require a skilled operator 
in order to achieve the best images and is unsuitable for imaging certain areas of the body 
such as the lungs.
22, 26
  
 
X-Ray CT uses similar principles to conventional x-ray imaging i.e. an x-ray will be 
differentially absorbed and reflected in different tissues of the body. As such the 
transmitted radiation can be detected and used to form an image.  However, CT imaging 
uses multiple x-ray tubes and detectors which are rotated around the patient.  Multiple cross 
sections are taken to give a three dimensional insight into the body (Figure 4).
28
   
 
 
 
Figure 4- X-ray CT scan of the lungs with a tumour highlighted.
29
 
 
CT scans offer high resolution imaging (50 μm) in a very short time space (50-100 ms) and 
have excellent specialist usage e.g. for imaging lungs.
22,
 
28
  However, unlike the other 
21 
 
modalities discussed thus far CT scans involve a relatively high dose of ionising radiation 
and therefore has extra safety considerations.
28
 
 
Optical imaging techniques such as bioluminescence and fluorescence, in general, have 
minimal uses in directly imaging patients since light in the ultraviolet-visible wavelength 
(100-650 nm) is absorbed by chromophores in the body.  They can however be used as an 
aid for analysing pathology of biopsied tissues.
21
  One exception involves the use of 
molecules labelled with fluorescent tags (fluorochromes) emitting near infrared (NIR) light 
(650-900 nm) detected using Fluorescence Molecular Tomography (FMT).
30
  In this 
method, energy from an external light source is used to illuminate tissue causing excitation 
of the fluorochrome. This subsequently de-excites emitting NIR radiation which is detected 
(Figure 5).
22 
 
 
 
Figure 5- FMT imaging of a murine tumour using a fluorochrome activated 
by the protease Cathepsin B.
30
 
 
Although this modality is still under development it is an attractive proposition due to its relative 
low cost, rapid imaging times (seconds to minutes) and use of targeted reporters.
22
  
 
SPECT involves the detection of photons emitted from radiopharmaceuticals by a gamma camera 
which is rotated around a patient allowing construction of three dimensional images.
31
   
Radiopharmaceuticals in SPECT generally consist of a gamma emitting radionuclide such as 
technetium-99 combined with a ligand which targets a disease specific biomarker.
21
  Although 
SPECT has a particularly low resolution (1 cm) and involves the use of ionising radiation it 
allows imaging of physiological processes (for example blood flow in the brain) at a lower cost 
than comparable techniques like PET.
22,
 
31
 
 
 
22 
 
1.1 Positron Emission Tomography (PET) 
 
1.1.1 The Principles of PET 
 
 
The majority of the aforementioned techniques (excluding SPECT and FMT) provide anatomical 
images of the body and are used to identify cancers based on structural changes within a tissue.  
PET on the other hand, provides a highly sensitive method of cancer detection by imaging 
physiological processes (e.g. glucose metabolism and cellular proliferation) occurring in the 
body.  This is performed through the use of imaging agents, or molecular probes, which are 
molecules labelled with positron (an antimatter electron) emitting radionuclides. Frequently used 
radionuclides include: fluorine-18 [
18
F], carbon-11 [
11
C], oxygen-15 [
15
O] or nitrogen-13 [
13
N] 
and less commonly used radionuclides are: copper-64 [
64
Cu], iodine-124 [
124
I], and gallium-68 
[
68
Ga].
32
    For the most part these are produced in a particle accelerator known as a cyclotron, a 
notable exception being [
68
Ga] which is produced in a specific generator.
32,
 
33
  
 
Positron emission is a form of radioactive decay occurring in proton-rich nuclei, whereby a 
proton is converted into a neutron releasing a positron and a neutrino in the process.  This results 
in the formation of a more stable nucleus.  Carbon-11 for example, will decay to form elemental 
boron and in the same way fluorine-18 will produce oxygen-18 (Figure 6).
32
  
 
 
 
Figure 6- Positron emission by decay of carbon-11 to boron, followed by positron-electron 
annihilation to produce two gamma photons.
34
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Once synthesised, a radiolabelled probe is either injected intravenously or inhaled by a patient 
and it then localises within specific areas of the body. Positrons emitted by the radionuclide 
travel a short distance within a tissue (typically 2 mm) before colliding with an electron;  this 
collision causes an annihilation resulting in the release of two 511 keV gamma photons at 180 
degrees to each other (Figure 6).  These photons are observed by arrays of detectors in PET 
scanners in a process known as coincident detection: only photons created in the same positron-
electron annihilation event arriving at opposite detectors within a few nanoseconds of each other 
are counted.
32
  Within the detector, these gamma photons interact with the crystalline material of 
a scintillator generating a pulse of light, which is amplified by photomultipliers creating an 
electrical impulse.  This is then further processed and corrected for errors such as attenuation and 
accidental coincidences giving rise to usable data.  The detector array forms a ring around the 
patient, therefore detection of photons by scintillators in the scanner arrays gives information on 
the concentration and location of the molecular probe within the patient allowing a 3-D image of 
the body to be generated (Figure 7).
35
 
 
 
  
 
Figure 7- PET image of a lung tumour using fluorine-18 labelled glucose ([
18
F]-
fluorodeoxyglucose or [
18
F]-FDG)
 36
  
 
The example depicted in Figure 7 shows a PET image of glucose metabolism in the body using 
the glucose analogue [
18
F]-FDG.  The darker areas represent higher concentrations of the labelled 
glucose probe and hence areas of higher metabolic rate, corresponding to a carcinoma of the 
lung.  Other darkened areas denote clearance of the probe in the bladder.
36
  For further 
information on the uptake of [
18
F]-FDG see Section 1.3.1.1. 
 
PET images are commonly analysed semi-quantitatively to gain further information on a 
malignancy using a parameter known as the standardised uptake value (SUV).  In cancer the 
SUV provides an index of the radioactivity concentration of the tumour compared to the initial 
injected radioactivity, divided by the body mass.  Areas of abnormal molecular probe uptake are 
24 
 
firstly identified, followed by calculation of the SUV in these regions of interest (ROI).
37
  
Quantification of the intensity of probe uptake in the ROI yields data which can be analysed to 
give information on a variety of aspects of the malignancy.  For example, SUVs allow 
differentiation between aggressive and indolent tumours, prediction of prognosis and can give 
early assessments of a patient’s response to therapy.21, 37, 38 
 
This highlights the major advantage of PET over other imaging modalities: its ability to provide 
physiological information on the area of the body being studied.  Apart from the aforementioned 
information gained from SUVs, further beneficial data gained from PET studies include: 
highlighting biological changes that occur in cancer before anatomical abnormalities can be 
detected and providing entire body imaging of a primary tumour and its metastases.  It is not only 
in cancer therapy where PET can provide additional insights into diseases; for example [
18
F]-
FDG can also be used as early indicator of Alzheimer’s disease.36  Moreover, the scanning time 
required to generate a PET image is relatively short (minutes), meaning less inconvenience for 
patients.
22
 
 
However, PET does have various limitations.  For example, in comparison to ultrasound, CT and 
particularly MRI it offers images with a particularly poor resolution of 1-2 mm, compared to 10-
100 μm in MRI.  This is a result of the distance travelled by the positron within a tissue prior to 
annihilation.  Furthermore, PET offers little anatomical imaging, to the extent that it becomes 
difficult to estimate tumour invasion of neighbouring tissues.
22
  One solution to this problem 
involves the use of joint PET/CT and PET/MRI systems.  These hybrid techniques allow the 
combination of the high resolution anatomical imaging of CT and MRI with the functional 
information gained from PET (Figure 8).
39
  
 
 
 
Figure 8- Combined PET/CT image showing multiple malignant tumours using [
18
F]-FDG.
21
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Other problems associated with PET stem from the radionuclides themselves which have short 
half-lives (Table 1).  As a result they have to be synthesised on site by cyclotrons or generators 
and must be quickly incorporated into their respective molecular probes to prevent significant 
loss of activity by radioactive decay.  This has cost implications and, as will be discussed in 
following sections, it can present synthetic challenges for probe generation.
22, 36
  
 
Radionuclide Half Life 
15
O 2 min 
13
N 10 min 
11
C 20 min 
18
F 109 min 
 
Table 1- Half-lives of commonly use radionuclides.
36
  
 
1.1.2 Development of PET Molecular Probes 
 
The development of new PET molecular probes for use in clinical settings is a complex and 
multidisciplinary process, consisting of a number of steps: selection of a suitable target, organic 
synthesis, radiolabelling, in vitro and in vivo evaluation and finally kinetic modelling of data.  
 
Development begins with identification of a suitable target (e.g. an enzyme, receptor or 
transporter) for imaging the desired process.  After selection of a target an appropriate compound 
to bind this target must be discovered.  This is normally performed using high throughput screens 
or by rational design based on crystal structures.  The properties of the compound can then be 
tailored based on in vitro and in vivo assays in a lead optimisation process.
40
   
 
With a suitable ligand identified an appropriate radionuclide must be chosen for labelling.  The 
choice of radionuclide is dependent on the biological process being studied: ideally the half-life 
of the radionuclide and that of the biological process should match.  Additionally, the half-life 
should be sufficient to allow radiolabelling, purification and formulation of the molecular 
probe.
41
   Techniques for introducing different radiolabels are discussed in further detail in 
Section 1.2. 
26 
 
The formulated molecular probe can then be subjected to in vitro testing for plasma stability and 
affinity studies carried out.  Finally, in vivo testing for can be carried out to evaluate 
pharmacokinetic properties of the PET probe.  For example, biodistribution studies can be used 
to determine the percentage of injected dose per gram tissue, (% ID/g) which in turn can be used 
to calculate the SUV.
40
 
 
1.1.3  Desirable Properties of PET Molecular Probes 
 
As alluded to in the previous section there are a number of desirable properties for PET probes to 
have.  These are defined by both the physical characteristics of the radionuclide and the chemical 
structure of the probe and include: specificity, selectivity, lipophilicity, affinity, specific activity, 
metabolic stability, clearance and radiochemical yield.  
 
Specificity and Selectivity 
 
A molecular probe should selectively bind to its target to ensure only the desired process is being 
measured.  Additionally, the probe should be designed to reduce the amount of non-specific 
binding to plasma proteins, cell membranes and other non-target tissues.  Excessive non-specific 
binding gives rise to a high background signal (noise), which reduces the contrast of the enzyme 
or receptor being targeted.  Non-specific binding has been shown to be related to the lipophilicity 
of a compound.
41, 42 
 
Lipophilicity 
 
Lipophilicity is the affinity of a molecule for lipophilic environments and is expressed as a 
logarithm of the partition coefficient ‘P’.  The partition coefficient is measured as a ratio between 
the concentration of a compound in octanol versus water (Equation 1).
43
   
 
 
 
Equation 1- Partition coefficient and distribution coefficient. 
27 
 
 
More accurately this value may be measured using the pH dependent distribution coefficient ‘D’. 
This value takes into account the degree of ionisation occurring at a specific pH and is the ratio 
of the concentration of unionised and ionised compound in both phases.  In PET, typical logD 
values are measured at physiological pH.  In general a probe needs to be sufficiently lipophilic to 
pass through cell membranes but not so lipophilic as to show significant non-specific binding to 
fatty tissues; ideal logD values will be less than three.
43,
 
44
 It should be noted, that non-specific 
binding cannot be attributed to lipophilicity alone and that a molecules ability to hydrolyse 
phospholipid bilayers can also play a role.
45
 
 
Clearance 
 
Ideally the probe should be rapidly cleared from plasma to reduce the blood pool background 
signal at the target tissue.  Similarly the probe should also be rapidly cleared from non-specific 
areas again to improve the signal to noise ratio.
32,
 
44
 
 
Affinity 
 
Affinity is the ability of a molecular probe to bind to its target.  Useful molecular probes 
generally have affinities in the range of 0.01−1.00 nM and in principle higher affinity should give 
rise to a higher signal to noise ratio.  However, as increased affinity is often associated with 
increased lipophilicity this is not always the case.  Additionally the density of the target must be 
taken into account, with lower target densities requiring probes with higher affinity.
42,
 
43
      
 
Specific Activity 
 
Specific activity (SA) is defined as the activity (A) of a radiolabelled probe per unit mass (GBq 
or mCi per µmol) (Equation 2).
46
 
 
 
 
Equation 2- Specific activity.
46
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High specific activities are desirable as they allow effective imaging of a target using small 
amounts of material (typical probes are administered in nano-molar quantities) without 
perturbing the system being studied by fully saturating the target.  Furthermore, using such low 
amounts of tracer means toxicity is less of an issue.
41
  It should be noted that although theoretical 
specific activity values for radionuclides are very high (e.g.carbon-11 ~ 341,000 GBq/µmol), due 
to isotopic dilution, unwanted side reactions during labelling and activity loss by decay the 
specific activity for administered probes tends to be much lower (e.g. carbon-11 ~3,000 
GBq/µmol).
44
   
 
Metabolism and Labelling Position 
 
Ideally, a PET probe will be stable to metabolism during the timeframe of scanning.  However, in 
many cases metabolism is unavoidable and therefore the position of the molecular probe 
subjected to radiolabelling must be carefully chosen.  The production of radiolabelled 
metabolites that show binding affinity for the target or accumulate within the target tissue must 
be avoided.
47
  In certain cases labelling of a molecule can be advantageous, increasing its 
metabolically stability, therefore simplifying kinetic modelling.  For an example of such a 
situation see Section 1.3.2.1. 
 
Radiolabelling and Radiochemical Yield 
 
While more of a synthetic concern, it is nonetheless a desirable property that a molecular probe 
be rapidly radiolabelled and in good radiochemical yields (RCY, the yield after radiochemical 
purification expressed as a percentage of the activity originally present).
46
  This number is often 
quoted as the decay-corrected radiochemical yield which takes into account the naturally 
occurring decay of the isotope.
41
  Unless specified RCY shall henceforth refer to decay correct 
radiochemical yields. 
 
These properties are desirable for all molecular probes, however one can further divide 
radiopharmaceuticals into three classes defined by their specific target: those based on enzyme–
mediated metabolic transformations (often analogues of endogenous compounds),   probes based 
on stoichiometric binding interactions with receptors and those which measure perfusion.
32
  The 
first class of probe will be the focus of much of the work contained in this thesis. 
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1.2  Introduction to PET Radiochemistry 
 
The production of a PET probe involves numerous steps.  Initially, the radionuclide is prepared 
in a cyclotron by bombarding a target system with a beam of protons or deuterons.  The target 
system is a vessel containing a target material required for the production of a specific 
radionuclide.  The radionuclide is trapped in such a form that it can be directly reacted or further 
functionalised and then reacted with a ‘cold’ non-radioactive precursor with a compatible 
reactive functionality.
41
  The cold compound is generally more chemically complex and is 
reacted with the radioactive synthon in the final stages of the synthesis (Figure 9). 
 
 
 
Figure 9- Simple schematic showing the synthesis of a positron emitting molecular probe. 
 
In some cases, removal of protecting groups (PG) is required after radiolabelling although it is 
desirable to have as few steps as possible after labelling in order to minimise loss of activity by 
radioactive decay.  Finally, the PET probe must be purified, usually by (high performance liquid 
chromatography) HPLC, and then formulated for use.
48
  This entire process should ideally be 
completed within three half-lives from the end of bombardment (EOB) of the target material.
49
  
As such each step must be carried out in a time efficient manner.  Lengthy purification in 
particular can have drastic effects on yield and specific activity.  Purification time by HPLC can 
be minimised by increasing the solvent flow rate, reducing the column length and increasing the 
temperature of the column itself.  This however is dependent on the degree of separation between 
the product and by-products.
49
  An alternative is the use of solid phase extraction (SPE): pre-
packed chromatographic cartridges which allow the removal of specific contaminants.  Using this 
method can allow rapid purification but is often limited for use with a specific product.
48
  
 
As shown in Table 1 there are many common radionuclides available for synthesising molecular 
probes.  However, the short half-lives of [
15
O] and [
13
N] mean there is relatively little complex 
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radiochemistry that can be performed with these emitters.  On the other hand, [
11
C] and 
particularly [
18
F] have sufficiently long half-lives to allow some flexibility in their synthetic use. 
 
1.2.1  Fluorine-18 Radiochemistry 
 
Fluorine-18 is currently the most widely used radionuclide in PET radiochemistry.  Attractive 
properties of [
18
F] include its long half-life when compared to [
11
C], [
13
N] and [
15
O] and the fact 
that it produces the highest resolution PET images due to its low positron energy and hence short 
linear positron trajectory in tissues.  The emergence of [
18
F]-FDG as an important tool in the 
detection and staging of cancer has driven interest in [
18
F] radiochemistry research as well as the 
use of PET in clinical and research institutions as a whole.
41
 Radiochemistry with [
18
F] can be 
broadly divided into two categories: electrophilic and nucleophilic fluorination reactions. 
 
1.2.1.1 Nucleophilic Fluorination Reactions with [
18
F] Fluoride 
 
Nucleophilic fluorination reactions make use of [
18
F] fluoride [
18
F
-
] generated using the
 
18
O(p,n)
18
F nuclear reaction.  In this case the target material is [
18
O] enriched H2O, which 
undergoes proton bombardment releasing a neutron and forming a solution of [
18
F
-
].  Fluoride in 
this form ([
18
F] HF) requires additional modification in order to increase its nucleophilicity.  The 
obtained solution is therefore trapped on an ion-exchange resin and eluted with a K2CO3 solution.  
It is then treated with the phase transfer agent kryptofix-222 (K222) in order to complex the 
potassium cation, further increasing the reactivity of fluoride anion.  Reactions are generally 
carried out in polar aprotic solvents again with increasing reactivity in mind.
50, 51
  
 
An important consideration when carrying out nucleophilic fluorinations is the functionality of 
the cold precursor i.e. the requirement of a suitable leaving group.  For simple aliphatic 
substitutions triflates, tosylates, mesylates, bromides and iodides are all acceptable (Scheme 1).
41
   
 
 
 
Scheme 1- Synthesis of [
18
F]-FDG 3 by nucleophilic fluorination.
51
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The reaction of protected pyranose 5 with [
18
F] KF.K222 is the most utilised radiochemical 
reaction today and provides a highly relevant demonstration of this type of reaction.  The 
requirement of protecting groups to prevent competing nucleophilic attack by other reactive 
functionalities is a major issue with these procedures.  Deprotection and purification increase the 
synthesis time, limiting the amount of useful steps that can be carried out beforehand.
41, 51
 
 
When attempting nucleophilic fluorinations of aromatic compounds the situation becomes more 
complex.  In order for successful reaction, not only is a suitable leaving group necessitated but in 
addition, the presence of electron withdrawing groups ortho or para to the leaving group are 
required for activation of the aromatic ring.  Despite these constraining factors these nucleophilic 
aromatic substitutions (SNAr) have become widely used (Scheme 2).
52
 
 
 
 
Scheme 2- Synthesis of 4-[
18
F]-fluorobenzaldehyde.
52
 
 
Reacting para-nitrobenzaldehyde with [
18
F] KF.K222 is an excellent method for generating [
18
F]-
fluorobenzaldehyde 8, which in itself is a highly versatile intermediate.  [
18
F]-
fluorobenzaldehyde and analogues of this molecule can be further reacted in a number of 
different ways to generate more complex molecular probes.  For example reacting N-(tert-
butyl)hydroxylamine with 8 yields 9 designed for use in in vivo visualisation of free radicals.
53
  
This is an example of indirect labelling strategy using [
18
F
-
].   
 
Another common indirect fluorination strategy involves reacting [
18
F] labelled alkyl azides with 
alkynes using the copper catalysed Huisgen cycloaddition.  This reaction is particularly amenable 
to PET chemistry as a result of the fast reaction times, high yields and mild conditions (Scheme 
3).
54
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Scheme 3- Labelling of an isatin-sulfonamide with [
18
F]-fluoroethylazide by Huisgen 
cycloaddition.
55
 
 
[
18
F]-Fluoroethylazide for example, is synthesised by reacting a precursor tosylate 10 with 
nucleophilic fluoride.  This can be then be reacted with various different alkynes, an appropriate 
illustration being the synthesis of radiolabelled isatin-sulfonamide 13, which binds caspases 3 
and 7 and hence can be used for imaging apoptosis.
55
  Using these indirect labelling strategies 
permits access to complex molecular probes that are not viable targets for direct labelling due to 
the harsh conditions employed in the initial radiolabelling step.  However, this also results in an 
increased number of steps in the radiosynthesis which must also be taken into consideration. 
 
1.2.1.2 Electrophilic Fluorination Reactions with [
18
F] Fluorine 
 
Electrophilic fluorination reactions traditionally make use of [
18
F] fluorine gas ([
18
F] F2) 
available from the 
18
O(p,n)
18
F and 
20
Ne(d,α)18F nuclear reactions.  Proton bombardment of [18O] 
O2 is the preferred method of [
18
F] F2 synthesis as a result of its higher efficiency.
56
  This is an 
example of a carrier added synthesis whereby a small amount of [
19
F] F2 (0.2%) is added to the 
target gas.  In the absence of stable fluorine, the radiolabelled gas can adsorb to the walls of the 
vessel containing the target gas reducing the amount of radioactive material isolated.
57
  
Compared to reactions with [
18
F
-
], the use of [
18
F] F2 suffers from a number of drawbacks, 
including: being more difficult to handle and use therefore requiring specialist equipment, lower 
specific activity as a result of carrier added fluorine and the high probability of producing 
unwanted fluorinated by-products due to reactivity of gaseous fluorine.
58
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Nevertheless, [
18
F] F2 has been applied in the successful radiolabelling of a variety of compounds 
including [
18
F]-5-fluorouracil 15.  Reacting uracil 14 with [
18
F] F2 in acetic anhydride furnishes 
15, which can be used as a prognostic agent in cancer therapy (Scheme 4).
59,
 
60
 
 
 
 
Scheme 4- Synthesis of [
18
F]-5-fluorouracil using [
18
F] F2.
59
 
 
Another example is the synthesis of [
18
F]-fluoro-L-DOPA 17.  Fluoro-destannylation of precursor 
16 with [
18
F] F2 is followed by acidic deprotection yielding 17, a molecular probe used in the 
study of Parkinson’s disease (Scheme 5).61  
 
 
 
Scheme 5- Synthesis of [
18
F]-fluoro-L-DOPA using [
18
F] F2.
61
  
 
Other less reactive and more selective reagents have emerged in the latest literature.  A recent 
report by Gouverneur et al. for example, describes the synthesis of a highly selective 
electrophilic fluorinating reagent [
18
F]-Selectfluor bis-triflate ([
18
F]-TEDA) 19 (Scheme 6).
58
  
 
 
 
Scheme 6- [
18
F]-TEDA synthesised using high specific activity [
18
F] F2.
58
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This protocol takes advantage of Solin’s methodology for the synthesis of high specific activity 
[
18
F] F2.  By reacting methyl iodide with [
18
F] KF.K222 [
18
F]-fluoromethane is produced.  The 
fluoromethane is then mixed with a small amount of carrier [
19
F] F2 and subjected to an electrical 
discharge, resulting in the exchange of [
18
F] and [
19
F] in plasma, producing [
18
F] F2 with specific 
activity up to 50 times greater than that available by traditional proton bombardment.
62
 1-
Chloromethyl-4-aza-1-azoniabicyclo[2.2.2]octane triflate  18 was then fluorinated with the  high 
specific activity fluorine to yield 19 and this in turn was reacted with silyl-enol ether 20 in a 
proof of concept reaction (Scheme 7).
58
 
 
 
 
Scheme 7- Fluorination using 19.
58
 
 
The reaction proceeded successfully with a radiochemical yield of 50%.  Owing to its selectivity 
and mild reaction conditions in comparison to directly using [
18
F] F2, [
18
F] selectfluor bis-triflate 
19 presents an exciting development for [
18
F] fluorinations.
58
 
 
Perhaps even more remarkable is the reported synthesis of an electrophilic fluorine source 
available directly from nucleophilic [
18
F] fluoride (Scheme 8).  
 
 
 
Scheme 8- Electrophilic fluorination of aryl palladium complexes with 23.
63
 
 
By controlling the properties of palladium (IV) complexes 22 and 23 through careful ligand 
selection Ritter et al. have developed complexes which can react with [
18
F
-
] and transform it into 
an electrophilic source.  The cold precursor 22 is specifically tailored for capturing nucleophilic 
35 
 
fluoride; once trapped the nature of complex 23 causes a reversal in the reactivity of the fluorine, 
thus furnishing an electrophilic [
18
F] fluorine source.  This complex can be used to oxidatively 
transfer fluorine to palladium (II) aryl complexes, before reductive elimination yields the desired 
product.  The utility of this reaction was demonstration through the fluorination of several aryl 
palladium precursors, generating [
18
F]-fluorodeoxyestrone 25 amongst others.
63
  Although the 
applications of complex 23 are potentially very exciting, it should be noted that both this and 
complex 24 are chemically complex, requiring glove box manipulations for their synthesis.  
Furthermore, the use of metals such as palladium requires careful purification to avoid toxicity.
64
 
While this is suitable for research settings it makes transfer to the clinic difficult.  
 
To summarise, while there are a number of challenges in using [
18
F] for radiolabelling including: 
a relatively small pool of biologically relevant molecules containing a carbon-fluorine bond, 
limited synthetic flexibility and the unknown effects of replacing functionality with [
18
F] (see 
Section 1.3.2.1).  It remains an attractive proposition for radiochemists due to its comparatively 
long half-life.  Moreover, recent developments, particularly in the area of electrophilic [
18
F] 
sources, are helping to further expand the usefulness of [
18
F] as a radiolabel. 
     
1.2.2  Carbon-11 Radiochemistry 
 
The most common synthesis of [
11
C] is via the
 
14
N(p,α)11C nuclear reaction.  In this case nitrogen 
gas is bombarded by a high-energy beam of protons, resulting in the formation of [
11
C] and an α-
particle (helium nucleus). In the presence of trace amounts of oxygen or hydrogen gas the [
11
C] 
reacts to form either [
11
C]-carbon dioxide ([
11
C] CO2) or [
11
C]-methane ([
11
C] CH4), which can 
then be trapped and used directly or manipulated to form other precursors (Scheme 9).
41
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Scheme 9- A selection of 
11
C precursors used in synthesis, adapted from Scott.
65
 
 
1.2.2.1 [
11
C] Methyl Iodide 
 
The most frequently used [
11
C] precursor is undoubtedly [
11
C] methyl iodide ([
11
C] CH3I).  [
11
C]
 
Methyl iodide can be
 
generated using two methods: the reduction of [
11
C] CO2 by lithium 
aluminium hydride, followed by reaction with hydroiodic acid; or radical iodination reaction of 
[
11
C] CH4 with iodine at high temperatures.
66, 67  
[
11
C] methyl iodide has found the majority of its 
use in simple nucleophilic substitution reactions with nitrogen, oxygen and sulfur heteroatoms.  
In cases where [
11
C] CH3I is insufficiently reactive, further conversion using a hot column of 
silver triflate can generate the more reactive [
11
C] CH3OTf species.
65
  Due to their simple nature 
(a typical methylation involves trapping [
11
C] CH3I/[
11
C] CH3OTf in solvent with the cold 
precursor and heating) and rapid reaction times these reactions have become the most widespread 
way of synthesising [
11
C] labelled molecular probes.
41
  
 
There are a number of interesting modifications and additions to basic methyl iodide 
methodology.  Jacobsen and Mishani, for example, have demonstrated an appealing approach for 
introducing radiolabelled [
11
C]-dimethylamine moieties (common to many drug molecules) into 
PET probes.  [
11
C] CH3I can be reacted with methylamine to yield [
11
C]-dimethylamine 27, 
which can then be used in the synthesis of numerous analogues (Scheme 10).
68
 
 
37 
 
 
 
Scheme 10- [
11
C]-dimethylamine as a precursor.
68
 
 
The principal advantage of this method is the reversal in reactivity profile: using [
11
C] CH3I as a 
radiolabel in a nucleophilic form expands the number of labelling strategies available as well as 
demonstrating differing functional group tolerance to [
11
C] CH3I.
65
   
 
Hooker et al. have developed a novel approach for the generation of [
11
C]-formaldehyde by the 
oxidation of [
11
C] CH3I (Scheme 11).
69
 
 
 
 
Scheme 11- Synthesis and reaction of [
11
C]-formaldehyde.
69
 
 
Treatment of trimethylamine N-oxide (TMAO) 29 with [
11
C] CH3I results in the formation of 
intermediate 30 which decomposes upon heating resulting in the formation of [
11
C]-
formaldehyde 31.  The usefulness of this intermediate was demonstrated with the synthesis of 33 
from tryptamine 32 using the Pictet-Spengler reaction (Scheme 11).  Oxidation of [
11
C] CH3I 
using TMAO provides a rapid and efficient synthesis of [
11
C]-formaldehyde in comparison to 
previous methods involving reduction and oxidation of [
11
C] CO2.
69
 
 
[
11
C] CH3I has also found use in palladium-catalysed coupling reactions (Scheme 12).
41
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Scheme 12- Palladium cross couplings using [
11
C] CH3I.
64, 70
 
 
Due to their tolerance to a wide variety of functional groups Stille couplings have become the 
most widely used cross couplings in PET radiochemistry.  An important example is in the 
synthesis of the nucleoside 1-(2’-deoxy-2’-fluoro-β-D-arabinofuranosyl)-[methyl-11C]-thymine or 
[
11
C]-FMAU 35 a potential marker for proliferation in cancer.
64
  However, a major disadvantage 
of these reactions is the use of organo-stannanes.  These compounds and the subsequent by-
products produced are highly toxic and require careful removal during purification.  Suzuki 
couplings represent a viable solution to this problem.  Hostetler et al. for example, reported the 
successful coupling of aryl boronic esters and acids 36 with [
11
C] CH3I.  Although these 
reactions have a more restricted functional group tolerance in comparison to Stille couplings, 
they report high radiochemical yields and purity and avoid the toxicity issues associated with the 
use of stannanes.
70
  
 
Also worthy of mention are polymer-supported [
11
C] methylations.  In these reactions the cold 
precursor 37 is attached to a solid support and then treated with [
11
C] CH3I.  After completion of 
the reaction only the successfully labelled precursor can be washed from the polymer-support.  
This ensures high purity avoiding the need for HPLC purification reducing loss of activity by 
decay during chromatography (Scheme 13).
71
  
 
 
  
39 
 
 
 
Scheme 13- Polymer-supported methylation and release of labelled product.
71
  
 
Due to their ease of use, high radiochemical yields and versatility so-called microfluidic ‘loop’ 
methods have found growing use in the methylation of simple precursors.  These methods 
involve coating the inside surface of a plastic or stainless steel HPLC loop with a solution of the 
cold precursor and then passing a stream of gaseous [
11
C] CH3I through the system.  With the 
loop itself acting as a reaction vessel, the crude mixture can be directly injected onto the HPLC 
column for purification following reaction.  This avoids the loss of material due to transfer from 
reaction vessels (Scheme 14).  
 
 
 
Scheme 14- Schematic of a loop system used for [
11
C] methylation reactions e.g. methylation to 
form [
11
C]-raclopride 40.
72
 
 
Other advantages of this methodology include its efficiency: using smaller volumes of solvent 
not requiring any temperature control for trapping or reaction, and rapid reaction rates.
72
  See 
section 3.2.2 for further discussions of microfluidic reactions.  
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1.2.2.2 [
11
C] Carbon Monoxide 
 
The carbonyl group is one of the most widely abundant functionalities found in biologically 
relevant molecules.  The ability to introduce [
11
C] carbon monoxide ([
11
C] CO) to molecular 
probes is therefore highly desirable.   [
11
C] CO is produced by the reduction of [
11
C] CO2 over 
molybdenum and zinc catalysts at high temperatures and has found its greatest application in 
palladium-catalysed carbonylation reactions.
41
  
 
These reactions involve four components: the transition metal catalyst, an aryl or vinyl halide, a 
nucleophile and [
11
C] CO.  They proceed via a typical catalytic cycle: oxidative addition of the 
halide species, insertion of [
11
C] CO to form an acyl-palladium complex, followed by 
nucleophilic attack and reductive elimination to the product (Scheme 15).
73
     
 
 
 
 
 
Scheme 15- General mechanism for carbonylative palladium cross couplings.
73
  
 
Initial investigations of this chemistry suffered from low radiochemical yields as a result of the 
poor solvent solubility of carbon monoxide, thus limiting the rate of the insertion step.
73
  Recent 
developments using high pressure micro-autoclaves have overcome these issues, allowing 
reactions to be performed at pressures in excess of 350 atm enhancing the solubility of [
11
C] 
CO.
74
 
 
Such advances have allowed the synthesis of a variety of ketones and amides using Suzuki, Stille 
and Buchwald-Hartwig carbonylative coupling procedures (Scheme 16).
75,
 
76,
 
77
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Scheme 16- Palladium catalysed carbonylative cross couplings.
73
 
 
Free-radical carbonylations of alkyl iodides have also been used to synthesise radiolabelled 
esters, amides and carboxylic acids from [
11
C] CO (Scheme 17).
78,
 
79
 
 
 
 
Scheme 17- Free radical carbonylations of alkyl iodides.
73
 
 
Although seemingly analogous to palladium catalysed carbonylations, these reactions provide 
several distinct advantages. For example, without the risk of β-hydride elimination radical 
carbonylations can make use of alkyl halides and triflates as well as aryl and vinyl halides.  
Additionally this method is tolerant to functional groups such as carboxylic acids and alcohols, 
which are normally protected in syntheses using [
11
C] CO2 and Grignard reagents.
79
  
 
1.2.2.3 [
11
C] Carbon Dioxide 
 
In contrast to [
11
C] CO and [
11
C] CH3I, there are relatively few examples using [
11
C] carbon 
dioxide ([
11
C] CO2) as the labelling species.  A notable exception is in the formation of 
radiolabelled carboxylic acids and acid chlorides by the reaction of [
11
C] CO2 with Grignard 
reagents (Scheme 18).  
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Scheme 18- Reactions of [
11
C] CO2 with Grignard reagents.
80, 81
 
 
In both these examples, the [
11
C] CO2 is first of all reacted to form the Grignard salt 55 and 58 
and then further functionalised as required.  The synthesis of [
11
C] labelled sodium acetate 58, 
used for the diagnosis of prostate cancer is an important demonstration of this strategy.
80, 81  
However, as previously mentioned the functional group tolerance of these methods can limit their 
usefulness. 
 
1.2.2.4 [
11
C] Hydrogen Cyanide and other Reactions 
 
There are numerous biologically relevant molecules containing the nitrile functionality, making it 
an ideal target for radiolabelling.  [
11
C] Hydrogen cyanide ([
11
C] HCN), produced by the reaction 
of [
11
C] CH4 with NH3 at high temperatures using a platinum catalyst, provides a suitable reagent 
for the introduction of this group (Scheme 19).
82
   
 
 
 
Scheme 19- Introducing [
11
CN] group to aryl halides.
83,
 
84
   
 
[
11
C] HCN can be reacted directly with aryl halides 59 using palladium catalysis or it may be 
converted to [
11
C] CuCN and then used to introduce the nitrile group via a Rosenmund-von 
Braun reaction.
83,
 
84
  With the nitrile functionality in place amides, tetrazoles and carboxylic 
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acids can be conveniently synthesised allowing the generation of a wide range of radiolabelled 
molecules.
41
  
 
It should be noted that there are a number of reactions such as rhodium catalysed carbonylations 
using and the use of [
11
C] labelled phosgene that have been omitted.  These will be covered in 
section 2.0.2 discussing the synthesis of [
11
C] labelled isocyanates. 
 
These examples serve to highlight the diverse array of reactions available to the radiochemist 
utilising [
11
C] and demonstrates the synthetic versatility of this radionuclide in comparison to 
[
18
F].  Furthermore, as carbon is an element endogenous to the body it means that a tracer 
labelled with [
11
C] it will follow the same biological pathways as the original molecule, 
providing a ‘true tracer’ of the process being analysed.97  However, there are limitations 
associated with [
11
C] chiefly its relatively short half-life.  This places restrictions on the number 
of steps that can be used and unlike [
18
F] requires the presence of an on-site cyclotron.  
Additionally gaseous [
11
C] CO2 and [
11
C] CH4 are difficult to handle requiring specialist 
equipment.
73
  It should be noted that a short half-life can be beneficial clinically, allowing repeat 
studies to be carried out with a similar or lower dose than radionuclides with a longer half-life.
85
  
 
1.2.3 Oxygen-15 and Nitrogen-13 Radiochemistry 
 
As is this case with [
11
C] both [
15
O] and [
13
N] are examples of nuclei whose stable isotopes are 
elements endogenous to the body.  They are found in most biologically active compounds and 
therefore are seemingly ideal candidates for radiolabelling molecular probes.  Unfortunately, as 
previously mentioned, their short half-lives restrict the amount of useful synthetic radiochemistry 
that can be performed using these radionuclides (Table 1).   
 
Oxygen-15 can be produced in two forms: as [
15
O] O2, made in the 
14
N(d,n)
15
O nuclear reaction 
by bombarding a nitrogen-oxygen mixture with high energy deuterons, and as [
15
O]  H2O made 
by irradiation of water with protons 
16
O(p,pn)
15
O.
86
  Both [
15
O] O2 and [
15
O] H2O can be used for 
blood flow studies in the brain and other organs.
87
 
 
Nitrogen-13 is generated from H2O using the 
16
O(p,α)13N nuclear reaction in the form of [13N] 
nitrate and nitrite salts.  The commonly used form for labelling is as [
13
N] ammonia.  This can be 
prepared via the reduction of the aforementioned nitrogen salts using an Al/Cu/Zn alloy or can be 
44 
 
made directly by the addition of ethanol to the target to scavenge radical hydroxyl groups thus 
preventing oxidation.  Much like [
15
O] O2 and H2O [
13
N] NH3 can be used in blood flow studies.  
Other uses include the enzymatic synthesis of amino acids, the reaction of acid chlorides to form 
amides and the synthesis of [
13
N]-cisplatin 62 for measuring uptake of cisplatin in the brain 
(Scheme 20).
88, 89
 
 
 
 
Scheme 20- Synthesis of [
13
N]-cisplatin.
89
  
 
While [
15
O] and [
13
N] have demonstrated usefulness for the synthesis of a small number of 
probes, particularly those suited for perfusion studies.  When compared to [
18
F] and [
11
C] their 
use in complex radiochemical syntheses is at best limited. 
 
Now that the desirable properties of PET radiopharmaceuticals have been established and the 
synthetic methods for generating them described, some currently used molecular probes will be 
reviewed.  This will be followed by an examination of more recent developments in imaging 
proliferation in cancer as well as outlining potential targets for the next generation of PET 
proliferation probes. 
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1.3  PET Imaging Probes 
 
1.3.1  PET Probes for Imaging Glucose Metabolism 
 
1.3.1.1 [
18
F]-Fluorodeoxyglucose ([
18
F]-FDG) 
 
There are a vast number of radiotracers available for imaging cancers using PET.  The current 
‘gold standard’ molecular probe is undoubtedly the glucose analogue [18F]-FDG, in which the  
C-2 hydroxyl group of glucose is replaced with an [
18
F] radionuclide (Figure 10).  The 
radiosynthesis of [
18
F]-FDG has been previously covered (Scheme 1 Section 1.2.1.1). 
 
 
 
Figure 10- [
18
F]-FDG 1 and D-Glucose 63.
90
 
 
Cancerous cells show increased consumption of glucose and therefore an increased consumption 
of [
18
F]-FDG in comparison to normal cells.  As mentioned previously (see Section 1.0.1) 
cancerous cells are able to reprogram the manner in which they carry out glucose metabolism, 
limiting energy production to glycolysis.
7
  This causes the net production of two (adenosine 
triphosphate) ATP molecules per molecule of glucose compared with thirty six ATP molecules in 
standard aerobic conditions.  As such, additional glucose is required to generate the same amount 
of energy.
91
   Enhanced glucose uptake is caused by an upregulation in expression of the glucose 
transporting membrane protein Glut 1, mediated by the transcription factors hypoxia inducing 
factor-1α (HIF-1α) and HIF-2α.92   
 
When glucose is taken up by a cell for the purpose of glycolysis it follows a specific pathway to 
ATP production.  However, when [
18
F]-FDG is taken up, it only follows the initial steps of the 
glycolytic pathway (Figure 11).  
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Figure 11- Uptake and usage of glucose and [
18
F]-FDG in the glycolytic pathway.
36
  
 
When [
18
F]-FDG is transported into a tissue it is phosphorylated to 6-phospho-[
18
F]-FDG under 
the control of hexokinase.  Once in this state it cannot be further metabolised due to the presence 
of the C-2 fluorine, which is incompatible with phosphohexose isomerise and glycolysis cannot 
continue.
90
  In addition, Glut transporters cannot deal with phosphorylated forms of glucose and 
remove 6-phospho-[
18
F]-FDG from the cell.
21
  [
18
F]-FDG is therefore, trapped within the 
cancerous cell in its mono-phosphorylated state and will accumulate permitting imaging of a 
tumour.  The amount of [
18
F]-FDG retained in the lesion is proportional to the rate of glycolysis 
and so [
18
F]-FDG is said to be a marker that images the rate of glycolysis.
51
  
 
1.3.2  PET Probes for Imaging Proliferation: Nucleosides 
 
Another class of compound commonly used for imaging tumours, and the primary focus of this 
thesis, are radiolabelled nucleosides.  These probes differ from [
18
F]-FDG in the physiological 
processes they image and their biodistribution patterns.  Although these different classes have 
overlapping uses their different characteristics ensure they also have specific roles.  For example, 
the natural biodistribution of [
18
F]-FDG sees significant accumulation in the brain, heart, 
inflammatory tissues and bladder with lesser uptake in the liver and kidneys; whereas the 
nucleoside analogue [
18
F]-FLT shows reduced accumulation in the brain and in inflamed 
tissues.
93
   
 
1.3.2.1  3’-Deoxy-3’-[18F]-fluorothymidine ([18F]-FLT) 
 
As was previously mentioned, cancerous cells show rapid proliferation and hence exhibit 
increased DNA synthesis in comparison to ordinary cells.  It can be easily envisaged that 
47 
 
imaging proliferation would allow for the detection of cancers; 3’-deoxy-3’-[18F]-
fluorothymidine ([
18
F]-FLT) 65 is a PET molecular probe highly suited to this purpose.
94
  [
18
F]-
FLT is an analogue of the deoxyribonucleoside thymidine, 64 in which the hydroxyl group in the 
3’ position has been replaced by an [18F] radionuclide (Figure 12).  
 
 
 
Figure 12- Deoxythymidine 64 and [
18
F]-FLT 65. 
 
The synthesis of [
18
F]-FLT proceeds via a simple nucleophilic substitution reaction on protected 
nucleoside precursor 66 using [
18
F] KF.K222, followed by hydrolysis to the product (Scheme 
21).
95
 
 
 
 
Scheme 21- Synthesis of [
18
F]-FLT.
95
 
 
There are two routes a cell can make use of to generate the nucleotides required for DNA 
synthesis, namely the DNA salvage and de novo pathways.
 
 In general, tissues utilise the de novo 
pathway.  However, rapidly proliferating tissues show a strong reliance on the salvage pathway.
96
 
 
The salvage pathway involves the synthesis of nucleotides using nucleosides and bases formed 
during DNA degradation.  Thymidine and [
18
F]-FLT are therefore actively transported into cells 
by carrier protein.  Once in the cell they are phosphorylated by thymidine kinase 1 (TK1), an 
enzyme expressed during the DNA synthesis phase of the cell cycle (Figure 13).
96
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Figure 13- The DNA Salvage Pathway for Thymidine (TdR) and [
18
F]-FLT.
96
  
 
Thymidine is subsequently subjected to further phosphorylation by nucleoside monophosphate 
and nucleoside diphosphate kinases (NMPK and NDPK) before being incorporated into DNA by 
DNA polymerase
96
. [
18
F]-FLT also undergoes further phosphorylation by NMPKs and NPDKs 
but cannot be incorporated into DNA due to the incompatibility of the 3’ fluorine with DNA 
polymerase.
97
  As such the detection of [
18
F]-FLT accumulation within rapidly proliferating cells 
provides a measure of TK1 activity.  Since TK1 activity has been shown to correlate with the 
extent of cellular replication, [
18
F]-FLT serves to image proliferation.  [
18
F]-FLT has also been 
shown in various studies to be a sensitive probe for assessing tumour response to treatment.
98, 99 
  
However, there are also a number of issues with [
18
F]-FLT.  The main concern is that its uptake 
and retention by tumours is in general significantly lower than that of thymidine.
98
  The likely 
cause of the problem of [
18
F]-FLT uptake will be evaluated by comparison with carbon-11 
radiolabelled thymidine. 
 
1.3.2.2  [
11
C]-Thymidine   
 
The most widely studied molecular probes for cellular proliferation are [
11
C] labelled thymidine 
compounds.  [
11
C]-thymidine nucleosides can be synthesised by labelling in two positions on the 
pyrimidine ring: either the 5-methyl position or the 2-carbonyl position.  5-[
11
C]-methyl 
thymidine 70 is synthesised by the double deprotonation of bromide precursor 68, followed by 
reaction of intermediate di-anion 69 with [
11
C] CH3I and then deprotection (Scheme 22).
100
  
Synthesis of 2-[
11
C]-thymidine 74 is a slightly more involved.  Firstly [
11
C] phosgene is 
generated by reaction of [
11
C] CH4 with chlorine at high temperature to produce [
11
C] CCl4, 
which can then be oxidised over iron to form phosgene.  This is further reacted with liquid 
ammonia to generate [
11
C] urea 72, which can be heated with diethyl β-methylmalate in the 
presence of sulfuric acid and sulfur trioxide to yield the radiolabeled thymine 73.  Finally the 
49 
 
base is enzymatically condensed with 2’-deoxyribose-1-phosphate using thymidine 
phosphorylase (Scheme 22).
101
 
 
 
 
Scheme 22- Synthesis of 5-[methyl-
11
C]-thymidine 70 and 2-[
11
C]-thymidine 74.
100,
 
101
  
 
Unfortunately, these probes have several disadvantages which have led to [
18
F]-FLT being 
considered a more suitable candidate for cancer imaging.
98
  Principally is the fact that [
11
C]-
thymidine compounds are subject to rapid in vivo degradation by thymidine phosphorylase.  This 
results in the production of numerous metabolites, creating images of a lower quality than [
18
F]-
FLT and making kinetic studies more complex.
98,
 
102
  
 
Nevertheless, thymidine probes show a variety of properties that should be taken into account 
when considering the design of novel cancer imaging probes.  For example, these compounds are 
better substrates for many nucleoside carrier proteins and for TK1, in comparison to [
18
F]-FLT.
97
   
Additionally, and in contrast to [
18
F]-FLT, [
11
C]-thymidine compounds are suitable substrates for 
DNA polymerase.  Upon entering the salvage pathway (Figure 13) they are completely 
phosphorylated and incorporated into DNA.
97
  Studies in A549 tumour cells have shown that 
since [
18
F]-FLT is not incorporated into DNA it is subject to a degree of dephosphorylation by a 
putative nucleotidase (dNT).  As a result the phosphorylated [
18
F]-FLT can be transported out of 
the cell following dephosphorylation by this nucleotidase, which could explain its poor uptake.
103
  
Since thymidine shows improved uptake and retention within proliferating cells when compared 
to [
18
F]-FLT, it suggests that if one could design a [
11
C]-thymidine molecule stable to thymidine 
phosphorylase, it could overcome the limitations of both FLT and thymidine compounds.
103
  This 
would provide a metabolically robust compound that allows sensitive proliferation imaging. 
50 
 
Unfortunately, the stability of [
18
F]-FLT to breakdown by thymidine phosphorylase has been 
attributed to the replacement of the 3’ hydroxyl with [18F].102  As was previously mentioned, this 
[
18
F] radiolabel contributes to the uptake issues of FLT making it a poorer substrate for TK1 and 
unreactive with DNA polymerase.  It is clear that a different approach to enhancing the stability 
of nucleoside molecular probes is required. 
 
1.3.3  Recent Developments in Imaging of Proliferation  
   
1.3.3.1 Sulfur Based Pyrimidine Nucleosides 
 
A recent study by Toyohara et al. reported the synthesis of a sulfur based thymidine nucleoside 
proliferation marker 5-[Methyl-
11
C]thiothymidine using a Stille coupling with [
11
C] CH3I 
(Scheme 23).
104
  
 
 
 
Scheme 23- Synthesis of 5-[Methyl-
11
C]thiothymidine 76.
104
  
 
Although it should be noted that the results given are for in vivo studies in mice and not clinical 
data, this probe displays a number of exciting properties.  For example, it exhibits relative 
metabolic stability in plasma, indicating that it will not suffer from the poor image quality seen in 
[
11
C]-thymidine molecules.  It is also efficiently incorporated into DNA via the salvage pathway 
due to the presence of the 3’ hydroxyl group.  As a result, 5-[methyl-11C]-thiothymidine shows 
improved uptake in rapidly proliferating tissues in comparison to [methyl-
3
H]-FLT; these results 
were mirrored in tumour models with 76 again showing higher accumulation.
104,
 
105
   
 
Based on the initial data from in vivo mice studies for 5-[methyl-
11
C]-thiothymidine, [
11
C] 
thiothymidine nucleosides present an exciting prospect for the imaging of proliferation in cancers 
using PET.  They appear to show superior properties to the current PET proliferation markers 
[
18
F]-FLT and [
11
C]-thymidine and hence warrant further investigation.  
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1.3.3.2 2’-Deoxy-2’,2’-difluoro Nucleosides 
 
Radu et al have reported the synthesis of a deoxycytidine based nucleoside analogue: 1-(2’-
deoxy-2’-[18F]-fluoroarabinofuranosyl) cytosine also known as [18F]-FAC 78 (Figure 14).106  
 
 
 
Figure 14- Deoxycytidine 77 and [
18
F]-FAC 78.
106
  
 
Synthesis of [
18
F]-FAC begins with introduction of the [
18
F] fluoride radiolabel to furanose 
precursor 79.  This is subsequently transformed into bromide 81 using HBr in acetic acid, before 
being subjected to the Vorbrüggen glycosylation with bis-trimethylsilylated cytosine 82 and 
finally deprotected to the desired product 78 (Scheme 24).
107
  
 
 
 
Scheme 24- Synthesis of [
18
F]-FAC.
107
 
  
In a similar fashion to deoxythymidine and [
18
F]-FLT, [
18
F]-FAC is taken up via a nucleoside 
salvage pathway in this case the deoxycytidine pathway.  There are however, a number of 
differences in the pathways and the uptake of [
18
F]-FAC itself.  The initial phosphorylation for 
example, is performed by deoxycytidine Kinase (dCK) in place of TK1 (Figure 15).  Another 
52 
 
key difference is evidence showing that [
18
F]-FAC is a substrate for DNA polymerase and 
therefore is incorporated into DNA.
96,
 
106
   
 
 
 
Figure 15- The DNA salvage pathway showing routes taken by deoxycytidine (Cyd) and [
18
F]-
FAC.
96
 
 
Thus, [
18
F]-FAC uptake occurs in cells showing increased expression of dCK including: myeloid 
and lymphatic cancers, a number of solid tumours, as well as lymphocytes and activated T-cells.   
[
18
F]-FAC therefore serves to image dCK activity in these cells, allowing imaging of immune 
activation.  Usefully [
18
F]-FAC shows a different biodistribution pattern to [
18
F]-FLT and [
18
F]-
FDG with significant quantities of the probe found in the thymus, spleen, intestines, bone 
marrow and liver.
106, 108
  Another interesting potential use of [
18
F]-FAC is in predicting the 
response to specific classes of nucleoside based chemotherapeutic agents. Cytarabine, 
fludarabine, gemcitabine and decitabine are all cytotoxic pro-drugs activated by dCK that suffer 
from poor response in tumour cells displaying reduced dCK activity.
109
  Measuring [
18
F]-FAC 
uptake would allow evaluation of the likelihood of a positive response to these drugs.
108
   
 
Although [
18
F]-FAC was the primary focus of Radu’s report, mention was also made of another 
deoxycytidine nucleoside analogue, 2’-deoxy-2’,2’-difluorocytidine (dFdc or gemcitabine) 84, 
which showed superior selectivity and retention in proliferating T-cells in comparison to [
18
F]-
FAC.  This could be attributed to the additional hydrogen bonding in the dCK active site between 
the ribo-fluorine and a tyrosine residue.
110
  dFdc was not investigated for use as a PET imaging 
probe due to envisaged synthetic difficulties in generating a precursor to dFdc suitable for  
labelling with [
18
F] fluoride (Figure 16).
106
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Figure 16- [
18
F]-FAC 78 and dFdc 84.
106
  
 
While not strictly used for imaging proliferation, the useful properties exhibited by [
18
F]-FAC 
and the improvements shown by dFdc warrant further investigation of this molecule through the 
use of different radiolabelling strategies.   
 
Furthermore, the principle of replacing an arabino-fluorine with a germinal difluoro moiety 
could be applied to other nucleosides with the aim of altering their selectivity for thymidine 
kinase and deoxycytidine kinase enzymes (Figure 17). 
 
 
 
Figure 17- [
11
C]-FMAU.
64
 
 
For example, [
11
C] and [
18
F]-FMAU have both been shown to be stable in vivo and are 
incorporated into DNA giving them advantageous properties in comparison to [
18
F]-FLT and 
[
11
C]-Thymidine (Figure 17).
111, 112
  Unfortunately, FMAU is known to be a better substrate for 
the cell cycle independent TK2 in comparison to TK1.  This suggests that FMAU is perhaps not 
an ideal candidate for imaging the proliferation of tumours, as the uptake of TK2 selective 
nucleosides has been previously demonstrated not to correlate with the proliferation of 
tumours.
104
  However, FMAU has also been shown to be a substrate for dCK.
106
  Bearing in-
mind the aforementioned favourable binding interactions for difluoro nucleoside analogues with 
dCK, it would be of interest to synthesise a di-fluoro analogue of this molecule and compare its 
selectivity for TK1, TK2 and dCK and utility as PET proliferation probe with that of [
11
C]/[
18
F]-
FMAU. 
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1.4  Aims and Objectives 
 
For the past ten years the Aboagye group has researched PET based imaging of proliferation in 
cancerous cells with a focus on [
18
F]-FLT.  As a result of the recent developments in sulfur based 
pyrimidine and 2’-deoxy-2’,2’-difluoro nucleoside analogues, chemistry discovery efforts will 
now be focussed on the study of these molecules. 
 
Sulfur Based Pyrimidine Nucleosides 
 
The aim of this project was the development of novel methodology to facilitate synthesis of a 
number of [
11
C] labelled thiothymidine nucleoside analogues.  This was to be followed by an 
evaluation of their use as PET probes for imaging proliferation (Figure 18).  
 
 
 
Figure 18- 2-[
11
C]-thiothymidine analogue with variable ‘R’ group. 
 
The synthesis of these compounds was based on the generation of a novel precursor β-lactam 
nucleoside 86.  This would be heated to undergo an elimination reaction to yield an intermediate 
azetone 87, which would then be reacted with a variety of [
11
C]-isocyanates to allow the late 
stage introduction of the radiolabel (Scheme 25). 
 
 
  
Scheme 25- A simplified illustration of the proposed synthesis of the 2-[
11
C]-thiothymidine 
analogues. 
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The theoretical basis for azetones, their potential reactivity and the methods for producing [
11
C]-
isocyanates will be discussed in full in Sections 2.0.1 and 2.0.2. 
 
2’-Deoxy-2’,2’-difluoro Nucleosides 
 
The aim of this project was to synthesise and radiolabel an analogue of dFdc with an [
11
C] 
radiolabel in the 5-position of the cytosine ring 89* using a Stille coupling strategy (Scheme 
26).
64
 
 
 
 
Scheme 26- Proposed synthesis of analogue 89*. 
 
It was hoped that using stannane precursor 88 would permit easy access to 89*, circumventing 
the envisioned synthetic difficulties of producing an [
18
F]-dFdc analogue while maintaining the 
desirable properties of selectivity and retention.  Furthermore, a similar synthetic strategy could 
be applied to the synthesis of a 2’,2’-difluoro analogue of [11C]-FMAU 90* (Figure 19). 
 
 
 
Figure 19- Di-fluoro [
11
C]-FMAU analogue [
11
C]-dFMAU 90*. 
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RESULTS AND DISCUSSION 
 
 
2. Sulfur Based Pyrimidine Nucleosides 
 
2.0  Overview 
 
The aims of this project, as previously discussed (Section 1.4), were twofold:  development of 
novel methodology to allow radiolabelling of precursor β-lactam nucleoside 86 and synthesis of 
precursor 86 itself (see Section 2.2.1 for a proposed route). 
 
2.0.1  Azetones 
 
Outlined in Scheme 27 the generation of an azetone intermediate and subsequent reaction with an 
[
11
C] isocyanate would allow the late stage induction of a radiolabel as part of novel 
methodology for the synthesis of pyrimidine bases.  Azetones, as a result of the anti-aromatic 
nature of their structure and its resonance forms (in violation of Hückel’s 4n + 2 rule), are highly 
reactive and unstable compounds (Scheme 27).
113,
 
114
 
 
 
 
Scheme 27- Resonance forms of a generic unfunctionalised azetone. 
 
During the late 1960s and early 1970s, Arbuzov and co-workers reported the synthesis of a 
number of stable azetones through the reaction of benzoyl isocyanates with a variety of alkynes 
(Scheme 28).
115,
 
116,
 
117
  Unfortunately, these results could not be reproduced by other researchers.
 
118, 119
 Pericás et al., reported the synthesis of 2-phenyl-4,5-di-t-butoxy-l,3-oxazin-6-one 95 from 
similar starting materials to those used by Arbuzov and  unambiguously assigned the structure 
using X-ray crystallography.  They suggested that perhaps the products isolated by Arbuzov were 
not azetones but rather the corresponding 1,3-oxazin-6-ones derivatives (Scheme 28).
120
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Scheme 28- Azetone synthesis reported by Arbuzov and 1,3-oxazin-6-one synthesis by 
Pericás.
117,
 
120
 
 
In fact, the only other claim to isolation of an azetone was made by Wentrup et al. who reported 
the formation of an N-adamantylazetone 98 in equilibrium with its corresponding imidoylketene 
97. Using vacuum pyrolysis (FVP) of l-adamantyl-4-methyl-5-phenyl-2,3-dihydropyrrole-2,3-
dione 96, products were monitored by mass spectrometry and I.R. within an argon matrix at 18 
o
K (Scheme 29).
121
   
 
 
 
Scheme 29- Generation of an azetone by FVP.
121
 
 
Benzo-fused forms of azetones (benzazetones) on the other hand, are known to be stable and 
have been synthesised and fully characterised.
114
  Initially reported to be formed by the reaction 
of N-alkyl anthranil salts with triethylamine, benzazetones have been occasionally described in 
the literature including a more recent radiochemical synthesis by Långström et al (Scheme 30).
114,
 
122,
 
123
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Scheme 30- Cold and radiochemical syntheses of benzazetones.
114,
 
123
 
 
Unfortunately, these stable azetone derivatives are not suited for the desired methodology and the 
isolation of un-fused azetones in ambient conditions seems unlikely. However, despite 
discounting the possibility of forming stable azetones, Pericás et al. suggested the probability of 
an intermediate azetone 103 in their synthesis of 95.  These claims were substantiated through the 
use of computational methods (Scheme 31).
120
  
 
 
 
Scheme 31- Proposed mechanistic pathway to 95, via an intermediate azetone 103 and 
imidoylketene 104.
120
 
 
Moreover, there here have been sporadic reports in the literature of reactions purporting to 
proceed via an intermediate azetone.
124, 125,
 
126
  Of particular note are the examples of Alajarin et 
al. who described the synthesis of 1,3-oxazin-6-ones derivatives from N-Acyl-4-acyloxy-β-
lactams, which followed on directly from the work of Pericás (Scheme 32).
127
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Scheme 32- Synthesis of 1,3-oxazin-6-one derivative 108. 
 
In this case, the proposed pathway involved an E1cB style β-elimination of acetate from 105 to 
generate the azetone 106.  This underwent a retro-[4-exo-dig] ring opening to generate the 
imidoylketene 107, which reacted in a [6-exo-dig] ring closure to form 108.
127
  The authors 
subsequently published follow up computational studies on this process.  Results complemented 
those of earlier work suggesting that proceeding via an azetone is the most energetically 
favourable pathway, despite being un-favoured by Baldwin’s rules, to accessing the 1,3-oxazin-
6-one analogues.
128
  
 
From these observations one can conclude that there appears to be limited physical evidence for 
the existence of azetones such as 103 and 106.  However, indirect evidence from computational 
studies and from reactions purporting to proceed via these intermediates, suggests that 
developing methodology with the aim of utilising an azetone intermediate is an endeavour 
worthy of investigation.  
 
In more detail, our proposed methodology involved the use of a β-lactam nucleoside precursor 
functionalised with a sulfoxide 109, which could be heated to undergo syn-elimination forming 
the intermediate azetone 87 and benzene sulfenic acid (Scheme 33).
129
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Scheme 33- Proposed mechanistic route to nucleosides 113. 
 
Electrocyclic ring opening of the unstable anti-aromatic lactam would result in the formation of 
intermediate imidoylketene 111.  This would subsequently undergo, by analogy with related 
transformations, stepwise addition with a variety of [
11
C]-isocyanates leading to the isolation of 
nucleosides 113.
130,
 
131
 
 
2.0.2  Carbon-11 Labelled Isocyanates 
 
Having outlined the proposed methodology for generating novel 2-[
11
C]-thiothymidine 
nucleosides and discussed the theoretical basis behind this proposition, it would be prudent to 
briefly review the methods available for generating the required 
11
C radiolabelled isocyanate 
precursors. 
 
The most widely investigated method for generating [
11
C]-isocyanates involve reactions with 
radiolabelled phosgene.  As previously mentioned [
11
C] phosgene is generated either by the 
reaction of [
11
C] CH4 with chlorine at elevated temperatures, followed by oxidation over iron 
granules in a stream of oxygen; or by reacting [
11
C] CO with platinum tetrachloride.
73
  Phosgene 
is then typically reacted directly with an amine, sometimes in the presence of base, to generate an 
isocyanate (Scheme 34).
132, 133 
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Scheme 34- Formation of phenyl-[
11
C]-isocyanate 115 and urea by-product 116.
132
 
Note: RCY given for urea formed by administering excess aniline. 
 
However, these methods tend to suffer from side reactions leading to the production of 
symmetrical [
11
C]-ureas as a result of administration of excess amine.  Particularly in the case of 
PET where microscale quantities are used and especially when using gaseous amines, this can 
prove to be problematic.
133
 
 
Brown and co-workers have developed a number of methods for overcoming the problems 
associated with the formation of ureas as a side product.  One such example involves the reaction 
of phosgene with sulfinylamines (Scheme 35).
134
 
 
 
 
Scheme 35- Synthesis of [
11
C]-isocyanates 118 using sulfinylamines.
134
  
 
Sulfinylamines are well suited to this purpose being sufficiently reactive to form an isocyanate 
with phosgene but without sufficient nucleophilicity to further react with the isocyanate and form 
ureas.  This permits further functionalization to unsymmetrical ureas as desired.
134
  A further 
alternative developed by Brown et al. involves making use of the N,N-
bis(trimethylsilyl)methylamine 121 (Scheme 36).
135
 
 
 
 
Scheme 36- Synthesis of methyl-[
11
C]-isocyanate 122 using silyl-amines.
135
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Unfortunately, these methods generally suffer from low radiochemical yields and the production 
of phosgene itself is capricious.
73
  More attractive methods make use of [
11
C] CO or [
11
C] CO2 
which are much more readily available. 
 
An effective method for producing radiolabelled isocyanates and ureas without the use of [
11
C] 
phosgene has been demonstrated by Långström et al.  This method utilises the rhodium catalysed 
carbonylation of azides to form isocyanates (Scheme 37).
136
   
 
 
 
Scheme 37- Proposed pathway for [
11
C]-isocyanate formation by carbonylation.
136, 137
 
 
The initial decomposition of azide 123 results in the production of an intermediate nitrene, which 
undergoes reaction with [
11
C] CO and the rhodium catalyst to yield a further intermediate in the 
form of  isocyanate 126 or an isocyanate co-ordinated rhodium complex 125.  The isocyanates 
can then undergo undergo further conversion to ureas 128 and carbamates 127.
136
   
 
The ideal situation would involve the use of [
11
C] CO2 as it is available directly from the 
cyclotron without the need for any further manipulation.  A promising example was reported by 
Van Tilburg et al. whereby phenyl-[
11
C]-isocyanate was formed by the reaction of phenyl-
triphenylphosphinimine with carbon dioxide (Scheme 38).
138
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Scheme 38- Reaction of [
11
C] CO2 with phenyl-triphenylphosphinimine to from isocyanate 
115.
138
  
 
Trapping of [
11
C] CO2 in a solution of the triphenylphosphinimine 129 in THF with subsequent 
heating allowed the formation of the desired product 115, which was then further reacted to form 
an unsymmetrical [
11
C] labelled urea 130.  This was the only example used to illustrate the 
usefulness of this protocol.  The potential for use of a variety of other phosphinimines was 
suggested, although the structural diversity of available phosphinimines may still prove be a 
limiting factor.
138
  
 
Inspired by the work of Hooker et al. Wilson and co-workers have recently published a method 
for the synthesis of a wide variety [
11
C]-isocyanates from [
11
C] CO2 (Scheme 39).
69, 139
 
 
 
 
Scheme 39- Synthesis of [
11
C]-isocyanates 135 by fixation of [
11
C] CO2.
139
 
 
This protocol involves the fixation of [
11
C] CO2 using 2-tert-butylimino-2-diethylamino-1,3-
dimethylperhydro-1,3,2-diazaphosphorine (BEMP) 131 in a solution of acetonitrile at ambient 
temperatures and pressures.  Displacement of BEMP by an amine results in the formation of a 
carbamate salt 133, which then upon addition of POCl3 is dehydrated to form the isocyanate 
64 
 
135.
139
  The authors demonstrated the scope of this reaction by successfully synthesising a 
variety of isocyanates and reacting these to form both [
11
C] carbamates and ureas.  As a result of 
the wide scope, mild conditions and the use of readily available [
11
C] CO2 this appears to be a 
most promising method.  However, it should be noted this protocol does require careful 
stoichiometric control of reagent addition to avoiding the formation of symmetrical ureas, a 
problem inherent in many of these discussed methods.
139
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
2.1  Methodology Studies 
 
2.1.1  Synthesis of Sulfoxide Precursors   
 
To assess the validity of the devised strategy for synthesising thymidine analogues from the 
corresponding β-lactam nucleosides and isocyanates, preliminary investigations were performed 
using more chemically simple systems.  It was envisaged that a suitable sulfoxide precursor 
could be accessed by the thiation and oxidation of an unsubstituted nitrogen-protected β-lactam 
(Scheme 40). 
 
 
 
Scheme 40- Sulfoxide precursors for trial methodology studies. 
 
Consultation of the literature prior to attempting this synthesis revealed conflicting views 
regarding the viability of enolates formed from unsubstituted β-lactams.  Urbach and Kano, 
reported successful enolisation and reaction of N-silyl and N-para-methoxyphenyl (PMP) 
protected unsubstituted lactams.
140,
 
141
  However, Wilson and Miller suggested that these systems 
were unsuitable for this purpose as a result of enolate instability, self-condensation and reaction 
via the alkoxide anion.
142, 143
  To test these competing theories, synthesis and enolisation of both 
N-tert-butyldimethylsilyl (TBS) and N-PMP protected lactams 141 and 146 were performed 
(Scheme 41).     
 
 
 
Scheme 41- Synthesis of N-silyl protected β-lactam 143. 
 
Protection of 2-azetidinone 140 with TBSCl proceeded smoothly giving 141 in good yields.
140
  In 
corroboration with the report of Williams et al. initial attempts at thiation of 141 using standard 
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conditions (addition of the lactam to LDA, followed by stirring at −78 oC and then treatment with 
a solution of diphenyl disulfide) yielded only starting material.  Fortunately, it was discovered 
that by modifying the addition of reactants so that both the lactam 141 and diphenyl disulfide 
were added simultaneously to a solution of LDA, sulfide 142 could be isolated in satisfying 
yields.  Perhaps concurrent addition of the lactam and electrophile permitted immediate reaction 
of diphenyl disulfide with the enolate, which was highly unstable over more prolonged periods. 
 
With multiple grams of sulfide 142 now in hand a variety of conditions were screened for 
oxidation to the sulfoxide (Table 2). 
 
Entry Conditions Time Sulfoxide 
Yield (%) 
Sulfone 
Yield (%) 
Starting 
Material (%) 
 
1 
NBS, Phosphate 
Buffer, H2O2, 
MeCN, 35
o
C 
 
 
48 h 
 
0 
 
0 
 
20 
 
2 
NaIO4: SiO2 
CH2Cl2, 140 
o
C 
Microwave 
 
2.5 min 
 
18 
 
 
13 
 
11 
 
 
3 
 
Ac2O, H2O2, 
SiO2, CH2Cl2, 
 
 
 
36 h 
 
 
79 
 
 
0 
 
 
0 
 
Table 2- Conditions evaluated for oxidation of 142. 
 
Utilising hydrogen peroxide in acetonitrile with a phosphate buffer and catalytic N-
bromosuccinimde resulted mainly in decomposition with some starting material recoverable 
(Table 2, entry 1).
144
 Microwave mediated oxidation using sodium metaperiodate supported on 
silica gel was more successful (Table 2, entry 2).
145
  However, full conversion was not observed, 
with over oxidation to the sulfone and decomposition also evident.  Making use of milder 
conditions by reacting 142 with hydrogen peroxide and catalytic acetic anhydride at ambient 
temperature resulted in full conversion after 36 hours, with no over oxidation or decomposition 
observed (Table 2, entry 3).
146
 
 
Having developed a suitable synthetic route for accessing diastereomeric sulfoxide precursors for 
the methodology studies, N-PMP protected lactam-sulfoxide 148 was also synthesised (Scheme 
42).  
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Scheme 42- Synthesis of N-paramethoxyphenyl protected β-lactam 148. 
 
Following the protocol of Easton et al., reaction of 3-bromopropionyl chloride 144 with para-
anisidine gave amide 145 in excellent yields.  In an improvement over the literature procedure it 
was discovered that β-lactam 146 could be cyclised and isolated in a 72% yield by 
recrystallization from DMF, compared to 58% reported by flash silica column 
chromatography.
147
  Problems were encountered during initial attempts at thiation of 146 due to 
insolubility of this lactam at −78 oC in THF.    Thankfully, the enolate of 146 proved to be 
sufficiently soluble at low temperature.  Therefore, by increasing the temperature of the lactam-
diphenyl disulfide solution, followed by slow addition to a −78 oC solution of LDA in THF, 
solubility was maintained, allowing for successful reaction. Subsequent oxidation furnished 
exclusively sulfoxide 148.
146
 
 
Through completion of the synthesis of sulfoxides 143 and 148 it was demonstrated that 
enolisation and subsequent reaction of lactams 141 and 146 is possible given suitable 
modifications of addition methods.  Moreover, attempts could now be made at syn-elimination of 
the sulfoxides and trapping of any resulting imidoylketenes.   
 
2.1.2  Trial Reactions of Sulfoxide Precursors 
 
For the purpose of these studies having two differently protected lactams was beneficial: the N-
silyl protected lactam could be easily deprotected and subjected to further functionalization if the 
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methodology proved successful, whereas the N-PMP protected lactam would provide more 
robust protection should the TBS group prove labile to the heating needed for elimination of the 
sulfoxide to occur.
129,
 
148
  
 
Sulfoxide 143 was subjected to various different conditions in an attempt to induce elimination 
of the sulfoxide (Table 3). 
 
 
 
Table 3- Attempted elimination of sulfoxide 143.  
 
Entry Conditions* Yield (%) 
 
1 
 
Toluene-d
8
, 130 
o
C,  
0.1 M, 4 h 
 
 
0 
 
2 
5eq. Tosyl isocyanate, 
Toluene, 130 
o
C, 
 0.1 M, 4 h 
 
 
0 
 
3 
5eq. Tosyl isocyanate, 
THF, 130 
o
C, 0.1 M, 
 24 h 
 
 
0 
 
 
 
4 
5eq. Tosyl isocyanate, 
Furan, THF, 
130 
o
C, 0.1 M, 24 h 
 
 
0 
 
*All reactions performed in a sealed tube. 
 
Initial attempts were promising: a test reaction performed in deuterated toluene showed 
consumption of starting material leading to decomposition (Table 3, entry 1).  It was hoped that 
this decomposition was proceeding via the azetone and therefore the imidoylketene, thus a 
number of attempts were made at trapping this intermediate.  Trapping reactions carried out 
using tosyl isocyanate in either toluene or THF were unsuccessful leading only to decomposition 
(Table 3, entries 2 and 3).   It was thought that benzenesulfenic acid produced as a by-product of 
the syn-elimination could be causing the observed decomposition.  A further attempt was 
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therefore made using furan as a trap for the acid (Table 3, entry 4); however this again was 
unsuccessful.  Another possible reason behind these observations could be the poor thermal 
stability of the sulfoxide itself, particularly due to the potential lability of the TBS group.   
 
Indeed, these concerns proved to be justified as demonstrated in the attempted elimination of 
sulfoxide 148 (Table 4).  
 
 
 
Table 4- Attempted elimination of sulfoxide 148. 
 
Entry Conditions Result 
1 
Toluene-d
8
, 130 
o
C, 
0.1 M, sealed tube,  
24 h 
 
 
Starting material 
2 
Toluene-d
8
, 130 
o
C, 
0.1 M, microwave,  
24 h 
 
 
Starting material 
3 
Toluene-d
8
, 160 
o
C, 
0.1 M, sealed tube,  
24 h 
 
 
Starting material 
4 
Toluene-d
8
, 160 
o
C,  
0.1 M, microwave,  
24 h 
 
 
Starting material 
 
 
As in the case for sulfoxide 143 a test reaction was firstly carried out to observe consumption of 
148.  Despite prolonged heating at high temperatures only starting material was recovered (Table 
4, entry 1).  Using microwave radiation and increasing the reaction temperature again gave no 
conversion (Table 4, entries 2, 3 and 4).  Clearly syn-elimination of the sulfoxide was not 
occurring in these systems.  Consequently, this also suggested that the observed decomposition 
of lactam 143 was due to instability of the TBS group to high temperatures rather than 
elimination and formation of the azetone.   
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2.1.3  Synthesis and Trial Reactions of Selenoxide Precursors  
 
As a result of the unsuccessful sulfoxide fragmentations a more reactive system was proposed:  
the syn-elimination of selenoxides to their corresponding alkenes is known to occur 
spontaneously at room temperature.
149
  It was therefore hoped that the increased reactivity of the 
selenoxides would allow the desired elimination reactions to occur where they had been 
unsuccessful in the more stable sulfoxide systems (Scheme 43). 
 
 
 
Scheme 43- Proposed synthesis and elimination of N-PMP protected selenoxide. 
 
It was envisaged that selenylation of 146 could be carried out using a procedure similar to that 
described for thiation of 146.  Oxidation of selenide 149 would be performed with DMDO at low 
temperatures to reduce the number of by-products in the mixture before warming the selenoxide 
150 to room temperature to undergo elimination.  
 
Problems were encountered when attempting selenylation of 146:  using a slight excess of LDA 
and phenylselenyl bromide resulted in the recovery of a large portion of starting material (60%), 
as well as a mixture of the desired mono-selenide 149 and the bis-selenide 151. Presumably the 
pKa of alpha carbonyl proton in 149 was lower than those in 146 resulting in a second 
deprotonation and reaction with another equivalent of the selenyl bromide to form 151.  It was 
therefore decided to attempt full conversion to 151 by using additional equivalents of 
phenylselenyl bromide and LDA.  This resulted in starting material consumption and the 
formation of a mixture of the mono and bis-selenylated products in more acceptable yields 
(Scheme 44). 
71 
 
 
 
Scheme 44- Synthesis of selenide 149. 
 
The bis-selenide was then successfully mono-de-phenylselenylated using the enolate of 
acetophenone resulting in exclusive generation of 149 (Scheme 44).   
 
With the desired selenide now available, oxidation to the selenoxide was performed using 
DMDO.  As previously mentioned, DMDO was seen as an ideal reagent for this step due to the 
production of relatively unreactive acetone as a by-product which would make attempted reaction 
with the isocyanate more likely (Scheme 45).
150
 
 
 
 
Scheme 45- Oxidation to and attempted elimination of selenoxide 150. 
 
As in previous examples, attempted eliminations were first carried out in the absence of an 
isocyanate to ascertain starting material consumption.  Unexpectedly oxidation of 149 resulted in 
almost quantitative formation of the stable selenoxide 150.  This was considered somewhat 
peculiar as stable selenoxides are generally only isolatable in systems lacking β-protons.151, 152  
Nevertheless, isolation of 150 was deemed advantageous as the elimination reaction could be 
carried out as a separate step using solvents entirely unreactive to the intermediate ketene.  When 
refluxed in toluene the selenoxide was fully converted, undergoing disproportionation to furnish 
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both keto β-lactam 152 and selenide 149 as products.  This disproportionation implied that the 
reaction was occurring via a bimolecular process.  In order to avoid this and favour elimination, 
the experiment was repeated at a low concentration (0.005 M) and at higher temperature by slow 
addition (10 hours) of 150 to refluxing xylenes.  Unfortunately the same result was obtained.   
 
By nature β-lactams are strained systems.153  It is therefore possible that elimination was not 
observed as a result of this strained nature preventing the selenoxide from effecting 
deprotonation in the β-position (Scheme 46).   
 
 
 
Scheme 46- Transition state required for elimination.  
 
2.1.4  Synthesis of Alternative Azetone Precursors  
 
With both the sulfoxide and selenoxide systems failing to react via the anticipated pathways it 
was clear that an alternative approach to generating the azetone was needed.  Pyrolysis of 
carboxylate salts is a common method for inducing decarboxylation.  It was therefore proposed 
that heating potassium salt 153 in the presence of 18-crown-6 would result in decarboxylation, 
followed by elimination, giving rise to the desired azetone intermediate (Scheme 47). 
 
 
 
Scheme 47- Formation of the azetone 154 by decarboxylative elimination from 153. 
 
β-lactam 155 has been reported in the literature and was suggested as suitable starting point for 
the synthesis of a carboxylate salt analogous to 153 (Scheme 48).
154
   
 
73 
 
 
 
Scheme 48- Proposed synthesis of 158. 
 
Starting from 155, base mediated epimerisation leading to the thermodynamically favoured trans-
diastereomer could be followed by cleavage of the benzyl group of 156 to give the corresponding 
alcohol.  Consequently, functionalization as a tosylate 157 and hydrolysis of the ester would 
furnish potassium salt 158. 
 
The synthesis began with the Staudinger cycloaddition of imine 160 (formed by condensation of 
ethyl glyoxylate 159 with para-anisidine) with benzyloxyacetyl chloride to give the cis-β-lactam 
155 (Scheme 49).
154, 155
 
 
 
 
Scheme 49- Synthesis and attempted epimerisation of 155.
154
 
 
Epimerisation alpha to the ethyl ester proved to be difficult and a variety of conditions were 
evaluated (Table 5). 
  
Entry Conditions Result 
1 Na2CO3, MeCN:H2O, 0.03 M Starting material 
2 NHMe2, benzene, 0.1 M Starting material 
3 DBU, CH2Cl2, 0.1 M Starting material 
 
Table 5- Attempted epimerisation of lactam 155. 
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The initially used conditions were based on the work of Alcaide et al. who reported the 
instability of similarly functionalised β-lactams to harsher conditions.156 Unfortunately in these 
cases only starting material was recovered (Table 5, entries 1 and 2).  Using a stronger base also 
resulted in no observable conversion (Table 5, entry 3).
157
 It was thought that by synthesising the 
corresponding aldehyde of 155 the system could be made more susceptible to the epimerisation 
conditions by decreasing the pKa of the proton alpha to the carbonyl functionality.   
 
Aldehyde 164 was easily accessed in three steps using the procedure of Alcaide et al. (Scheme 
50).
158
    
 
 
 
Scheme 50- Synthesis of aldehyde 164.
158
 
 
Condensation of para-anisidine with glyoxal 161 gave di-imine 162 in good yields.
159
 Staudinger 
cycloaddition of 162 with benzyloxyacetyl chloride furnished β-lactam 163, which could then be 
hydrolysed directly to the desired aldehyde.   With aldehyde 164 in hand further attempts at 
epimerisation could be made.  Unfortunately these efforts also resulted in the recovery of starting 
material (Table 6).
156
   
 
 
 
Table 6- Attempted epimerisation of aldehyde 164. 
 
Entry Conditions Result 
1 Na2CO3, MeCN:H2O, RT, 0.03 M starting material 
2 NHMe2, benzene, RT, 0.10 M starting material 
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With attempted epimerisation of the β-lactams 155 and 164 proving to be unsuccessful a new 
strategy was envisaged whereby the desired trans-geometry could be accessed by simple SN2 
reaction (Scheme 51). 
 
 
 
Scheme 51- Suggested synthesis of trans-β-lactam 166. 
 
Based on similar literature examples it was thought that displacing the triflate in 165 with sodium 
iodide would give exclusively the trans-lactam 166.
160
 Synthesis of 165 was relatively simple 
using lactam 155 as a starting point (Scheme 52).  
 
 
 
 
Scheme 52- Synthesis of triflate 165. 
 
A number of conditions were screened in order to find a suitable procedure for deprotection of 
benzyl ether 155 (Table 7).   
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Entry Conditions Result 
1 H2, Pd(OH)2/C, MeOH, 0.12 M Starting material 
2 NH4HCO2, Pd/C, MeOH, 
reflux, 0.30 M 
167 36%, 168 15% 
169 14% 
 
3 H2, Pd/C, THF, 0.03 M 167 97% 
 
Table 7- Deprotection of benzyl ether 155. 
 
Initial attempts at hydrogenation using Pearlman’s Catalyst proved to be unsuccessful due to 
solubility issues of 155 in methanol (Table 7, entry 1).
154
  Increasing the temperature to reflux 
and using ammonium formate overcame the solubility problems but also lead to the formation of 
two side products (Table 7, entry 2).
161
  The presence of these could be attributed to heating of 
the mixture coupled with the action of ammonia released during the reaction: 168 is a product of 
trans-esterification with methanol and 169 is the epimerised form of the desired product.  In order 
to prevent the formation of by-products, milder reaction conditions and a different solvent were 
used.  Carrying out the hydrogenation in THF with palladium on carbon permitted deprotection 
at room temperature and resulted in excellent yields of 167 (Table 7, entry 3).
162
     
 
Functionalization of 167 as its triflate ester occurred quantitatively and was followed by 
displacement of the triflate using sodium iodide.
160
  Interestingly a 1:1 mixture of diastereomers 
166 and 170 was recovered after reaction.  Since a large excess of sodium iodide was used this 
outcome can be rationalised by the displacement of one iodide by another until an equilibrium 
mixture is reached (Scheme 53). 
 
 
 
Scheme 53- Synthesis of potassium salt 171. 
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Fortunately, these diastereomers could be easily separated.  The final step in this synthesis was 
the hydrolysis of ethyl ester 166 to the corresponding potassium salt, which was accomplished in 
fair yields using potassium trimethylsilanolate (Scheme 53).
163
   
 
With desired salt in hand the fragmentation reactions could now be attempted (Table 8). 
 
 
 
Table 8- Attempted fragmentation of 171 and trapping of intermediate 172. 
 
Entry Conditions Reaction Time Result 
1 MeOH, 60-160 
o
C, 300 W, 
0.1 M 
30 min at each 
temperature 
 
Decomposition 
2 Antracene 5eq., 18-crown-6, 
 o-xylenes, 125 
o
C, 0.5 M 
 
16 h Decomposition 
3 175 10 eq., 125 
o
C 16 h 176 and 177,  
55% 
  
4 Adamantyl isocyanate 5eq., 
 18-crown-6, o-xylenes, 125 
o
C, 0.5 M 
2 h 180 6% 
 
 
 
As was the case with the sulfoxide and the selenoxide preliminary investigations were performed 
in the absence of other reactants in order to assess starting material consumption. Heating 171 in 
methanol using microwave irradiation at a variety of temperatures showed that temperatures in 
excess of 120 
o
C were required for starting material consumption (Table 8, entry 1).  It was 
hoped that using methanol would result in trapping of the resultant intermediate ketene providing 
evidence of the azetone, however this proved not to be the case and decomposition was instead 
observed. 
 
It was therefore decided to attempt trapping with a variety of different reagents.  Efforts to 
capture the proposed imidoylketene intermediate in a Diels-Alder process with anthracene 
resulted only in decomposition of the starting material (Table 8, entry 2).  A similar attempt 
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using diene 175 again resulted in decomposition of 171 with the isolation of the Diels-Alder 
product between two molecules of 175 (Scheme 54). 
 
 
 
Scheme 54- Synthesis of diene 175 and reaction to form regioisomers 176 and 177. 
 
Diene 175 was synthesised in two steps by the opening and isomerisation of commercially 
available 2-methyl-2-vinyloxirane 173, followed by protection of the resultant alcohol with 
chloromethyl methyl ether (MOMCl).
164
 As a consequence of the highly volatile nature of both 
174 and 175 yields for this synthesis were lower than may be expected, however sufficient 
material was synthesised in order to attempt the trapping reactions. 
 
A final attempt at trapping was made using adamantyl isocyanate, which was chosen as the 
distinctive 
1
H-NMR adamantyl peaks would allow easy identification of incorporation into 
products (Table 8, entry 4 and Scheme 55).   
 
 
 
Scheme 55- Synthesis of urea 180 and proposed mechanistic route. 
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In this case, alongside unidentifiable decomposition, small quantities of urea 180 were isolated 
contaminated with another by-product.  While by no means providing clear proof that this is the 
case, one possible explanation for the isolation of 180 is via an intermediate azetone (Scheme 
55).  Decarboxylation and elimination of 171 followed by ring opening of the azetone to form 
imidoylketene 172, could be followed by hydrolysis to para-anisidine, which could then react 
with adamantly isocyanate to furnish urea 180.  While every effort was made to ensure the 
reaction was performed under anhydrous conditions it is possible that some moisture may have 
been retained by the hydroscopic salt allowing for hydrolysis of the imine.  It can therefore be 
suggested that if the reaction is proceeding via an azetone intermediate the majority of the 
imidoylketene is decomposing via other pathways with small amounts being hydrolysed 
explaining the observations. 
 
However, in the reports of Pericás and Alajarin, reactions of imidoylketenes formed from 
azetones were hypothesised to proceed via an intramolecular process (see Section 2.0.1 Schemes 
31 and 32).
120,
 
127
    It has also been demonstrated that imidoylketenes generated from more stable 
sources are liable to undergo dimerisations (Scheme 56).
165
   
 
 
 
Scheme 56- Dimerisation of imidoylketene 182 reported by Zhou et al.
165
 
 
This suggests that if the reaction was proceeding through an azetone, one could expect to see 
some additional evidence of intramolecular reaction or dimerisation.  It is therefore also 
conceivable that decomposition to para-anisidine may be occurring by another unknown 
pathway. 
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2.2  Towards the Synthesis of Thiothymidine Nucleoside 85 
 
2.2.1  Overview and Proposed Synthesis 
 
In parallel to the methodology studies, efforts were also focussed on the development of a 
synthetic route for accessing the aforementioned novel β-lactam nucleoside precursor 193 and 
hence the thio-thymidine analogues themselves.  A route was proposed which would complement 
and make use of the methodology studies (Scheme 57).   
 
 
 
Scheme 57- Proposed synthesis of thiothymidine analogues 85. 
 
The synthesis would begin with Mitsunobu reaction of literature known alcohol 185 with 
methanesulfonic acid simultaneously introducing a leaving group and the desired 
stereochemistry.  This would be followed by displacement of the mesylate in 186 with 
triphenylmethyl mercaptan, removal of the silyl protecting group and Appel reaction to furnish 
iodide 188.  Coupling of 188 and 189 and subsequent trans-esterification would yield Barton 
ester 191.  This could then be subjected to a radical decarboxylation, generating 192 which is in a 
suitable from to be subjected to the methodology that would be developed concurrently. 
81 
 
2.2.2   Synthesis of β-Lactam Coupling Partner 189 
 
β-lactam 189 was obtained using a two-step procedure described by Baggaley et al (Scheme 
58).
166
 
 
 
 
Scheme 58- Synthesis of lactam 189.
166
  
 
The acetylation of glycine ethyl ester hydrochloride with 3-bromopropionyl chloride gave amide 
195 in high yields.  Cyclisation to lactam 189 was carried out in the presence of potassium 
hydroxide.  Yields, while being a good match for the literature, were relatively low as the result 
of the competing elimination process producing 196.
166
  
 
2.2.3   Synthesis and Inversion of Alcohol 185 
 
Alcohol 185 was easily accessible in four steps starting from D-glucose (Scheme 59).       
                                    
 
 
Scheme 59- Synthesis alcohol 185. 
 
The synthesis began with the protection of glucose 63 as its benzylidene acetal 197 using 
benzaldehyde dimethyl acetal.
167
  Oxidative cleavage of 197 using sodium metaperiodate and an 
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excess of sodium bicarbonate was directly followed by reduction of the intermediate with sodium 
borohydride to give benzylidene-erythritol 198 in excellent yields.
168
 Finally the primary alcohol 
of 198 was protected as its silyl ether using TBSCl and standard conditions to furnish 185.
169
 
  
It was originally envisaged that alcohol 185 could be displaced using methane sulfonic acid 
under Mitsonobu conditions to yield the inverted mesylate 186 as described by Anderson et al 
(Scheme 57).
170
  Unfortunately these conditions were sufficiently acidic to result in silyl-
deprotection of 185. Milder conditions using benzoic acid, followed by hydrolysis and 
functionalization of the resultant alcohol to from 186 were therefore proposed (Scheme 60).
 171
    
 
 
 
Scheme 60- Proposed route to mesylate 186. 
 
Despite prolonged heating at reflux, the Mitsonobu reaction would not proceed to completion 
giving poor yields of benzoate ester 199.  Possible reasons for the lack of full conversion can be 
attributed to hindrance associated with the cyclic system and the bulk of the silyl protecting 
group which could also hinder reaction at the alcohol.
172
   
 
These results were unsatisfactory and it was clear a different approach was required for accessing 
the inverted alcohol 200.  A two-step oxidation and selective reduction protocol proved to be 
more successful (Scheme 61). 
 
 
 
Scheme 61- Oxidation-reduction protocol for synthesis of 200. 
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Swern oxidation of alcohol 185 to ketone 201 was followed by reduction using L-selectride.  This 
process was high yielding and the reduction was highly diastereoselective furnishing almost 
exclusively axial alcohol 200.
173,
 
174
  The conformation was unambiguously assigned based on 
1
H-NMR coupling constants.    
 
2.2.4   Introducing the Sulfide Functionality: Synthesis of Thioether 203 
 
With the inverted alcohol now accessible, the next step was to introduce the sulfur moiety to 
form thioether 187.  As was previously outlined (Scheme 57 Section 2.2.1) the lithium salt of 
triphenylmethyl mercaptan was to be used to form 187.   However, due to the difficulty in 
handling this thiolate, the substitution reactions were first of all trialled using a simpler system 
with thiophenol as the nucleophile (Table 9) 
 
 
 
Table 9- Introducing the sulfide functionality to form 203. 
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Entry Starting 
Material 
Reaction 
Conditions 
Temperature 203:204 
     Ratio 
Yield of   
203 (%) 
1 Mesylate Thiophenol, 
NaOH, DMF, 
Toluene (0.06 M) 
 
Room temp 0 : 0 0 
2 Triflate Thiophenol, 
NEt3, DMSO 
(0.15 M) 
 
Room temp 50:50 20 
3 Triflate Thiophenol, 
NaH, DMSO- 
THF 
 
Room temp 14:86 5 
4 Triflate Thiophenol, 
NEt3, CH2Cl2 
(0.10 M) 
 
0 oC 64:36 28 
5 Triflate Thiophenol, 
NEt3, CH2Cl2 
(0.50 M) 
 
−10  oC 70:30 32 
6 Triflate Thiophenol, 
NEt3, CH2Cl2 
(0.50 M) 
 
−30  oC 80:20 40 
7 Triflate Thiophenol, 
NEt3, CH2Cl2 
(0.50 M) 
 
−55 oC 80:20 38 
8 Triflate Thiophenol, 
Na2CO3, CH2Cl2 
(0.10 M) 
 
Room temp 60:40 22 
9 Triflate Thiophenol, 
Na2CO3, MeCN 
(0.50 M) 
 
0 oC 64 : 36 30 
10 Triflate Thiophenol, 
Na2CO3, MeCN 
(0.50 M) 
 
−10  oC 68:32 30 
 
 
11 Triflate Thiophenol, THF 
18-crown-6, 
tBuOK (0.50 M) 
−30 oC 65:35 25 
12 Triflate Thiophenol, THF 
18-crown-6, 
tBuOK (0.50 M) 
−55 oC 72:28 48 
 
 
This transformation proved to be particularly challenging as a result of the competing elimination 
reaction.  Both the triflate 202 and the mesylate 186 were easily accessible from alcohol 200 
using standard conditions.  Unfortunately the mesylate proved to be insufficiently reactive, with 
attempted displacement yielding only starting material (Table 9, entry 1).
175
 Attempting the 
displacement using 202 was met with greater success: a preliminary reaction in DMSO and 
85 
 
triethylamine yielded both the desired 203 and the elimination product 204 in a 50:50 ratio, based 
on analysis of the crude 1H-NMR (Table 9, entry 2).
176
  This provided a solid basis for further 
optimisation.  
 
One idea was to pre-form the thiolate using sodium hydride to prevent the base from causing 
elimination (Table 9, entry 3).  However, the sulfur anion was found to be sufficiently reactive to 
cause elimination itself.  Following on from this, different conditions of concentration and 
temperature were evaluated using triethylamine and sodium carbonate as the bases (Table 9, 
entries 4–10).177, 178  From these studies it was generally found that lowering the temperature 
increased the ratio of product to elimination product, with the best conditions utilising a higher 
concentration and triethylamine as the base (Table 9, entry 6).  A final set of conditions using 
potassium tert-butoxide and THF at high concentrations were attempted.  At −55 oC these 
conditions provided the highest yields (Table 9, entry 12).   
 
Having completed the synthesis of thioether 203, it was deemed prudent to validate the 
downstream reactions using this compound as a test system (Scheme 62).  
 
 
 
Scheme 62- Deprotection and functionalization of thioether 203, followed by attempted 
alkylation of lactam 189 with 206. 
 
Silyl deprotection of thioether 203 proceeded smoothly using tetra-n-butylammonium fluoride 
(TBAF) and was followed by iodination of alcohol 205 in good yields using the Appel 
reaction.
179
   Attempted alkylation of the enolate of β-lactam 189 with iodide 206, gave no 
conversion.  Since the focus of this project was the synthesis of 85, with a different thioether in 
place, further attempts at this alkylation were not made. 
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2.2.5   Attempted Synthesis of Thioether 187 
 
Having established conditions to allow the generation of thioethers from triflate 202, attention 
could now be focussed on the synthesis of 187 containing the triphenylmethane-sulfide moiety.   
Chadwick et al. reported the synthesis and isolation of lithium triphenylmethanethiolate co-
ordinated with 15-crown-5, by deprotection of the corresponding mercaptan with n-BuLi under 
strictly anhydrous conditions.
180
  It was hoped this product could be used directly in similar 
conditions to the formation of 203 (Scheme 63).  
 
 
 
Scheme 63- Attempted synthesis of lithium triphenylmethanethiolate 209.
180 
 
 
Unfortunately despite repeated attempts using glovebox techniques and Schlenk equipment to 
ensure the driest conditions isolation of the product was unsuccessful.  As a result, efforts to 
directly react the mercaptan 208 with 202 were made (Table 10).  
 
 
 
Table 10- Attempted reaction of 202 with triphenylmethanethiol. 
 
Entry         Conditions Temperature Result 
 
1 
Triphenylmercaptan, THF 
18-crown-6,
t
BuOK, 
(0.5 M) 
 
 
−55 oC 
 
202 and  
204 
 
 
2 
Triphenylmercaptan,  
Toluene, 15-crown-5,  
n-BuLi, (0.5 M) 
 
 
−55 oC 
 
204 
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Unfortunately, using the conditions established for the reaction of 202 with thiophenol yielded 
only starting material and the elimination product (Table 10, entry 1).  A further attempt made 
using Chadwick’s conditions also produced similar results (Table 10, entry 2).  It is likely that 
the bulky mercaptan is hindering reaction at the triflate preventing any substitution.  Reviewing 
the literature showed similar types of reaction using conditions at reflux.
181, 182
  However these 
are unsuited for this situation as such conditions are likely to favour elimination as well as 
decomposition of the unstable triflate 202.  An alternative method for generating sulfide 187 was 
therefore sought. 
 
2.2.6   Alternative Routes to Thioether 187 
 
It was hoped that reacting 202 with thioacetic acid or a derivative salt, followed by hydrolysis of 
the resulting thioester 210 would provide the free thiol which could then be protected with trityl 
chloride to give the desired sulfide (Scheme 64 and Table 11).   
 
 
 
Scheme 64- Alternative route to thioether 187. 
 
Entry 
 
Conditions Result 
1 KSAc, DMF, 0.15 M 
 
204 
2 KSAc, DMF, −30 
o
C, 0.15 M 
 
204 
3 KSAc, DMF, −55 
o
C, 0.5 M 
 
204 
4 KSAc, THF, 18-crown-6 
−55 oC, 0.5 M 
 
204 
5 AcSH, Cs2CO3 DMF, −55 
o
C, 
0.5 M 
 
204 
 
Table 11- Attempted reaction of 202 with thioacetate salts. 
 
Based on literature precedence, directly reacting 202 with potassium thioacetate was attempted at 
room temperature.
183
  This lead only to elimination (Table 11, entry 1).  Neither decreasing the 
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reaction temperature, nor making use of previously established conditions had any effect on the 
outcome of the reaction (Table 11, entries 2-4).  A final attempt using thioacetic acid and a 
caesium base also resulted in elimination (Table 11, entry 5).
184
  These results suggest that the 
thioacetate anion was insufficiently nucleophilic to favour the desired substitution reaction over 
the competing elimination. 
 
Potassium ethyl xanthate was proposed as more nucleophilic sulfur source and could be reacted 
in a similar fashion to the thioacetate salts (Scheme 64 and Table 12).
185
  
 
Entry 
 
Conditions Result 
1 EtOCS2K, DMF, 0.04 M 
 
204 
2 EtOCS2K, DMF, 0 
o
C, 0.2 M 
 
204 
3 EtOCS2K, DMF, −20 
o
C, 0.04 M 
 
204 
4 EtOCS2K, THF, 18-crown-6 
−10 oC, 0.2 M 
 
204 
5 EtOCS2K, DMF, −40 
o
C, 0.2 M 
 
204 
 
Table 12- Attempted reaction of 202 with xanthate salts. 
 
Initial attempts at room temperature based on literature procedures again resulted in elimination 
(Table 12, entry 1).
185
  It was quickly apparent that decreasing the reaction temperature and 
altering concentration had little effect on the outcome of the reaction, with elimination occurring 
in all cases (Table 12, entries 2-5). 
 
Since substitution reactions on 202 were clearly unviable, a different route to 187 was required.  
It was thought that thionation of ketone 201, followed by reduction of the resulting thioketone 
211 to form the thiol and then trityl protection as previously described would yield the desired 
thioether (Scheme 65). 
 
 
 
Scheme 65- Alternative route to 187 via thioketone 211. 
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A number of attempts were made at the formation of the thioketone 211 making use of both 
Lawessons’ reagent and phosphorous pentasulfide under a variety of reaction conditions (Table 
13).
186, 187 
  
 
Entry 
 
Conditions Reaction Time Result 
        1 P4S10, HMDO, Toluene, 
Reflux, 1.0 M 
                1 h         Decomposition 
 
2 
 
Lawessons’ reagent, 
Toluene, Reflux, 1.0 M 
 
1 h 
 
Decomposition 
 
3 
 
P4S10, Pyridine, Reflux, 0.1 M 
 
1 h 
 
Decomposition 
 
        4 
 
P4S10,  Pyridine, CH2Cl2, 
        Reflux, 0.1 M 
 
 
1 h 
 
 
Decomposition 
 
 
Table 13- Attempted thionation of ketone 201. 
 
Despite a variety of attempts, decomposition was observed in all cases (Table 13, entries 1-4).  
This can be attributable to the presence of enolizable protons alpha to the ketone which allows 
for the formation of dimeric sulphides leading to degradation of the compounds.
188
  
 
Having made numerous unsuccessful attempts at synthesising thioether 187, it was apparent that 
the route being used was not viable.  Thioether 187 either needed to be developed from an 
alternative starting point or perhaps another route for generating the nucleoside altogether was 
required.   Due to time constraints further investigations of this project were not possible. 
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2.3  Conclusion and Further Work   
 
The goal of developing methodology to allow the synthesis of thymidine nucleobase analogues 
by reaction of isocyanates with imidoylketene intermediates, generated from β-lactams, was 
unsuccessful.  Nevertheless efficient syntheses were developed for accessing novel β-lactam 
structures functionalised as sulfoxides, selenoxides and potassium salts 143, 148, 150 and 171 
(Figure 20). 
 
 
 
Figure 20- Novel β-lactam structures synthesised. 
 
Of particular note was isolation of the stable selenoxide 150 due to the rarity of such molecules 
in the literature.  Additionally, while no desired trapping of isocyanates was observed, potassium 
salt 171 may have fragmented to an azetone as evidenced by the isolation of urea 180. 
 
The synthesis of β-lactam nucleoside precursor 193 and hence nucleoside analogues 85 was not 
completed.  Problems were encountered in attempted installation of the sulfide moiety in 
thioether 187 as a result of a competing elimination process.  The route concluded following a 
ten step synthesis of sulfide 206 (Figure 21).  
 
 
 
Figure 21- Sulfide 206. 
 
Looking forward, an alternative method of generating the desired azetone could be through the 
use of a nucleoside precursor such as 213 (Scheme 66).  
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Scheme 66- Alternative method for accessing nucleoside analogues 85. 
 
This method is particularly attractive as 1,3-oxazine-2,4-(6H)-dione 215 is a literature known 
compound and thus the usefulness of the proposed methodology could be easily assessed.  215 is 
readily synthesised from the reaction of maleic anhydride with trimethylsilyl azide (Scheme 
67).
189,
 
190
   
 
 
 
Scheme 67- Synthesis of 215.
189
 
 
Furthermore the corresponding nucleoside of 215 has been synthesised via Vorbrüggen reaction 
with modified ribose sugar 216 by Chwang and Bobek (Scheme 68).
191,
 
192
   
 
 
 
Scheme 68- Synthesis of nucleoside 217 and alternative glycosyl donor thiofuranose 218.
191
 
 
One could therefore envisage that replacement of ribose 216 with benzyl 3,5-di-O-benzyl-2-
deoxy-1,4-dithio-D-erythropentofuranoside 218 would allow access to a thio-nucleoside 
analogous to 213 (Scheme 68).  218 is available in seven steps from 2-deoxy-D-ribose and its use 
as a glycosyl donor in Vorbrüggen reactions is well known.
193
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Finally, there are reported examples using similar compounds to those proposed for the 
formation and reaction of imidoylketenes (Scheme 69).
165
 
 
 
 
Scheme 69- Reported methodology for generating imidoylketenes from 219.
165
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3. Synthesis and Radiolabelling of 2’-Deoxy-2’,2’-difluoro Nucleoside Analogues 
 
3.0  Overview 
 
Outlined in the project aims and objectives (Section 1.4) the synthesis and radiolabelling of two 
2’,2’-difluoro nucleoside analogues 90* and 89* was planned.  It was believed these could be 
obtained from their corresponding protected nucleosides 221β and 222β by iodination, 
stannylation and finally Stille coupling with [
11
C] CH3I as described by Samuelsson et al 
(Scheme 70).
64
 
 
 
 
Scheme 70- Planned synthesis of 90* and 89*, both compounds were expected to be accessible 
via similar methods. 
 
Chou et al. have reported the synthesis of both 221β and 222β from simple starting materials and 
their work was used as a basis for this project.
194
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3.1  Cold Synthesis of dFMAU 90 
 
3.1.1   Synthesis of Protected Glyceraldehyde 225 
 
Chou’s methods made use of 2,3-O-isopropylidene-D-glyceraldehyde 225 as a starting material, 
which can be readily synthesised from D-mannitol (Scheme 71).
195
 
 
 
 
Scheme 71- Synthesis of protected glyceraldehyde 225. 
 
D-Mannitol 226 was easily protected as its diacetonide 227 using acetone and zinc chloride.
195
  
Cleavage of the diacetonide to unstable aldehyde 225 was carried out using silica supported 
sodium metaperiodate as described by Shing et al.  It was reported that simple filtration of the 
reaction mixture yielded products of suitable purity for further reaction; however, this was not 
found to be the case.
196
  Pure aldehyde was hence obtained by distillation of the crude residue as 
reported by Schmid and Bryant.
197
   
 
3.1.2   Synthesis of Ribonolactone 228 
 
Ribonolactone 228 was synthesised in four steps from aldehyde 225 starting with a Reformatskii 
reaction to introduce the key difluoro-moiety (Scheme 72). 
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Scheme 72- Synthesis of ribonolactone 228.
194
 
 
The Reformatskii reaction of ethyl bromodifluoroacetate with 225 presented some difficulties.
198
  
An initial attempt made using zinc dust activated by acetic acid lead to poor conversion.
199
  This 
was rectified by altering the method of activation: stirring with 0.2 equivalents of iodine served 
to fully activate the zinc and lead to satisfying yields of diastereomeric 229.
200
  A 2.3:1.0 ratio of 
trans and cis diastereomers were recovered, which is in agreement with the polar Felkin-Anh 
model. 
 
Benzoylation of alcohol 229 was followed by deprotection of the acetonide 230 under acidic 
conditions. Spontaneous 5-exo-trig cyclisation of the resultant intermediate to 231, under 
aezeotropic distillation is favoured by Baldwin’s rules.  Lactone 231 was further benzoylated to 
give an epimeric mixture of 228, which was recrystallized to furnish exclusively the ribo anomer 
in similar yields to the literature.
194
  
 
 3.1.3   Synthesis of Protected Nucleoside 221β 
 
With sufficient quantities of 228 available, the synthesis was continued with introduction of the 
uracil nucleobase (Scheme 73).   
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Scheme 73- Synthesis of protected nucleoside 221β.194 
 
Ribonolactone 228 was selectively reduced using lithium tri-tert-butoxyaluminum hydride to 
yield lactol 232.  This was subsequently mesylated to furnish 233 in excellent yields over the two 
steps.  Silylated uracil 234 was synthesised by refluxing uracil 14 with hexamethyldisilizane 
(HMDS) in the presence of ammonium sulphate.  234 was directly reacted with mesylates 233 
under the Vorbrüggen protocol to give the blocked anomeric nucleoside.  In an improvement 
from the literature procedure, recrystallization from ethyl acetate then dichloromethane was 
found to give exclusively the desired β-anomer.194   
 
3.1.4   Completion of the Synthesis 
 
The synthesis of 90 was completed by functionalization of the protected nucleoside 221β as a 
stannane followed by Stille coupling with methyl iodide (Scheme 74).   
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Scheme 74- End stage synthesis of 90. 
 
Refluxing 221β with iodine monochloride in CH2Cl2 resulted in starting material recovery.
201
 
Altering iodinating conditions to ceric ammonium nitrate and iodine gave 235 in good yields.
202
  
Removal of the benzoyl protecting groups in 235 using methanolic ammonia was followed by 
coupling of the iodide 223 with hexamethylditin to furnish stannane 224.
104
  Preliminary attempts 
at the Stille coupling of 224 with methyl iodide were unsuccessful resulting in starting material 
recovery.  It was observed that the reported colour change (from purple to deep yellow) 
corresponding to the in situ formation of the bis(tris(2-tolyl)phosphine)palladium (Pd[P(o-tolyl)3]2) 
catalyst was not occurring during the course of the reaction.
64
 This suggested that there were 
issues with the quality of the commercially available tris(dibenzylideneacetone)dipalladium 
(Pd2(dba)3) catalyst.   The catalyst was therefore synthesised from palladium dichloride (PdCl2) 
and dibenzylideneacetone according to the procedures of Ukai et al and recrystallized as its 
chloroform adduct to ensure high purity (Scheme 75).
203
  
 
 
 
Scheme 75- Preparation of the catalyst 237.
203
 
 
Fortunately, this catalyst proved to be sufficiently pure for successful reaction, generating the 
desired product 90.   
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3.2  Radiochemical Synthesis of [
11
C]-dFMAU 90* 
 
3.2.1  Production of Carbon-11 Methyl Iodide 
 
Following the successful synthesis of cold dFMAU preparations were made for the synthesis of 
the radiolabelled nucleoside.  Due to the discontinuation of carbon-11 production at the 
Hammersmith Campus, all radiochemistry was performed with our collaborators at the Wolfson 
Brain Imaging Centre (WBIC), University of Cambridge headed by Dr Franklin Aigbirhio and 
under the supervision of Dr Patrick Riss.  
 
[
11
C] CH3I used in the radiochemical synthesis was produced using the so-called ‘dry method’ by 
radical iodination of [
11
C] CH4 at high temperatures using the GE Medical Systems PET trace 
MeI Microlab instrumentation.  In more detail: [
11
C] CO2 from the cyclotron target is firstly 
adsorbed on molecular sieves in oven A (Figure 22).
204,
 
205
 
 
 
 
Figure 22- Schematic of [
11
C] CH3I synthesis module. VM = valve, OM = oven.
204
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Hydrogen is then released into the system and oven A is sealed and heated, releasing the [
11
C] 
CO2 which is reduced by hydrogen and the nickel catalyst to form [
11
C] CH4.  The [
11
C] CH4 is 
released under a flow of helium into the methyl iodide conversion components of the system 
containing ovens B, C and D.    Iodine is heated to 700 
o
C and vaporised on oven B and is 
reacted with [
11
C] CH4 to form [
11
C] CH3I on oven C.  [
11
C] CH3I is subsequently trapped on the 
adsorbent Porapak polymers in oven D.  Recirculation of [
11
C] CH4 through the system is 
continued until conversion to [
11
C] CH3I is complete.  Finally, any unreacted [
11
C] CH4 is 
released as waste before the trapped [
11
C] CH3I is released and trapped in a solution of DMF 
heating oven D in a stream of helium.
204,
 
205
  
 
3.2.2  Synthesis of [
11
C]-dFMAU 90* 
 
Radiolabelling of 224 using [
11
C] CH3I was successfully carried out according to the procedures 
of Samuelsson et al. to give the novel radiolabelled nucleoside 90* (Scheme 76).
64
 
 
 
 
Scheme 76- Radiolabelling of 224 with [
11
C] CH3I.
64
 
 
When the synthesis was performed manually, decay-corrected radiochemical yields of 16% (n=2) 
and radiochemical purity of >97% (after HPLC) were achieved after reacting for five minutes.  In 
order to minimise contact with radioactivity and perform a more streamlined and efficient 
production, the synthesis was adapted for automation using the GE Tracerlab FXC
®
 synthesis 
module. This resulted in similar radiochemical purity but unfortunately gave lower radiochemical 
yields of 5% (n=3).  This was thought to be a result of blocked filters and tubes during transfer of 
the reaction mixture from the reaction vessel to the HPLC caused by palladium deposits. 
Confirmation of the product identity was performed by spiking a crude analytical sample of the 
radiolabelled material with authentic cold sample of 90 (Figure 23).  
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(A)                               (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23- (A) UV and activity traces for radiolabelled 90* and (B) traces for a sample spiked 
with cold 90. 
 
Further efforts to optimise the synthesis of 90* involved investigations into developing a method 
suited for use with a microfluidic reactor.  Microfluidic syntheses involve the controlled injection 
of reaction components through a network of small channels, typically with 10-500 µm 
dimensions, which form a microfluidic reactor.
206
  Microfluidic systems offer numerous 
advantages which are particularly useful to the PET radiochemist, including:  rate acceleration by 
increased mixing of components and enhanced heat transport as a result of the increased surface 
area (particularly important when considering the short half-lives of PET radionuclides), the 
ability to easily perform reactions using small amounts of reagent (in µM-pM range) as is typical 
in PET syntheses, ease of automation which allows direct integration with HPLC purification for 
example and the small space requirements which allow easier shielding of the user from 
radioactivity.
206, 207
 
 
For these reasons, it was hoped that using the Advion NanoTek
®
 microfluidic system would 
allow for an automated synthesis of the radiolabelled product while also decreasing the reaction 
time.  A variety of conditions were investigated (Table 14).  
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Entry 
 
Temperature (
o
C) Flow Rate (1:1) Result 
1 130 60 µL min
-1
 No Conversion 
2 140 60 µL min
-1
 No Conversion 
3 150 60 µL min
-1
 No Conversion 
4 160 60 µL min
-1 No Conversion 
5 170 60 µL min
-1
 No Conversion 
6 180 60 µL min
-1
 No Conversion 
7 190 60 µL min
-1
 No Conversion 
8 200 60 µL min
-1
 No Conversion 
9 140 30 µL min
-1
 No Conversion 
10 140 25 µL min
-1
 No Conversion 
11 140 20 µL min
-1
 No Conversion 
12 140 15 µL min
-1
 No Conversion 
 
Table 14- Conditions evaluated for the microfluidic radiochemical synthesis of 90*. 
 
Note: Total reactor volume = 30 µL. 
Flow rate corresponds to injection of 
11
CH3I in DMF from one pump and the remaining reaction components in 
DMF from another in a 1:1 mixture. 
 
Initial conditions were based upon those used in the standard radiolabelling reaction to form 90*, 
the difference being the residence time in the reactor (i.e. reaction time) was 15 seconds in 
comparison to five minutes when performed in a vial (Table 14, entry 1).  In this case, no 
conversion of the starting material was observed.  It was thought the problem could be due to 
temperature differences between the reactor and the reaction mixture itself.  The temperature was 
therefore increased incrementally to a maximum of 200 
o
C to no avail (Table 14, entries 2-8).  A 
second line of thought centred on the residency time within the reactor itself, decreasing the flow 
rate leading to an eventual residency time of one minute also did not result in conversion of 224 
(Table 14, entries 9-12).  Aside from the reaction time, the failure to isolate any product could be 
attributed to the lower concentration of reactants caused by the larger surface area of the 
microfluidic system.  Indeed, in Samuelssons’ report, it was noted that lowering the reaction 
concentration gave reduced yields.
64
  Perhaps it is a combination of both the lower reaction 
concentration and reduced reaction time which lead to these results. 
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Despite being unable to isolate any product from the microfluidic synthesis and the relatively low 
radiochemical yields attained from the Tracerlab system, biological testing of radiolabelled 90* 
for TK1 selectivity was nevertheless carried out.  It should be noted that compounds prepared in 
radiochemical yields of less than 5% (decay-corrected) are still suitable for biological studies, as 
such the yield of 90* was less problematic than may be expected.
208
   
 
3.3  Biological Assay of [
11
C]-dFMAU 90* 
 
The assay used to test the activity of 90* for TK1 was developed by Roberta Sala our 
collaborator at the Hammersmith Campus and is adapted from the work of Toyohara et al.
209
  
Briefly, TK1 expressing cells (TK1+) were grown until they achieved 60-70% confluency, 
whereupon they were lysed and suspended in a homogenised buffer suited for reaction.  These 
cells were then incubated with radiolabelled 90* and additional reaction buffer, allowing the 
extent of phosphorylation to be assessed (Table 15). 
 
Entry Conditions* Incubation Time  Phosphorylation 
 (%) 
1 Buffer, 90*, 37 
o
C 
 
40 min 0 
2 Buffer, TK1+ cell lysate, 
90*, 0 
o
C 
 
40 min 0 
3 Buffer, TK1- cell lysate, 
90*, 37 
o
C 
 
40 min 0 
4 Buffer, TK1+ cell lysate, 
90*, 37 
o
C 
 
20 min 0 
5 Buffer, TK1+ cell lysate, 
90*, 37 
o
C 
 
40 min < 1 
6 Buffer, TK1+ cell lysate, 
90*, CIP, 37 
o
C 
 
40 min 0 
 
Table 15- Results for TK1 assay of 90*. 
 
*Each experiment was repeated three times and carried out using 20 µL of cell lysate, 180 µL of buffer (50 mM 
Tris-HCl pH 7.5, 2.5 mM ATP, 2.5 mM MgCl2) and 100 µL of activity (50 MBq in 5 mL).  Experiments performed 
under the guidance of Dr Patrick Riss at the WBIC University of Cambridge. 
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A number of control experiments were carried out in order to validate the results of the assay. 
Negative controls performed with cell lysates not expressing TK1 (TK1-) and with TK1+ cell 
lysates but at 0 
o
C, as expected, resulted in zero phosphorylation of 90* (Table 15, entries 2 and 
3).  A blank experiment containing no cell lysate gave an identical result (Table 15, entry 1).  
Unfortunately, incubation of TK1+ cell lysate with 90* for 20 minutes and 40 minutes resulted in 
minimal phosphorylation of the nucleoside (Table 15, entries 4 and 5).  These results suggest that 
90* is not a substrate for TK1.  A final experiment was performed using standard conditions with 
the addition of the alkaline phosphatase (CIP).  Had a new peak been observed in any previous 
experiments, this would have allowed confirmation that it was a product of phosphorylation. 
 
Since 90* shows no TK1 activity, assays to assess its dCK activity need to be performed.  
Following discussions with our collaborators several other factors were suggested that could 
account for these results:  90* was formulated in 6% EtOH:H2O and low phosphorylation rates 
with non-radioactive samples in EtOH have been observed in the past.  Additionally there might 
be traces of palladium or tin left in the formulation, which could have poisoned the kinase, 
leading to low conversion. 
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3.4  Towards the Synthesis of 5-Methyl-Gemcitabine 89 
 
3.4.1   Modification of the Synthetic Route  
 
With the cold and radiosynthesis of 90 completed, focus was turned to the synthesis and 
radiosynthesis of methylated gemcitabine.  As previously mentioned, it was thought that the 
strategy for generation of this compound would be similar to that used in accessing 90. However, 
in this case a slight modification of the route was required to account for the N4-amine in 89 
(Scheme 77).  
 
 
 
Scheme 77- Proposed synthesis of 89. 
 
Amines are known to be poisons for a number of catalysts including platinum and palladium.
210
  
Consequently, it was envisaged that protection of the N4-amine of 238 would be required to 
prevent catalyst poisoning as well as decrease the chance of other side-reactions with methyl 
iodide and during the palladium catalysed steps.  Indeed, Reddington et al. have reported the 
necessity of such protection in 5-iodo-2’-deoxycytidine for successful Heck reaction with N-
allyl-trifluoroacetamide.
211
 
 
3.4.2   Synthesis of Gemcitabine 84 
 
Making use of mesylate intermediate 233 as a starting point, the synthesis of benzoyl-protected 
gemcitabine were completed according to methods of Chou (Scheme 78).
194
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Scheme 78- Synthesis of gemcitabine 84.
194
 
 
Cytosine was silylated to form 82 by refluxing in HMDS in the presence of ammonium sulfate.  
This was then reacted with mesylate 233 (synthesis described in Scheme 71 Section 3.1.3) using 
the Vorbrüggen reaction to give the blocked anomeric nucleoside 222.  The yield of 222 was 
slightly lower in comparison to the given literature values.
194
  This was thought to be partly due 
to changing solvents from 1,1,2-trichloroethane to 1,2-dichloroethane which meant the reaction 
was performed at a lower temperature and took longer to complete.  Should the reaction be 
repeated 1,1,2-trichloroethane will be used.  Isolation of the desired β-anomer 222β could be 
easily performed by slurrying the anomeric mixture in warm methanol followed by filtration to 
recover the insoluble beta-product.  Basic deprotection of the blocked nucleoside led to almost 
quantitative yields of cold gemcitabine.
194
 
 
3.4.3   Attempted Synthesis of 89 
 
Iodination of the 5-position of cytosine ring proved to be somewhat challenging, requiring a 
variety of conditions to be screened before a suitable method was discovered (Table 16). 
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Table 16- Iodination of nucleosides 222β and 84. 
 
Entry       Starting Material Conditons Yield 
 
1 84 I2, HIO3, AcOH:H2O:CCl4 
(1:0.12:1), 0.13 M, 45 
o
C, 4 h 
 
27% 
2 84 NIS, DMF, 200W, 70 
o
C,  
1.0 M, 10 min 
 
29% 
3 222β I2, HIO3, AcOH:H2O:CCl4 
(1:0.12:1), 0.13 M, 45 
o
C, 4 h 
 
10% 
4 84 I2, HIO3, AcOH:H2O:CCl4 
(1:0.12:1), 0.03 M, 45 
o
C, 4 h 
 
61% 
 
 
Protocols making use of iodine and iodic acid were found to be amongst the most commonly 
used methods for iodinating cytidine and deoxycytidine in the literature.
212
  Unfortunately using 
these conditions with 84 in a mixture of tetrachloromethane, acetic acid and water resulted in 
poor yields of 238 as well as the formation of an unidentified by-product (Table 16, entry 1).  
This side-product proved difficult to separate from 238 using flash silica column chromatography 
and contributed to the low yields.  Using microwave irradiation and N-iodosuccinimde resulted 
in incomplete reaction and poor yields of 238 (Table 16, entry 2).
213
    Cheng et al reported high 
yields for the iodination of cytidine, using iodine and iodic acid, with acetyl protection of the 
alcohol functionalities in place.
214
  Disappointingly attempts at replicating this procedure with 
222β gave low yields of 243 with a number of side products also observed.  A final set of 
conditions whereby a lower concentration was used and purification was performed by 
recrystallization, led to good yields of 238 (Table 16, entry 4).
215
  It is probable that 
recrystallization of the crude mixture from water was the main factor behind the observed 
increase in yield as this negated the need for difficult chromatographic separation of 238 and the 
by-products.  
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With iodide 238 now easily accessible, acetylation of the N4-amine was carried out to ensure the 
nucleoside was suitably functionalised for use with palladium chemistry (Scheme 79).  
 
 
 
Scheme 79- Acetylation of 238.
216
 
 
Efforts to selectively protect the amine with a single equivalent of acetic anhydride, in DMF, 
resulted in incomplete reaction and low yields.
211
  Increasing the equivalents of acetic anhydride 
to a slight excess resulted in a mixture of protected products.  As a result it was decided to 
attempt global protection of 238.  Fortunately this strategy proved to be more successful 
furnishing 244 in adequate yields.
216
  
 
The penultimate step of the synthesis was stannylation of 244 to generate a precursor suitable for 
radiolabelling (Scheme 80). 
 
 
 
Scheme 80- Protodestannylation of 244 to 245. 
 
Attempted stannylation of 244 with hexamethylditin lead mainly to decomposition with 245 the 
product of protodestannylation identifiable by 
1
H NMR.
104
  Unfortunately 245 could not be 
isolated cleanly, although high resolution mass spectrometry allowed confirmation of its identity.  
The replacement of hexamethylditin with the more sterically encumbered and less reactive 
bis(tributyltin) was suggested as a means of avoiding this problem.  However, with only small 
quantities of precursor 222β available and other projects showing promising developments, as 
well as providing possible alternative solutions to the problems of radiolabelling deoxycytidine 
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analogues, it was decided to switch focus to these assignments with the possibility of revisiting 
the stannylation reaction in the future. 
 
3.5  Conclusion and Further Work 
 
The synthesis and radiolabelling of the novel nucleoside analogue 90* was successfully 
completed in 14 steps, making use of a Stille coupling to introduce the radiolabel (Figure 24). 
 
 
 
Figure 24- Novel radiolabelled nucleoside 90*. 
   
Despite proving not to be a substrate for TK1, 90* could still prove to be useful for PET 
applications should it show activity for dCK.  It is hoped assays for dCK will be performed in the 
future in order to assess this probes utility. It must also be noted that carrying out the 
radiosynthesis of 90* in a clinical PET lab meant only intermittent visits to Cambridge were 
possible.  As a result of the sporadic nature of this work, as well as the departure of the authors’ 
primary laboratory supervisor, the specific activity of 90* remains uncalculated.  Should the 
probe prove useful in other assays and carbon-11 production facilities remain unavailable at 
Hammersmith Hospital, further collaborations will need to be established in order to calculate 
this value. 
 
Attempted synthesis of 5-methyl-gemcitabine concluded with an unexpected protodestannylation 
reaction yielding 245 during efforts to form stannane 244 (Figure 25).   
 
 
 
Figure 25- 245 product of protodestannylation. 
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Potential solutions to a number of the challenges experienced in the syntheses of these 
nucleosides were identified in work which is discussed in the following chapter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
4. 2’-Deoxy-2’,2’-difluoro Nucleoside Analogues for Radiolabelling with Fluorine-18 and 
other Biomedical Applications 
 
4.0  Overview 
 
4.0.1  Alternative Radiolabelling Strategies for 2’,2’-difluoro Nucleosides  
 
One of the main problems encountered during radiosynthesis of 90* was not specifically a 
synthetic challenge but rather the lack of carbon-11 production facilities locally.  The ability to 
synthesise 2’-deoxy-2’,2’-difluoro nucleosides analogues suitable for radiolabelling with 
fluorine-18 was desirable for two reasons: firstly, it would allow use of the fluorine-18 services 
available at Hammersmith Hospital and secondly, it would also provide a radiolabelled 
nucleoside with a substantially longer half-life.  
 
With this in mind, a deoxyuridine-nucleoside analogue hydroxymethylated in the 5-position was 
proposed as a suitable precursor for fluorination (Scheme 81).  
 
 
 
Scheme 81- Proposed route to a [
18
F]-dFMAU analogue 248. 
 
Hydroxymethylation of uracil bases using a KOH (aq) solution and para-formaldehyde was first 
reported with full characterisation by Cline et al. in the 1950s.
217
  Since then there have been a 
number of reports describing the use of this reaction and its modifications with varying degrees 
of success.  Recent examples include the hydroxymethylation of uracil, uridine and deoxyuridine 
analogues by Gavriliu, Chung, Hudson and Dai.
218, 219, 220, 221 
 If a nucleoside such as 247 could 
be accessed then functionalization of the alcohol as a tosylate followed by displacement with 
[
18
F]-KF would provide a viable strategy to accessing a [
18
F] labelled analogue of dFMAU 90. 
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4.0.2  2’,2’-difluoro Nucleoside Analogues for Other Biomedical Applications 
 
The synthesis of 247 would also present the opportunity for the synthesis of a variety of other 
nucleoside analogues with chemically interesting structures and potentially useful biological 
properties (Figure 26). 
 
 
 
Figure 26- 2’-Deoxy-2’,2’-difluoro nucleoside analogue targets. 
 
Nucleoside reverse transcriptase inhibitors have revolutionised the treatment of HIV/AIDS 
(human immunodeficiency virus/acquired immunodeficiency syndrome) since their introduction 
in the late 1980s.
222
  Azidothymidine (AZT) 254 in this respect is a pioneer for this class of drug 
molecule and remains clinically relevant today (Figure 27).   
 
 
 
Figure 27- AZT.
222
 
 
The success of AZT can be attributed to its high selectivity for HIV reverse transcriptase in 
comparison to DNA polymerase as well as the presence of the azido group which permits facile 
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crossing of phospholipid bilayers as well as the blood brain barrier.
223,
 
224
  An AZT analogue 
such as 249 could perhaps mimic some of the interesting properties of this drug.  Starting from 
247, azide 249 should be relatively simple to synthesise using the methods of Seio et al. (Scheme 
82).
225
 
 
 
 
Scheme 82- Proposed synthesis of AZT analogue 249. 
 
[
18
F]-FOT 255 is a nucleoside analogue previously described in our group with potential use in 
the imaging of proliferation in cancer.
226
   During the synthesis a Huisgen cycloaddition was used 
to introduce the triazole functionality (Figure 28).  
 
 
 
Figure 28- [
18
F]-FOT.
226
 
 
Assuming the synthesis of the protected azide 256 (Scheme 82) was successful, the opportunity 
to carry out a Huisgen cycloaddition to generate the corresponding nucleoside triazole analogue 
252 would become available (Scheme 83).  
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Scheme 83- Proposed synthesis of [
18
F]-FOT analogue 252.  
 
The cold synthesis and radiosynthesis of 252 would be a logical step in assessing the utility of 
nucleosides bearing the triazole functionality as PET proliferation markers for cancer. 
 
Covalently linked bivalent nucleosides have also shown potential for use in several areas, 
including: combined allosteric and direct inhibition of HIV reverse transcriptase, the study of 
DNA repair mechanisms and as inhibitors of ribonucleotide reductase (an important target for 
chemotherapeutic agents).
227,
 
228,
 
229
   Using 247 and a simple linker would provide a means of 
accessing these types of structure, with the addition of the difluoro-moiety, in the form of 
dinucleoside 250 (Scheme 84).   
 
 
 
Scheme 84- Proposed synthesis of dinucleoside analogue 250. 
 
Optical imaging techniques such as fluorescent imaging (see Section 1.0.2 for a greater 
discussion of optical imaging techniques) have applications for in vitro cellular imaging and in 
fluorescence based assays.
230
  Labelling 247 with dansyl chloride, for example, could provide 
another means of evaluating the usefulness of 2’-deoxy-2’,2’-difluoro nucleoside analogues for 
imaging tumours (Scheme 85). 
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Scheme 85- Proposed syntheses of dansylated nucleoside 251. 
 
Finally, the modified nucleoside analogue 5-(β-D-glucopyranosyloxymethyl)-2’-deoxyuridine 
258 is expressed by a number of Kinetoplastida protozoa including the parasites Trypanosoma 
Brucei and Leishmania which cause the diseases sleeping sickness and Leishmaniasis.
231
 It has 
been demonstrated that 258 is essential for the survival of the Leishmania parasite, although its 
function has yet to be unambiguously determined.
231
  Synthesis of 258 was carried out by de Kort 
et al. with the aims of evaluating the biological and physical effects of incorporating this 
nucleoside into DNA in order to further understand its function.
232
   Generation of a similar 
analogue could be used to complement these studies (Scheme 86).    
 
 
 
Scheme 86- Proposed synthesis of glycosylated nucleoside 253.
232
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4.1  Synthesis of Hydroxymethylated Nucleoside 270β  
 
4.1.1  Trial Reactions with Uracil 
 
In order to verify the suitability of the hydroxymethylation procedure, trial reactions were carried 
out with uracil (Table 17). 
 
 
 
Table 17- Trial reactions with uracil. 
 
Entry Conditions Yield  
 
1 (CH2O)n, 0.5 N KOH (aq) 
60 
o
C, 72 h 
 
66% 
2 (CH2O)n, 0.5 N KOH (aq) 
200 W, 90 
o
C, 2 h 
 
58% 
3 (CH2O)n, NEt3, H2O 
60 
o
C, 16 h 
 
73% 
 
 
Stirring uracil with para-formaldehyde in 0.5 N KOH (aq) according to the protocol described by 
Cline gave the product in 66 % yield (Table 17, entry 1).
217
 Abdel-Raham et al. reported an 
improvement of this procedure using microwave heating and higher temperatures to dramatically 
accelerate the reaction; these conditions allowed the generation of 259 in two hours, albeit in 
reduced yields (Table 17, entry 2).
233
  The final conditions investigated used triethylamine in 
water in place of 0.5 N KOH (aq) and gave the best yields of 259 after stirring for 16 hours 
(Table 17, entry 3).
220
  It was decided to adopt these conditions for future endeavours as they not 
only gave best yield, but also had the simplest purification avoiding the use of acidic resins as in 
the previous examples (Table 17, entries 1 and 2).
217,
 
233
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4.1.2  Attempted Hydroxymethylation of Nucleosides 
 
Having established the most suitable method for hydroxymethylation of uracil, the reaction could 
now be used for the synthesis of a nucleoside analogous to 247 (Scheme 87). 
 
 
 
Scheme 87- Hydroxymethylation of 260.
220
 
 
The reaction was firstly attempted on the free nucleoside 260.  It was found that acetonitrile was 
required in addition to water in order to maintain full solubility of the reactants.
221
  Yields for this 
step were poor and completion required heating for 72 hours.  Nevertheless, 261 could be 
isolated and it was hoped that further attempts would prove to be more successful (Scheme 88).   
 
 
Scheme 88- Hydroxymethylation of 262. 
 
260 was firstly protected as its methoxymethyl ether 262.
234
  Protection was necessary to allow 
differentiation between the primary hydroxyl groups following hydroxymethylation, to permit 
further functionalization. A MOM protection was chosen as it would be stable to the reaction 
conditions while also ensuring the molecule was sufficiently polar to maintain solubility.  The 
protected nucleoside 262 was further reacted to furnish 263 along with small amounts of an 
inseparable side product, a result corroborated by the reports of Chung et al.
235
  Unfortunately 
yields for this reaction were also poor.  Attempts made using the other conditions outlined in 
Table 17 gave similarly low yields.  
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With small quantities of the hydroxymethylated nucleoside 263 available it was deemed prudent 
to utilise this material to trial the synthesis of one of the desired analogues.  In this case 
introduction of the dansyl group, considered to be the simplest transformation, was performed 
(Scheme 89). 
 
 
 
Scheme 89- Attempted synthesis of dansylated analogue 251. 
 
Dansylation of 263 furnished 264 in low yields.
236
  This was attributed to the presence of 
impurities from the previous step.  Nonetheless, sufficient material was recovered to allow 
attempts to be made at deprotection on a small scale (Table 18). 
 
Entry Conditons Result 
 
1 MgCl2, n-PrSH, 
CH2Cl2, 0.5 M 
Starting 
Material 
 
2 ZnCl2, n-PrSH, 
CH2Cl2, 0.5 M 
Starting 
Material 
 
3 ZnBr2, n-PrSH, 
CH2Cl2, 0.5 M 
Starting 
Material 
 
4 6.0 N HCl, THF, 
0.5 M 
 
Epimerisation 
 
Table 18- Attempted deprotection of nucleoside 264. 
 
Unfortunately despite trying numerous conditions removal of the methoxymethyl ether groups of 
264 proved to be unsuccessful.  Initial efforts using milder conditions with a variety of Lewis 
acids and 1-propanethiol yielded only starting material (Table 18, entries 1, 2 and 3).
237
 Making 
use of harsher conditions resulted in epimerisation of the nucleoside (Table 18, entry 4).
238
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As a result of the poor yields for the hydroxymethylation step and difficulties in removing the 
methoxymethyl ether protecting groups, it was clear a different approach to generating large 
quantities of an intermediate analogous to 247 needed for synthesis of the desired analogues was 
required. 
 
4.1.3  Alternative Routes to Hydroxymethylated Nucleosides 
 
Dai et al. also reported difficulties when attempting hydroxymethylation on a similar protected 
nucleoside system.  As a solution they performed a palladium catalysed carbonylation on a 5-
iodo-nucleoside precursor, followed by Luche reduction to the corresponding primary alcohol.
221
  
Inspired by these results attempts were made to apply this protocol to the generation of a 
nucleoside similar to 247 (Scheme 90).  
 
 
 
Scheme 90- Attempted carbonylation of 265.
221
 
 
The synthesis started with protection of iodide 223 (reported in section 3.1.4) using 1,3-dichloro-
1,1,3,3-tetraisopropyl disiloxane (TIPDSCl) proceeding in a good yield.
239
  Unfortunately 
attempts at carbonylation led to incomplete reaction as well as the production of a number of 
side-products which prevented clean isolation of the desired material. Dai et al. reported the 
carbonylation using 50 psi of carbon monoxide.
221
  These pressures could not be attained using 
the available equipment and was cited as a probable cause for the incomplete reaction.     
 
Reviewing the literature revealed other alternative strategies for accessing hydroxymethylated 
nucleosides akin to 247 including photochemical mono-bromination of thymidine nucleosides 
followed by hydrolysis.
240
  However, since the original reactions with uracil (Table 17) were 
high yielding and did not require the use of specialist equipment it was decided to revisit these 
and use a different approach to incorporating this moiety. 
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Brulíková and Uchida described the synthesis of nucleotide analogues modified in the 5-position 
by pre-functionalization of the nucleobases used in the Vorbrüggen reaction.
241,
 
242
  Encouraged 
by these reports attempts were made at directly using 5-hydroxymethyluracil 259 with the 
mesylate precursor  233 (Scheme 91).   
 
 
 
Scheme 91- Attempted Vorbrüggen reaction of 266 and 233.  
 
Silylation of this 259 and subsequent coupling with mesylates 233 (see Section 3.1.3 for 
synthesis) was unsuccessful.  Zhang et al. also reported problems with this transformation on 
similar nucleosides, citing solubility issues of 266 during the glycosylation.  Silyl protection of 
259 prior to coupling was purported to alleviate these difficulties (Scheme 92).
243
 
 
 
 
Scheme 92- Vorbrüggen glycosylation of 268 and 233.
243
 
 
Protection of 259 with tert-butyldiphenylsilyl chloride (TBDPSCl) and subsequent silylation 
with HMDS proceeded smoothly to furnish 268.  Coupling of 268 with mesylates 233 gave the 
desired nucleoside 269 as a mixture of anomers.  Separation of the anomers proved to be 
difficult. Only partial separation was possible by column chromatography and re-crystallisation 
was not possible.  Based on the crystallisation of similar nucleosides in the literature, it was 
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hoped that removing the bulky non-polar TBDPS group would render the nucleoside more 
susceptible to re-crystallisation (Scheme 93).
244
  
  
 
Scheme 93- Deprotection of 269 and separation of the anomers. 
 
Unexpectedly deprotection of 269 using excess of TBAF lead to epimerisation of the nucleoside 
giving rise to a one-to-one anomeric mixture.
245
    This could be rationalised by the presence of 
water in the TBAF solution, which would lead to the formation of HF and this could in turn 
cause the observed epimerisation.  Indeed, Hogrefe et al. have reported the presence of 
significant quantities of water even in newly purchased bottles of TBAF.
246
  Pleasingly, 
recrystallization of the anomeric mixture from chloroform allowed complete separation of the 
anomers.  The identity of the β-anomer was ascertained by 2D-NOESY experiments (see 
Supporting Data).  Further confirmation of this assignment was obtained by deprotection of 270β 
to 261 and comparison of the NMR data with that of an authentic sample of 261 formed from 
literature known compounds. (Scheme 87, Section 4.1.2).   
 
Using this route, multi-grams quantities of 270β could be made rapidly and efficiently, thus 
permitting continued efforts into synthesis of the desired analogues (Figure 24). 
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4.2  Synthesis of 2’-Deoxy-2’,2’-difluoro Nucleoside Analogues 
 
4.2.1  Synthesis of Fluorinated Nucleoside 271  
 
The fluorinated nucleoside analogue 271 was the primary target in the hope that a rapid 
turnaround of the ‘cold’ compound would give sufficient time for radiochemistry to be 
performed.  As outlined previously (Scheme 79 Section 4.0.1) functionalization of 270β with a 
suitable leaving group was to be followed by displacement with fluoride (Table 19). 
 
 
 
Table 19- Synthesis of protected fluorinated nucleoside 271. 
 
Entry Conditions Result 
1 Tf2O, Pyridine, THF, 
−78 oC to 0 oC 
 
Decomposition 
2 TsCl, Pyridine, THF 
 
Decomposition 
3 DAST, THF, −15 oC  
 
271, 35% 
 
 
Unfortunately efforts at forming the tosylate and triflate of 270β resulted in decomposition 
(Table 19, entries 1 and 2).
247
  It was thought this could be due to reaction through the 
unprotected uracil amide of 270β, a process which was also evident in the protection of 260 with 
MOMCl (Scheme 86 Section 4.1.2).  Furthermore, reaction at this position is known in the 
literature an example being in the synthesis of [
18
F]-FOT.
226
  The use of fluorinating reagents 
such as diethylaminosulfur trifluoride (DAST) was suggested as alternative method for 
producing the desired nucleoside.  DAST was the reagent of choice as the synthesis of [
18
F]-
DAST has been reported in the literature meaning this protocol would be translatable to a 
radiochemical synthesis.
248
  Fluorination of 270β using DAST under standard conditions was 
successful (Table 19, entry 3).
249
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The final step of the synthesis was deprotection of the benzoyl groups in 271 using ammonia in 
methanol, unfortunately this lead to the isolation of amine 272 (Scheme 94).   
 
 
 
Scheme 94- Attempted deprotection of fluorinated nucleoside 271. 
 
It was proposed that the uracil system was causing activation of the primary fluoride of 271 
increasing its lability and permitting displacement by ammonia to give 272.  Additional attempts 
at deprotection gave similar results, lending further credence to this hypothesis (Table 20).   
 
Entry Conditions Result 
1 K2CO3, MeOH 273 76% 
2 K2CO3, EtOH 274 72% 
3 K2CO3, 
i
PrOH Starting material 
 
Table 20- Attempted deprotection of 271.  
 
Using potassium carbonate with methanol and ethanol furnished the deprotected methyl (273) 
and ethyl (274) of ethers of 270β respectfully (Table 20, entries 1 and 2).250  A final attempt 
using isopropanol as the solvent yielded starting material.  In this case steric hindrance appears to 
have prevented any reaction. (Table 20, entry 3).  
 
From these results it was clear that a different protecting strategy was needed as basic 
deprotection resulted in substitution of the fluoride group.  Future endeavours could make use of 
acid sensitive trityl or acetyl protecting groups to prevent the unwanted substitution reactions. 
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4.2.2  Synthesis of AZT and FOT Analogues 249 and 252 
 
The AZT analogue 249 was easily synthesised in three steps from 270β (Scheme 95). 
 
 
 
Scheme 95- Synthesis of AZT analogue 249.
225
 
 
Hydroxymethylated nucleoside 270β was converted to the chloride and then displaced with 
sodium azide as described by Seio et al to give 276 in a good yield over two steps.
225
  Cleavage 
of the benzoyl groups in 276 yielded the desired AZT analogue 249 in an excellent yield.  With 
azide 276 readily available the synthesis of FOT analogue 252 was carried out (Scheme 96). 
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Scheme 96- Synthesis of FOT analogue 252.
226
 
 
Using standard copper catalysed azide-alkyne cycloaddition conditions with 276 and 3-butyn-1-
ol, triazole 277 was generated in a 54% yield.
226
  Having proven useful in previous efforts, 
DAST was used for fluorination to form 278; this was followed by basic de-protection to give the 
final compound 252.  Yields for the final two steps were relatively low: 21% and 34% 
respectively.  However, this was not of great concern as these steps were performed using small 
quantities of material (less than 10 mg of 278 was used in the de-protection) and it is believed 
that yields would see improvement on scale-up.   
 
Having completed the synthesis of 252, efforts were made to develop a route more suitable for 
radiochemistry.  [
18
F]-DAST may be synthesised; however the specific activity of this reagent is 
comparatively low therefore the use of [
18
F] fluoride is preferable.
248
  An alternative strategy was 
proposed involving synthesis of a tosylate analogue of 277. (Scheme 97)  
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Scheme 97- Synthesis of radiochemical precursor 281.
251
 
 
Having experienced problems in forming the tosylate of 270β (Table 19 Section 4.2.1) the 
decision was made to introduce the tosyl functionality at earlier stage of the synthesis;  as such, 
3-butyn-1-ol 279 was reacted with tosyl chloride to form 280, which was used directly in the 
Huisgen cycloaddition with 276.
251
  Tosylate 281 was recovered in good yields, providing a 
suitable precursor for radiochemical synthesis of 252.  
 
4.2.3  Synthesis of Dansylated and Dinucleoside Analogues 250 and 251 
 
It was originally envisaged that dansylation of 270β would allow easy access to analogue 250 
(Scheme 85).  However, bearing in mind the previously encountered problems when attempting 
to functionalise the primary alcohol of 270β as well as the issues in deprotection of fluoride 271 
(Scheme 94 Section 4.2.1), it was decided instead to convert 270β  to the corresponding amine.  It 
was hoped that replacement of the alcohol with an amine, followed by reaction with dansyl 
chloride would provide the more stable sulfonamide functionality.  The required amine was 
accessible by reduction of azide 276 (Table 21). 
 
 
 
Table 21- Reduction of 276 to amine 282. 
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Entry Conditions Result 
1 H2, Pd/C, MeOH, 60 
o
C Debenzoylation 
2 H2, Pd/C, 1,4-dioxane, 60 
o
C  14% 
3 PPh3, THF-H2O 74% 
 
 
Problems were encountered when attempting reduction of 276 by hydrogenation.  Heating 276 
with methanol (to ensure solubility) and palladium on carbon under hydrogen gave a number of 
side products with displacement of the benzoyl protecting groups evident (Table 20, entry 1).
252
  
Altering the solvent to 1,4-dioxane, in which 276 was fully soluble,  in an effort to alleviate these 
problems gave a sluggish reaction that did not fully complete (Table 20, entry 2).  Fortunately, 
reduction using Staudinger methodology provided a mild procedure for accessing the desired 
amine in good yields (Table 20, entry 3).
253
 With 282 now in hand synthesis of the dansylated 
analogue was completed. (Scheme 98) 
 
 
 
Scheme 98- Synthesis of dansylated analogue 284.
236
 
 
Pleasingly reaction of 282 with dansyl chloride proceeded smoothly to furnish 283.
236
  The 
sulfonamide linkage also ensured that displacement by ammonia during deprotection did not 
occur yielding exclusively 284.  
 
With some quantity of amine 282 remaining from endeavours towards 284, the opportunity for 
synthesis of a bivalent nucleoside analogous to 251 was apparent (Scheme 99). 
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Scheme 99- Synthesis of bivalent nucleoside analogue 285. 
 
Two equivalents of 282 were reacted with a single equivalent of CDI to generate the di-
nucleoside 285.
254
  The urea linkage in 285 also proved stable to deprotection using the standard 
conditions to give the final product 286.  
 
4.2.4  Synthesis of Glycosylated Nucleoside Analogue 253  
 
The final target was the glycosylated nucleoside 253.  De Kort et al. reported the synthesis of a 
similar analogue 258 (Scheme 86 Section 4.0.2) by glycosylation of a hydroxymethylated 
nucleoside using modified D-glucose.
232
 This methodology would be the basis for our synthesis.  
The glycosyl donor was firstly synthesised according to the procedure of Sjölin et al. (Scheme 
100).
255
 
 
 
 
Scheme 100- Synthesis of glycosyl donor 288.
255
 
 
D-glucose was fully protected using benzoyl chloride to furnish 287.  This was then transformed 
using hydrobromic acid to form the glycosyl donor 288.
255
  The next step was to use 288 for 
Koenigs-Knorr glycosylation of nucleoside 270β (Table 22). 
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Table 22- Attempted glycosylation of nucleoside 270β with 288. 
 
Entry Conditions Result 
1 AgOTf, 3Å MS, MeCN Starting material 
2 Hg(CN)2, HgBr2, MeCN Starting material 
 
 
In de Korts’ report glycosylation was performed using mercury bromide and mercury cyanide.232  
In order to avoid using these highly toxic reagents and alternative protocol was identified using 
silver triflate as the promoter; unfortunately only starting material was recovered under these 
conditions (Table 21, entry 1).
255
  Returning to the Helferich reaction also only yielded starting 
material (Table 21, entry 2). 
 
It was decided to investigate the use of different glycosylation methods with different donors and 
so acetimidate 290 was synthesised (Scheme 101). 
 
 
 
Scheme 101- Synthesis of alternative glycosyl donor 290.
256
 
 
Selective deprotection of benzoyl protected glucose 287 using methylamine gave an anomeric 
mixture of glucopyranose 289.  Further reaction of 289 with trichloroacetonitrile furnished 
acetimidate 290 in good yields.
256
  With 290 in hand Schmidt glycosylation of 270β could be 
attempted (Scheme 102). 
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Scheme 102- Synthesis of glycosylated nucleoside 253.  
 
Pleasingly, making use of TMSOTf as the promoter gave 291 in good yields.
232
   Deprotection 
using ammonia in methanol yielded the final product 253.  
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4.3  Conclusion and Further Work 
 
Adapting the methods of Uchida and Zhang led to the development of a route permitting the 
facile generation of multiple gram quantities of hydroxymethylated nucleoside 270β.242, 243  By 
performing hydroxymethylation of uracil at an early stage of the synthesis, the somewhat 
cumbersome hydroxymethylation of nucleosides, which tend to lead to low yields, was avoided 
(Scheme 103).  
 
 
 
Scheme 103- Route to nucleoside 270β. 
 
It was also demonstrated that hydroxymethylated nucleoside 270β can be used for the synthesis 
of a diverse array of structures (Figure 29). 
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Figure 29- Nucleoside analogues synthesised. 
 
While problems were encountered in deprotection of the fluorinated analogue 271, it is believed 
that altering the protecting groups to avoid the use of basic deprotection would allow access to 
the final product.  Inspiration can be taken from the radiosynthesis of [
18
F]-FLT which makes use 
of the acid labile trityl protecting group (Scheme 21 Section 1.3.2.1).
95
  If these issues can be 
overcome radiolabelling with [
18
F]-DAST would be the logical next step.  Furthermore, this 
synthesis could be adapted for use in generating a similarly labelled dFdc analogue, which would 
provide a suitable solution to issues highlighted in the conclusion of chapter three (Section 3.5) 
(Figure 30). 
 
 
 
Figure 30- dFdc analogue 292. 
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The AZT analogue 249 could now be tested to determine its usefulness as an inhibitor of HIV 
reverse transcriptase.  In the case of the dimer 286, the synthesis acted as a proof of concept 
showing how these nucleosides can be linked together.  Further studies could focus on linking 
different nucleosides together and examining their properties as combined direct and allosteric 
inhibitors of HIV reverse transcriptase.  
 
Generation of the protected azide 276 permitted the synthesis, via a Huisgen cycloaddition, of 
252 an analogue of the PET tracer FOT (Scheme 104).
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Scheme 104- Synthesis of triazole nucleoside analogue. 
 
Having completed the synthesis of the cold compound and its tosylated precursor 281, future 
endeavours should focus on adapting this molecule for radiochemical synthesis by using [
18
F]-
KF to displace the tosylate.   
 
Dansylation to form 284 provided further demonstration of the diverse range of structures that 
can be formed from 270β.  Incorporation of other fluorophores such as rhodamine and 
fluorescein derivatives could be followed by an investigation of the use of these molecules for in 
vitro imaging (Figure 31).
230
 
 
 
 
Figure 31- Fluorescein labelled nucleoside. 
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Finally glycosylated analogue 253 was synthesised by Schmidt glycosylation of 270β using 
modified glucose.  As previously mentioned this molecule could be used to complement studies 
assessing the function of 258 and its role in Kinetoplastid protozoa.
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Experimental 
 
All chemicals were used as received or purified using standard procedures. Solvents were dried 
by standard techniques and distilled under nitrogen before use.  Tetrahydrofuran was distilled 
from sodium with benzophenone indicator. Toluene was distilled from sodium. Dichloromethane 
and methanol were distilled from calcium hydride. N,N-Dimethylformamide, dimethylsulfoxide, 
aceonte, 1,4-dioxane, acetonitrile, 1,2-dichloroethane, ethanol, tert-butanol, benzene  and o-
xylene were purchased anhydrous and used as received. All experiments were carried out in 
oven-dried glassware under an inert atmosphere of nitrogen or argon. 
 
Analytical thin layer chromatography (TLC) was performed using pre-coated Merck aluminium 
or glass backed plates (Silicagel 60 F254). Visualization was by ultraviolet light (366 nm and 
254 nm) and/or treatment with potassium permanganate or vanillin stains followed by heating as 
appropriate.  Flash column chromatography was carried out on Merck 9385 Kieselgel 60 (230-
400 mesh).  
 
NMR spectra were recorded on a Bruker DRX-400 spectrometer using an internal deuterium lock 
at ambient probe temperatures.  Alternatively, spectra were recorded at 500 MHz (
1
H NMR) and 
125 MHz (
13
C NMR) by the NMR Service, Imperial College London, Department of Chemistry. 
Chemical shifts () are quoted in parts per million (ppm) and are referenced to a residual solvent 
peak.  Coupling constants (J) are quoted in Hertz (Hz) to the nearest 0.1 Hz.  Assignments were 
determined on the basis of unambiguous chemical shift and coupling pattern. Additional 
experiments (COSY, DEPT-135, HSQC, HMBC and NOESY) were used to aid assignments but 
are not included. 
 
Low and high resolution mass spectrometry (EI, CI, ESI) were recorded by the Mass 
Spectrometry Service, Imperial College London, Department of Chemistry using a Micromass 
Platform II and Micromass AutoSpec-Q spectrometer. 
 
Microanalyses were determined at London Metropolitan University Microanalysis Service. 
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Infra-red (IR) spectra were obtained using a Perkin-Elmer Spectrum BX II FT-IR System 
monitoring from 4000-700 cm
-1
, with automatic background subtraction.  All samples were run 
neat.  Absorption maxima are reported in wave numbers (cm-1). 
 
Melting points were obtained on a Reichert-Thermovar melting point apparatus and are 
uncorrected.  
 
Optical rotations were measured at 25 °C on a Perkin-Elmer 241 polarimeter with a path length 
of 1 dm, using a sodium lamp (λ = 589 nm, D-line); [α]D
25
 values are reported in 10
-1
 deg cm
2
 g
-1
 
and concentrations (c) are quoted in g/100 mL. 
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Results and Discussion Section 2. 
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1-[tert-Butyl(dimethyl)silyl]azetidin-2-one 141 
 
 
 
A solution of DIPEA (3.7 mL, 21.2 mmol) in CH2Cl2 (8 mL) was added dropwise to a solution of 
2-azetidinone (1.00 g, 14.1 mmol) and tert-butyldimethylsilylchloride (2.44 g, 16.2 mmol) in 
CH2Cl2 (12 mL)  and the reaction mixture stirred for 24 hours at room temperature.  The solvent 
was then removed in vacuo and the resulting residue partitioned between Et2O (30 mL) and H2O 
(15 mL), aqueous layer extracted with Et2O (3 × 30 mL).  The combined organic layers were 
dried over MgSO4 and concentrated in vacuo to yield the crude product. The crude product was 
purified using flash silica column chromatography (20% EtOAc in 40-60 petroleum ether) to 
give the product (2.32 g, 89%) as a colourless oil. 
The data were in agreement with the published data.
140
 
 
1
H-NMR (400 MHz, CDCl3): H = 0.23 (s, 6H
4+5
), 0.95 (s, 9H
7
), 3.06 (t, 2H
3
, J=4.6Hz), 3.18 (t, 
2H
1
, J=4.6Hz). 
 
13
C-NMR (400 MHz, CDCl3):  C = -6.2 (C-4,5), 18.5 (C-6), 26.0 (C-7), 36.7 (C-1), 39.0 (C-3), 
172.9 (C-2). 
 
MS (ES+) m/z = 186 [M+H]
+
. 
 
 
1-(tert-Butyldimethylsilyl)-3-(phenylthio)azetidin-2-one 142 
 
 
 
To a solution of diisopropylamine (2.5 mL, 17.8 mmol) in THF (30 mL) at 0 
o
C was added 1.0 M 
n-BuLi in hexanes (17.8 mL, 17.8 mmol) and the resulting solution stirred for 30 minutes at 0 
o
C.  
The solution was then cooled to −78 oC and added dropwise to a –78 oC solution of β-lactam 141 
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(2.2 g, 11.9 mmol) and diphenyl disulfide (2.86 g, 13.1 mmol) in THF (70 mL). The reaction 
mixture was allowed to slowly warm to room temperature overnight and then poured into 
saturated NH4Cl (aq) (180 mL) and extracted with CH2Cl2 (180 mL).  The organic layer was 
separated and washed with H2O (3 × 60 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified using flash silica column chromatography (5% EtOAc in 40-60 
petroleum ether) to yield the product (1.64 g, 47%) as a white solid. 
 
1
H-NMR (400 MHz, CDCl3): H = 0.10 (s, 3H
4/5
), 0.11 (s, 3H
4/5
), 0.80 (s, 9H
7
), 3.02 (dd, 1H
3
, 
J=6.4Hz, J=3.0Hz), 3.53 (m, 1H
3
), 4.41 (dd, 1H
1
, J=5.7Hz, J=3.0Hz), 7.31 (m, 3H-Ar), 7.55 (m, 
2H-Ar).   
 
13
C-NMR (400 MHz, CDCl3): C = -6.3 (C-4,5), 18.3 (C-6), 25.7 (C-7), 44.4 (C-3), 53.3 (C-1), 
128.2 (CH-Ar), 129.1 (CH-Ar), 131.4 (C-8), 133.7 (CH-Ar), 171.1 (C-2). 
 
IR vmax (neat) = 2943, 2924, 2856, 1729 cm
-1
 
 
MS (ES+) m/z = 294 [M+H]
+
. 
HRMS (ES+) calculated 294.1348 for C15H24NOSSi, observed 294.1354 [M + H]
+
. 
 
mp (CH2Cl2)= 68-70 
o
C. 
 
 
1-(tert-Butyldimethylsilyl)-3-(phenylsulfinyl)azetidin-2-one 143 
 
 
 
To a mixture of 142 (100 mg, 0.12 mmol), Ac2O (36 µL, 0.38 mmol) and SiO2 (68 mg) in 
dichloromethane (1.7 mL) was added 30% H2O2 (aq) (41 µL, 0.41 mmol).  The reaction mixture 
was stirred for 36 hours at room temperature then filtered through a sintered funnel and the 
collected solid washed with CH2Cl2 (10 mL).  The filtrate was washed sequentially with 
saturated NaHSO3 (aq) (10 mL), saturated NaHCO3 (aq) (10 mL) and Brine (10 mL), then dried 
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over MgSO4 and concentrated in vacuo.  The crude product was purified using flash silica 
column chromatography (20% EtOAc in 40-60 petroleum ether) to yield the product (83 mg, 
79%) as a white solid in a 1.0:1.3 mixture of diastereomers.  
 
1
H-NMR (400 MHz, CDCl3): H = 0.03 (s, 3H
4/5A
), 0.06 (s, 3H
4/5A
), 0.23 (s, 3H
4/5B
), 0.27 (s, 
3H
4/5B
), 0.80 (s, 9H
7A
), 0.97 (s, 9H
7B
), 3.19 (dd, 1H
3B
, J=6.7Hz, J=5.5Hz), 3.38-3.49 (m, 2H
3A
), 
3.67 (dd, 1H
3B
, J=6.8Hz, J=2.9Hz), 4.33 (dd, 1H
1B
, J=5.4Hz, J=2.9Hz), 4.72 (dd, 1H
1A
, J=5.3Hz, 
J=3.0Hz), 7.53 (m, 6H-Ar), 7.65 (m, 2H-Ar), 7.72 (m, 2H-Ar). 
 
13
C-NMR (400 MHz, CDCl3):  C = -6.5 (C-4/5B), -6.5 (C-4/5B), -6.3(C-4/5A), -6.2 (C-4/5A), 
18.2 (C-6B), 18.5 (C-6A), 25.7 (C-7B), 25.9 (C-7A), 35.9 (C-3B), 37.8 (C-3A), 69.5 (C-1A), 
71.8 (C-1B), 124.0 (CH-Ar), 125.3 (CH-Ar), 129.1 (CH-Ar), 129.4 (CH-Ar), 131.3 (CH-Ar), 
131.7 (CH-Ar), 138.7 (C-8A/B), 141.9 (C-8A/B), 165.0 (C=O), 165.7 (C=O). 
 
IR vmax (neat) = 2954, 2924, 2856, 1733, 1048 cm
-1 
 
MS (ES+) m/z = 310 [M+H]
+
, 332 [M+Na]
+
. 
HRMS (ES+) calculated 310.1297 for C15H24NO2SSi, observed 310.1304 [M+H]
+
. 
 
 
3-Bromo-N-(4-methoxyphenyl)propionamide 145 
 
 
 
To a solution of para-anisidine (5.00 g, mmol) in CH2Cl2 (16 mL) was added 3-bromopropionyl 
chloride (2.15 mL, 21.4 mmol) dropwise and the resulting solution stirred for 3 hours at room 
temperature.  The reaction mixture was then diluted with CH2Cl2 (100 mL), washed with H2O (2 
× 100 mL), dried over MgSO4 and concentrated in vacuo to yield the product as a purple powder 
(5.15 g, 94%).  The product was used directly in the next step with no further purification. 
The data were in agreement with the published data.
147
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1
H-NMR (400 MHz, CDCl3): H = 2.88 (t, 2H
1
, J=6.6Hz) 3.66 (t, 2H
2
, J=6.6Hz) 3.76 (s, 3H
8
) 
6.82 (m, 2H
6
) 7.38 (m, 2H
5
) 7.87 (s, 1H
9
). 
 
13
C-NMR (400 MHz, CDCl3):  C = 27.4 (C-1), 40.3 (C-2), 55.5 (C-8), 114.1 (C-6), 122.4 (C-
5), 130.5 (C-4), 156.7 (C-7), 168.3 (C-3). 
 
IR vmax (neat) = 3250, 2831, 1651, 1603 cm
-1 
 
MS (ES+) m/z = 258 [M+H]
+
. 
HRMS (ES+) calculated 258.0130 for C10H13NO2Br, observed 258.0135 [M+H]
+
. 
 
 
1-(4-Methoxyphenyl)azetidin-2-one 146 
 
 
 
NaH (60% in mineral oil, 1.33 g, 33.2 mmol) was washed with hexanes (2 × 20 mL) and then 
suspended in a CH2Cl2-DMF mixture (4:1, 850 mL).  To this was added, slowly over a period of 
6 hours, a solution of the propionamide 145 (5.20 g, 20.2 mmol) in a CH2Cl2-DMF mixture (4:1, 
340 mL).  The reaction mixture was then stirred overnight at room temperature before being 
quenched with saturated NH4Cl (aq) (800 mL).  The organic layer was separated and washed 
with brine (3 × 1000 mL), H2O (1000 mL), dried over MgSO4 and concentrated in vacuo leaving 
approximately 10 mL of DMF.  The product precipitated upon standing and cooling yielding the 
β-lactam (2.42 g, 70%) as white crystals. 
The data were in agreement with the published data.
147
 
 
1
H-NMR (400 MHz, CDCl3): H = 3.09 (t, 2H
3
, J=4.4Hz) 3.59 (t, 2H
1
, J=4.4Hz) 3.78 (s, 3H
10
) 
6.87 (m, 2H
6
) 7.30 (m, 2H
5
). 
 
13
C-NMR (400 MHz, CDCl3):  C = 36.1 (C-3), 38.1 (C-1), 55.5 (C-8), 114.4 (C-6), 117.4 (C-
5), 132.3 (C-4), 156.0 (C-7), 163.9 (C-2). 
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IR vmax (neat) = 2950, 1727 cm
-1 
 
MS (ES+) m/z = 178 [M+H]
+
. 
HRMS (ES+) calculated 178.0868 for C10H12NO2, observed 178.0865 [M+H]
+
. 
 
 
1-(4-Methoxyphenyl)-3-(phenylsulfanyl)azetdin-2-one 147  
 
 
 
To a solution of diisopropylamine (3.08 mL, 22.0 mmol) in THF (50 mL) at –78 oC was added 
1.1 M n-BuLi in hexanes (20 mL, 22.0 mmol) and the resulting solution stirred for 30 minutes at 
0 
o
C.  The solution was then cooled to –78 oC and a –15 oC solution of azetidinone 146 (1.95 g, 
11.0 mmol) and diphenyl disulfide (2.64 g, 12.1 mmol) in THF (42 mL) added dropwise. The 
reaction mixture was allowed to slowly warm to room temperature overnight, then poured into 
saturated NH4Cl (aq) (200 mL) and extracted with CH2Cl2 (300 mL).  The organic layer was 
separated and washed with H2O (2 × 400 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified using flash silica column chromatography (25% EtOAc in 40-60 
petroleum ether) to yield the product (1.27 g, 40%) as a yellow solid. 
 
1
H-NMR (400 MHz, CDCl3): H = 3.49 (dd, 1H
3
, J=6.0Hz, J=2.6Hz) 3.81 (s, 3H
8
) 4.01 (m, 
1H
3
) 4.55 (dd, 1H
1
, J=5.4Hz, J=2.6Hz) 6.88 (m, 2H-Ar) 7.32 (m, 5H-Ar) 7.58 (m, 2H-Ar). 
 
13
C-NMR (400 MHz, CDCl3):  C = 46.3 (C-3), 50.9 (C-1), 55.5 (C-8), 114.3 (C-6), 117.7 (C-
5), 128.0 (CH-Ar), 129.2 (CH-Ar), 131.4 (C-Ar), 132.1(C-Ar), 132.2 (CH-Ar), 156.3 (C-Ar), 
162.5 (C-2). 
 
IR vmax (neat) = 3048, 3003, 2943, 1733 cm
-1
 
 
MS (ES+) m/z = 286 [M+H]
+
. 
HRMS (ES+) calculated 286.0902 for C16H16NO2S, observed 286.0902 [M+H]
+
. 
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mp (CH2Cl2)= 82-85 
o
C. 
 
 
3-(Benzenesulfinyl)-1-(4-Methoxyphenyl)azetidine-2-one 148 
 
 
 
To a mixture of the sulphide 147 (800 mg, 2.8 mmol), Ac2O (0.29 mL, 3.1 mmol) and SiO2 (560 
mg) in CH2Cl2 (14 mL) was added 30% H2O2 (aq) (0.34 mL, 3.4 mmol).  The reaction mixture 
was stirred for 36 hours at room temperature then filtered through a celite padded frit.  The 
filtrate was then washed sequentially with saturated NaHSO3 (aq) (100 mL), saturated NaHCO3 
(aq) (100 mL) and brine (10 mL), then dried over MgSO4 and concentrated in vacuo.  The crude 
product was purified using flash silica column chromatography (50% EtOAc in 40-60 petroleum 
ether) to give the product (670 mg, 79%) as a pale yellow solid in a 1.0:1.3 mixture of 
diastereomers. 
 
1
H-NMR (400 MHz, CDCl3): H = 3.60 (dd, 1H
3A
, J=6.2Hz, J=5.4Hz) 3.77 (s, 3H
8B
) 3.79 (s, 
3H
8A
) 3.84 (m, 2H
3B
) 4.11 (dd, 1H
3A
, J=6.3Hz, J=2.5Hz) 4.35 (dd, 1H
1A
, J=5.2Hz, J=2.5Hz) 
4.58 (dd, 1H
1B
, J=4.6Hz, J=3.3Hz) 6.81 (m, 2H) 6.88 (m, 2H) 7.16 (m, 2H) 7.30 (m, 2H) 7.55 
(m, 6H-Ar) 7.70 (m, 2H-Ar) 7.75 (m, 2H-Ar). 
 
13
C-NMR (400 MHz, CDCl3):  C = 37.5 (C-3A), 44.8 (C-3B), 55.4, 55.5 (C-8A), 67.2, 69.4 (C-
1B), 114.4 (CH-Ar), 114.8 (CH-Ar), 117.4 (CH-Ar), 117.9 (CH-Ar), 123.9 (CH-Ar), 124.5 (CH-
Ar), 129.1 (CH-Ar), 129.5 (CH-Ar), 130.8 (C-Ar), 131.1 (C-Ar), 131.6 (CH-Ar), 131.8 (CH-Ar), 
138.9 (C-Ar), 141.6 (C-Ar),156.1 (C-Ar), 156.5 (C-Ar),156.7 (C=O), 157.2 (C=O). 
 
IR vmax (neat) = 3057, 2944, 2834, 1766, 1746 cm
-1 
 
MS (ES+) m/z = 302 [M+H]
+
, 365 [M+Na+MeCN]
+
. 
HRMS (ES+) calculated 302.0851 for C16H15NO3S, observed 302.0838 [M+H]
+
. 
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1-(4-Methoxyphenyl)-3,3-bis(phenylselanyl)azetidin-2-one 151 
 
 
 
To a solution of diisopropylamine (1.52 mL, 10.9 mmol) in THF (20 mL) at −78 oC was added 
1.57 M n-BuLi in hexanes (6.90 mL, 10.9 mmol) and the resulting solution stirred for 30 minutes 
at 0 
oC.  The solution was then cooled to −78 oC and a −15 oC solution of azetidinone 146 (840 
mg, 4.74 mmol) and phenyl selenium bromide (2.45 g, 10.4 mmol) in THF (20 mL) added 
dropwise. The reaction mixture was allowed to slowly warm to room temperature overnight and 
then quenched with H2O (60 mL), extracted into Et2O (2 × 60 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified using flash silica column chromatography 
(15% EtOAc in 40-60 petroleum ether) to yield the product (1.11 g, 48%) as a yellow oil and the 
monoselenide 149 (168 mg, 11%) as a yellow solid. 
 
1
H-NMR (400 MHz, CDCl3): H = 3.68 (s, 2H
3
) 3.74 (s, 3H
8
) 6.74 (m, 2H, Ar-H) 6.98 (m, 2H, 
Ar-H) 7.32 (m, 6H, Ar-H) 7.73 (m, 4H, Ar-H). 
 
13
C-NMR (400 MHz, CDCl3):  C = 48.2 (C-1), 53.3 (C-3), 55.4 (C-8), 114.2 (CH-Ar), 117.8 
(CH-Ar), 127.2 (C-Ar), 129.2 (CH-Ar), 129.4 (CH-Ar), 130.7 (C-Ar), 136.5 (CH-Ar), 156.3 (C-
Ar), 163.5 (C-2). 
 
IR vmax (neat) = 3072, 3023, 2960, 2838, 1733 cm
-1
 
 
MS (ES+) m/z = 490 [M+H]
+
, 553 [M+Na+MeCN]
+
. 
HRMS (ES+) calculated 489.9824 for C22H20NO2Se2, observed 489.9821 [M+H]
+
. 
 
mp (CH2Cl2)= 82-84 
o
C. 
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1-(4-Methoxyphenyl)-3-(phenylselanyl)azetidin-2-one 149 
 
 
 
To a solution of diisopropylamine (0.04 mL, 0.20 mmol) in THF (0.8 mL) at −78 oC was added 
2.06 M n-BuLi in hexanes (0.12 mL, 0.25 mmol) and the resulting solution stirred for 30 minutes 
at 0 
o
C.  The solution was then cooled to –78 oC and a −78 oC solution of acetophenone (0.23 
mL, 0.20 mmol) and the bis-selenide 151 (100 mg, 0.20 mmL) in THF (1.0 mL) added dropwise. 
The reaction mixture was allowed to slowly warm to room temperature overnight and then 
quenched with H2O (10 mL), extracted into Et2O (2 × 20 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified using flash silica column chromatography 
(15% EtOAc in 40-60 petroleum ether) to yield the product (40 mg, 61%) as a yellow solid. 
 
1
H-NMR (400 MHz, CDCl3): H = 3.47 (dd, 1H
3
, J=6.2Hz, J=2.5Hz) 3.80 (s, 3H
8
) 4.02 (m, 
1H
1
) 4.56 (dd, 1H
3
, J=5.4 Hz, J=2.5Hz) 6.85 (m, 2H, Ar-H) 7.21 (m, 2H, Ar-H) 7.30 (m, 3H, Ar-
H) 7.69 (m, 2H, Ar-H) 
 
13
C-NMR (400 MHz, CDCl3):  C = 42.6 (C-1), 46.4 (C-3), 55.4 (C-8), 114.3 (CH-Ar), 117.6, 
(CH-Ar) 126.2 (C-Ar), 128.5 (CH-Ar), 129.2 (CH-Ar), 131.5 (C-Ar), 135.0 (CH-Ar), 156.2 (C-
Ar), 163.2 (C-2). 
 
IR vmax (neat) = 3053, 2960, 1733 cm
-1 
 
MS (ES+) m/z = 334 [M+H]
+
. 
HRMS (ES+) calculated 334.0346 for C16H16NO2Se, observed 334.0338 [M+H]
+
. 
 
mp (Et2O) = 82-84 
o
C. 
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Dimethyldioxirane 
 
 
 
To a 1 litre 3-necked flask containing a mixture of NaHCO3 (45 g, 0.53 mol) in H2O (120 mL) 
and acetone (100 mL) at 0 
o
C, was added oxone (90 g, 0.59 mol) in 3 portions during 10 minutes.  
The reaction mixture was stirred for 15 minutes before being allowed to warm to room 
temperature and the product collected by distillation (30 mbar), as a pale yellow solution (0.10 M 
in acetone, by titration with thioanisole) into a chilled receiving flask at –78 oC.  The product was 
stored over anhydrous Na2SO4 at −25 
o
C.
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3-(Benzeneseleninyl)-1-(4-methoxyphenyl)azetidin-2-one 150 
 
 
 
To a solution of the selenide 149 (340 mg, 1.05 mmol) in acetone (5.3 mL) was added a 0.09 M 
solution of dimethyldioxirane in acetone (12.9 mL, 1.16 mmol) and the mixture stirred for 20 
minutes at room temperature.  The reaction mixture was then concentrated in vacuo and purified 
using flash silica column chromatography (2% MeOH in CHCl3) to yield the product (347 mg, 
98%) as a white solid in a 1.0:1.3 mixture of diastereomers. 
 
1
H-NMR (400 MHz, CDCl3): H =  3.53 (dd, 1H
3B
, J=7.1Hz, J=2.0Hz) 3.59 (dd, 1H
3A
, 
J=6.4Hz, J=5.3Hz) 3.73 (s, 3H
8B
) 3.75-3.77 (m, 1H
3B
) 3.78 (s, 3H
8A
) 4.07 (dd, 1H
3A
, J=6.4Hz, 
J=2.2Hz) 4.42 (dd, 1H
1A
, J=5.2Hz, J=2.3Hz) 4.77 (dd, 1H
1B
, J=5.0Hz, J=2.0Hz) 6.72-6.75 (m, 
2H-Ar) 6.85-6.89 (m, 2H-Ar) 6.94-6.96 (m, 2H-Ar) 7.27-7.29 (m, 2H-Ar) 7.42-7.48 (m, 3H-Ar) 
7.55-7.60 (m, 3H-Ar) 7.75-7.79 (m, 4H-Ar). 
 
13
C-NMR (400 MHz, CDCl3):  C = 37.5 (C-3A), 39.2 (C-3B), 55.4 (C-8B), 55.5 (C-8A), 62.0 
(C-1A), 64.0 (C1-B), 114.2(CH-Ar), 114.4 (CH-Ar), 117.6 (CH-Ar), 117.9 (CH-Ar), 125.7(CH-
Ar), 126.5 (CH-Ar), 129.4 (CH-Ar), 130.0 (CH-Ar), 130.4 (C-Ar), 131.1 (C-Ar), 131.8 (CH-Ar), 
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132.2 (CH-Ar), 135.1 (C-Ar), 139.1 (C-Ar), 156.6 (C-Ar), 156.7 (C-Ar), 157.8 (C=O), 158.2 
(C=O). 
 
IR vmax (neat) = 2966, 1737 cm
-1 
 
MS (ES+) m/z = 350 [M+H]
+
, 372 [M+Na]
+
. 
HRMS (ESI) calculated 350.0295 for C16H16NO3Se, observed 350.0293 [M+H]
+
. 
 
 
1-(4-Methoxyphenyl)-3-(phenylselanyl)azetidin-2-one 149 and 
l-(p-Methoxyphenyl)azetidine-2,3-dione 152 
 
 
 
Selenoxide 150 (100 mg, 0.30 mmol) in toluene (3 mL) was heated in a sealed tube at 120 
o
C for 
36 hours.  The reaction mixture was then concentrated in vacuo and purified using flash silica 
column chromatography (100% CHCl3) to yield selenide 149 (32 mg, 33%) and diketone 152 (17 
mg, 30%).  
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 3.84 (s, 3H
8
) 4.29 (s, 2H
3
) 6.96-7.00 (m, 2H
6
) 7.48-7.51 (m, 
2H
5
). 
 
13
C-NMR (400 MHz, CDCl3):  C = 55.6 (C-8), 59.6 (C-3), 114.8 (C-6), 119.0 (C-5), 130.7 (C-
4), 158.1 (C-7), 159.3 (C-2), 190.6 (C-1). 
 
IR vmax (neat) = 1814, 1741 cm
-1 
 
MS (ES+) m/z = 192 [M+H]
+
. 
HRMS (ES+) calculated 192.0622 for C10H10NO3, observed 192.0613 [M+H]
+
. 
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N-p-Methoxybenzyl-α-iminoglyoxalate 160 
 
 
 
To a solution of ethyl-glyoxylate (50% in toluene, 0.48 mL, 2.4 mmol) in CH2Cl2 (8 mL) was 
added dropwise a solution of para-anisidine (296 mg, 2.4 mmol) in CH2Cl2 (4 mL) and the 
resulting solution stirred for 30 minutes at room temperature before being treated with 4Å 
molecular sieves and stirred for a further 1 hour.  The reaction mixture was then filtered and 
concentrated in vacuo to yield the product (419 mg, 84%) as yellow oil, which was used directly 
in the next step with no further purification. 
The data were in agreement with the published data.
155
 
  
1
H-NMR (400 MHz, CDCl3): H = 1.40 (t, 3H
9
, J=7.1Hz) 3.84 (s, 3H
7
) 4.41 (q, 2H
8
, J=7.1Hz) 
6.91-6.94 (m, 2H
5
) 7.35-7.37 (m, 1H
4
) 7.94 (s, 1H
2
) 
 
13
C-NMR (100 MHz, CDCl3):  C = 14.3 (C-9) 55.5 (C-7) 61.9 (C-8) 114.5 (C-5) 123.6 (C-4) 
141.4 (C-3) 148.0 (C-2) 160.5 (C-6) 163.6 (C-1).  
 
 
Ethyl 3-(benzyloxy)-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylate 155 
 
 
 
To a −78 oC solution of imine 160 (230 mg, 1.11 mmol) and NEt3 (0.31 mL, 2.22 mmol) in 
CH2Cl2 (3 mL) was added benzyloxyacetyl chloride (0.26 mL, 1.67 mmol) dropwise.  The 
solution was then warmed to room temperature and stirred overnight.  The reaction mixture was 
then concentrated in vacuo and the crude residue purified using flash silica column 
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chromatography (20% EtOAc in 40-60 petroleum ether) to yield the product (201 mg, 51%) as a 
white solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H =  1.25 (t, 3H
16
, J=7.2Hz) 3.82 (s, 3H
8
) 4.28 (q, 2H
15
, 
J=7.2Hz) 4.74 (d
3
, 1H, J=5.2Hz) 4.83 (s, 2H
10
) 5.04 (d, 1H
1
, J=5.1Hz) 6.88-6.91 (m, 2H
6
)  7.30-
7.32 (m, 2H
5
) 7.36-7.40 (m, 5H
12,13,14
) 
 
13
C-NMR (100 MHz, CDCl3):  C = 14.2 (C-16) 55.5 (C-8) 59.2 (C-3) 62.0 (C-15) 73.3 (C-10) 
81.7 (C-1) 114.4 (CH-Ar) 118.4 (CH-Ar) 127.9 (CH-Ar), 128.2 (CH-Ar), 128.5 (CH-Ar) 130.4 
(C-Ar) 136.4 (C-Ar) 156.8 (C-Ar) 162.7 (C-2) 167.6 (C-9). 
 
IR vmax (neat) =2962, 1742 cm
-1 
 
MS (ES+) m/z = 356 [M+H]
+
. 
HRMS (ES+) calculated 356.1498 for C20H22NO5, observed 356.1506 [M+H]
+
. 
 
 
1,4-Bis(4'-methoxyphenyl)-1,4-diazabuta-1,3-diene 162 
 
 
 
A mixture of 40% glyoxal (aq) (0.50 mL, 4.30 mmol), para-anisidine (1.06 g, 8.60 mmol) and 
catalytic formic acid in MeOH (14 mL) were stirred at room temperature for 1 hour.  The 
precipitated solids were collected by filtration, washed with cold MeOH and dried under vacuum 
to give the product (805 mg, 70%) as a yellow powder. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 3.85 (s, 6H
11+12
) 6.93-6.98 (m, 4H) 7.32-7.36 (m, 4H) 8.42 
(s, 2H
1+2
). 
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13
C-NMR (100 MHz, CDCl3):  C = 55.5 (C-11+12), 114.6 (C6+9), 123.1 (C5+8), 143.0 
(C3+4), 157.6 (C7+10), 159.8 (C1+2). 
 
MS (ES+) m/z = 269 [M+H]
+
. 
HRMS (ES+) calculated 268.1290 for C16H17N2O2, observed 269.1310 [M+H]
 +
. 
 
 
3-(Benzyloxy)-4-formyl-1-(4-methoxyphenyl)azetidin-2-one 164 
 
 
 
To a suspension of the di-imine 162 (690 mg, 2.57 mmol) and NEt3 (0.43 mL, 3.09 mmol) in 
toluene (24 mL) was added a solution of benzoxyacetyl chloride (0.45 mL, 2.83 mmol) in 
toluene (12 mL) dropwise and the resulting solution stirred overnight at room temperature.  The 
reaction mixture was diluted with CHCl3 (100 mL), washed sequentially with saturated NaHCO3 
(aq) (50 mL) and H2O (2 × 50 mL), then dried over MgSO4 and concentrated in vacuo.   
A solution of the crude lactam (350 mg, 0.84 mmol) in CHCl3 (16 mL) was stirred with 5% HCl 
(aq) (8.4 mL) overnight at room temperature.  The reaction was then diluted with CHCl3 (50 
mL), washed sequentially with 1.0 M HCl (aq) (2 × 20 mL), H2O (20 mL) and brine (20 mL), 
then dried over MgSO4 and concentrated in vacuo.  The crude material was re-crystallised from 
EtOAc and hexanes (1:1) to yield the product (160 mg, 61%) as a brown solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 3.82 (s, 3H
9
) 4.51 (dd, 1H
3
, J=3.9Hz, J=5.2Hz) 4.75 (d, 
1H
10
, J=11.6Hz) 4.86 (d, 1H
10
, J=11.7Hz) 5.07 (d, 1H
1
, J=5.2Hz) 6.89-6.91 (m, 2H
7
) 7.28-7.30 
(m, 2H
6
) 7.36-7.41 (m, 5H
12-14
) 9.74 (d, 1H
5
, J=3.8Hz). 
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13
C-NMR (100 MHz, CDCl3):  C = 55.5 (C-9), 63.2 (C-3), 73.6 (C-10), 82.7 (C-1), 114.6 (CH-
Ar), 118.1 (CH-Ar), 128.3 (CH-Ar), 128.5 (CH-Ar), 128.6(CH-Ar), 130.5 (C-Ar), 135.8 (C-Ar), 
157.0 (C-Ar), 162.9 (C-2), 198.9 (C-5). 
 
IR vmax (neat) =2838, 1737, 1511 cm
-1 
 
MS (CI+) m/z = 329 [M+NH4]
+
. 
HRMS (CI+) calculated 329.1501 for C18H21N2O4, observed 329.1487 [M+NH4]
+
. 
 
 
Ethyl 3-hydroxy-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylate 167 
 
 
 
A round bottomed flask containing 10% Pd on carbon (50 mg, 0.05 mmol) was evacuated and 
backfilled with nitrogen three times and then evacuated and refilled with hydrogen.  To this was 
added a solution of β-lactam 155 (106 mg, 0.30 mmol) in THF (10 mL) and the mixture stirred 
under hydrogen (1 atm) overnight.  The reaction mixture was filtered through a celite padded frit 
and then concentrated in vacuo to yield the product as a white solid (77 mg, 97%). 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H =  1.31 (t, 3H
12
, J=7.1Hz) 3.71 (d, 1H
5
, J=9.5Hz) 3.78 (s, 
3H
10
) 4.32 (q, 2H
11
, J=7.1Hz) 4.69 (d, 1H
3
, J=5.2Hz) 5.21 (dd, 1H
1
, J=9.5Hz, J=5.1Hz) 6.85-
6.88 (m, 2H
8
) 7.27-7.30 (m, 2H
7
). 
 
13
C-NMR (100 MHz, CDCl3): C = 14.2 (C-12), 55.5 (C-10), 59.7 (C-3), 62.4 (C-11), 77.3 (C-
1), 114.5 (C-8), 118.4 (C-7), 130.3 (C-6), 156.9 (C-9), 164.3 (C-2), 168.7 (C-4). 
 
IR vmax (neat) = 3239, 2942, 1719 cm
-1 
 
MS (ES+) m/z = 266 [M+H]
+
. 
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HRMS (ES+) calculated 265.1028 for C13H16NO5, observed 266.1036 [M+H]
+
. 
 
 
Ethyl 1-(4-methoxyphenyl)-4-oxo-3-[(trifluoromethane)sulfonyloxy]azetidine-2-carboxylate 
165 
 
 
 
To a −78 oC solution of the alcohol 167 (70 mg, 0.26 mmol) and pyridine (90 µL, 1.14 mmol) in 
CH2Cl2 (1.75 mL) was added Tf2O (90 µL, 0.52 mmol) slowly and the mixture warmed to 0 
o
C 
and stirred for 1 hour.  The reaction mixture was diluted with CH2Cl2 (10 mL), washed with H2O 
(2 × 10 mL), combined aqueous layers re-extracted with CH2Cl2 (10 mL) and the combined 
organic layers dried over MgSO4 and concentrated in vacuo to yield the crude product as a 
yellow solid.  This was used directly in the following step with no further purification. 
 
 
Ethyl 3-iodo-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylate 166 and 170 
 
 
 
To a solution of triflate 165 (100 mg, 0.25 mmol) in acetone (2.5 mL) was added NaI (292 mg, 
1.95 mmol) and the resulting suspension stirred for 48 hours at room temperature.  The reaction 
mixture was then concentrated in vacuo and partitioned between Et2O (10 mL) and H2O (10 mL).  
The aqueous layer was re-extracted with Et2O (10 mL), the combined organic layers dried over 
MgSO4 and then concentrated in vacuo.  The crude material was purified using flash silica 
column chromatography (30% EtOAc in 40-60 petroleum ether) to yield the trans-β-lactam (33 
mg, 35%) and the cis-β-lactam (31 mg, 33%) as pale yellow amorphous solids. 
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Trans-diastereomer 166 
1
H-NMR (400 MHz, CDCl3): H = 1.31 (t, 3H
7
, J=7.2Hz) 3.82 (s, 3H
11
) 4.31 (m, 2H
6
) 4.63 (d, 
1H
3
, J=2.0Hz) 5.07 (d, 1H
1
, J=1.9Hz) 6.88-6.92 (m, 2H
9
) 7.29-7.32 (m, 2H
8
). 
 
13
C-NMR (100 MHz, CDCl3): C = 14.1 (C-1), 15.1 (C-7), 55.5 (C-11), 62.1 (C-3), 62.6 (C-6), 
114. (C-9), 118.2 (C-8), 130.6 (C-5), 157.0 (C-10), 160.4 (C-2), 168.3 (C-4). 
 
IR: vmax (neat) = 2984, 1760, 1512 cm
-1 
 
Cis-diastereomer 170 
1
H-NMR (400 MHz, CDCl3): H = 1.36 (t, 3H, J=7.2Hz) 3.82 (s, 3H) 4.31-4.44 (m, 2H
6
) 4.81 
(d, 1H
3
, J=5.7Hz) 5.43 (d, 1H
1
, J=5.7Hz) 6.89-6.92 (m, 2H
9
) 7.26-7.30 (m, 2H
8
). 
 
13
C-NMR (100 MHz, CDCl3): C = 14.3 (C-1), 17.5 (C-7), 55.5 (C-11), 56.6 (C-3), 62.4 (C-6), 
114.5 (C-9), 118.2 (C-8), 130.4 (C-5), 157.0 (C-10), 161.5 (C-2), 169.3 (C-4). 
 
IR: vmax (neat) = 2995, 1749, 1513 cm
-1 
 
MS (ES+) m/z = 376 [M+H]
+
. 
 
HRMS (ES+) calculated 376.0046 for C13H15NO4I, observed 376.0056 [M+H]
+
. 
 
 
3-Iodo-1-(4-methoxyphenyl)-4-oxoazetidine-2-carboxylic acid 171  
 
 
 
A solution of β-lactam 166 (76 mg, 0.20 mmol) in THF (1 mL) was treated with potassium 
trimethylsilanolate (43 mg, 0.30 mmol) and the resulting suspension stirred at room temperature 
for 10 minutes.  The reaction mixture was then concentrated in vacuo, dissolved in H2O (10 mL) 
and washed with EtOAc (2 ×10 mL).  Acidification of the aqueous layer using 1.0 M HCl (aq) 
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(15 mL) was followed by extraction into CH2Cl2 (2 x 10 mL).  Combined organic layers were 
dried over MgSO4 and concentrated under reduced pressure to yield the product (42 mg, 60%) as 
a yellow gum. 
 
1
H-NMR (400 MHz, CDCl3): H = 3.82 (s, 3H
10
) 4.66 (d, 1H
3
, J=2.0Hz) 5.13 (d, 1H
1
, J=2.0Hz) 
5.41 (br s, 1H
6
) 6.89-6.93 (m, 2H
8
) 7.30-7.34 (m, 2H
7
). 
 
13
C-NMR (100 MHz, CDCl3): C = 14.7 (C-1), 55.6 (C-10), 61.7 (C-3), 114.7 (C-8), 118.3 (C-
7), 130.4 (C-5), 157.2 (C-9), 160.5 (C-2), 171.8 (C-4). 
 
IR vmax (neat) = 3460, 2932, 1734, 1612 cm
-1 
 
MS (ES-) m/z = 346 [M-H]
-
. 
HRMS (ES-) calculated 345.9576 for C11H9NO4I, observed 345.9588 [M-H]
-
. 
 
 
2-Methylidenebut-3-en-1-ol 174 
 
 
 
To a −78 oC solution of HMDS (0.64 mL, 3.04 mmol) in Et2O (2.40 mL) was added 2.5 M n-
BuLi (1.14 mL, 2.85 mmol) dropwise.  The resulting mixture was warmed to room temperature 
during 30 minutes then 2-methyl-2-vinyloxirane (0.23 mL, 2.38 mmol) added and the solution 
refluxed for 24 hours.  The reaction mixture was then cooled to room temperature poured into 
cold 1.0 M HCl (aq) (20 mL), stirred for 1 hour and extracted into Et2O (3 × 10 mL). Combined 
organic layers were washed sequentially with saturated NaHCO3 (aq) (10 mL) and brine (10 
mL), then dried over MgSO4 and concentrated in vacuo to yield the crude product as a volatile, 
colourless oil. This was used directly in the next step with no further purification.  
 
1
H-NMR (400 MHz, CDCl3): H = 1.54 (s, 1H
6
) 4.38 (s, 2H
1
) 5.14-5.19 (m, 2H
5
) 5.29-5.34 (m, 
2H
4
) 6.43 (dd, 1H
3
, J=17.9Hz, J=11.1Hz). 
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13
C-NMR (100 MHz, CDCl3): C = 62.6 (C-1), 114.1 (C-5), 115.7 (C-4), 136.3 (C-3), 145.2 (C-
2).  
 
 
Methoxy[(2-methylidenebut-3-en-1-yl)oxy]methane 175 
 
 
 
To a solution of the crude isoprenol 174 (700 mg, 8.3 mmol) and DIPEA (3.04 mL, 17.5 mmol) 
in CH2Cl2 (70 mL) was added chloromethyl methyl ether (1.26 mL, 16.6 mmol) dropwise and 
the resulting solution stirred for 16 hours at room temperature.  The reaction mixture was 
quenched with H2O (200 mL) and extracted with CH2Cl2 (2 × 150 mL).  The combined organic 
layers were then washed with 1.0 M HCl (aq) (15-0 mL), dried over MgSO4 and concentrated in 
vacuo.  The crude material was purified by flash silica column chromatography (8% Et2O in 
pentane) to yield the product (596 mg, 56%, over 2 steps) as a volatile, colourless oil. 
   
1
H-NMR (400 MHz, CDCl3): H = 3.43 (s, 3H
7
) 4.28 (s, 2H
1
) 4.71 (s, 2H
6
) 5.14-5.23 (m, 2H
5
) 
5.31-5.36 (m, 2H
4
) 6.43 (dd, 1H
3
, J=17.8Hz, J=11.0Hz). 
 
13
C-NMR (100 MHz, CDCl3): C = 55.4 (C-7), 66.7 (C-1), 95.7 (C-6), 114.4 (C-5), 117.5 (C-4), 
136.6 (C-3), 142.2 (C-2).  
 
IR vmax (neat) = 2934, 2887, 1598 cm
-1 
 
HRMS: Did not provide spectra suitable for interpretation. 
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1-((methoxymethoxy)methyl)-5-(3-(methoxymethoxy)prop-1-en-2-yl)cyclohex-1-ene 176 
and 1-((methoxymethoxy)methyl)-4-(3-(methoxymethoxy)prop-1-en-2-yl)cyclohex-1-ene 
177 
 
 
 
A mixture of β-lactam salt 171 (75 mg, 0.20 mmol) and diene 175 (250 mg, 1.95 mmol) was 
heated at 125 
o
C for 16 hours in a sealed tube.  The reaction mixture was cooled to room 
temperature, diluted with EtOAc (15 mL) and washed with H2O (15 mL).  The organic layer was 
dried over MgSO4 and concentrated in vacuo to yield the crude product.  The crude product was 
purified using flash silica column chromatography (10% Et2O in pentane) to yield the product 
(72 mg, 58%) as a 1.0:1.0 mixture of regioisomers. 
  
1
H-NMR (400 MHz, CDCl3): H = 1.45-2.31 (m, 14H
3,4,5,6
), 3.39-3.40 (m, 12H
9,14
), 3.94 (br, s 
4H
7
), 4.08 (m, 4H
11
), 4.64-4.67 (m, 8H
8,13
), 4.96-4.98 (m, 2H
12
), 5.09-5.12 (m, 2H
12
), 5.67-5.77 
(m, 2H
1
). 
 
13
C-NMR (100 MHz, CDCl3): C = 25.5 (C-3), 26.5 (C-3), 27.5 (C-4), 27.6 (C-4), 30.9 (C-6), 
31.9 (C-6), 36.9 (C-5), 37.0 (C-5), 55.2 (C-9), 55.3 (C-14), 69.4 (C-11), 69.4 (C-11), 71.5 (C-7), 
71.8 (C-7), 95.5 (C-8/13), 95.7 (C-8/13), 110.5 (C-12), 110.5 (C-12), 124.6 (C-1), 125.0 (C-1), 
134.0 (C-2), 134.2 (C-2), 149.8 (C-10), 149.8 (C-10). 
 
IR vmax (neat) = 2926, 2883, 2839 cm
-1 
 
MS (ES+) m/z = 279 [M+Na]
+
. 
HRMS (ES+) calculated 279.1572 for C14H24O4Na, observed 279.1592 [M+Na]
+
. 
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1-(Adamantan-1-yl)-3-(4-methoxyphenyl)urea 180 
 
 
 
A suspension of β-lactam salt 171 (80 mg, 0.21 mmol), 1-adamantyl isocyanate (186 mg, 1.05 
mmol) and 18-crown-6 (55 mg, 0.21 mmol) in o-xylene (0.5 mL) was heated at 130 
o
C for 2 
hours.  The reaction mixture was cooled to room temperature, diluted with EtOAc (10 mL) and 
washed with H2O (15 mL).  The organic layer was dried over MgSO4 and concentrated in vacuo 
to yield the crude product.  The crude product was purified using flash silica column 
chromatography (30% EtOAc in 40-60 petroleum ether) to yield the product (4 mg, 6%) as an 
orange solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.63-1.69 (m, 6H
12
), 1.95 (dd, 6H
10
, J=9.6Hz, J=2.9Hz), 
2.02-2.10 (m, 3H
11
), 3.79 (s, 3H
8
), 4.36 (s, 1H
1
), 5.87 (s, 1H
3
), 6.83-6.87 (m, 2H-Ar), 7.14-7.18 
(m, 2H-Ar). 
 
13
C-NMR (100 MHz, CDCl3): C = 29.5 (C-11), 36.4 (C-12), 42.3 (C-10), 51.2 (C-9), 55.5 (C-
8), 114.5 (C-6), 124.5 (C-5), 131.4 (C-4), 155.3 (C-7), 157.0 (C-2). 
 
IR vmax (neat) = 3323, 2905, 1628, 1553 cm
-1 
 
MS (ES+) m/z = 301 [M+H]
+
. 
HRMS (ES+) calculated 301.1916 for C18H25N2O2, observed 301.1922 [M+H]
+
. 
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4,6-O-Benzylidene-D-glucopyranose 197 
 
 
 
To oven dried anhydrous D-glucose (10 g, 55.5 mmol) was added catalytic para-toluenesulfonic 
acid (50 mg), benzaldehyde dimethyl acetal (9.2 mL, 61.1 mmol) and DMF (40 mL).  The 
resulting suspension was heated under reduced pressure (330 mbar) at 60 
o
C for 30 minutes until 
the glucose had dissolved.  The reaction was quenched by cooling and the addition of excess 
NEt3 (1.5 mL), then concentrated in vacuo to yield the crude product.  The crude product was 
purified using flash silica column chromatography (0.1% NEt3 in EtOAc) to yield the product 
(7.3 g, 49%) as a white solid in a 1.0:1.5 mixture of α and β-anomers. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, DMSO-d6): H = 3.02 (td, 1H
6α
, J=7.9Hz, J=5.2Hz), 3.23-3.43 (m, 
5H
3α,4α,4β,5α,6β,
), 3.59-3.69 (m, 3H
2α,2β,5β
), 3.80 (td, 1H
3β
, J=10.0Hz, J=4.8Hz), 4.09 (dd, 1H
2β
, 
J=9.9Hz, J=4.8Hz), 4.16 (dd, 1H
2α
, J=10.2Hz, J=4.0Hz),  4.43-4.47 (m, 1H
7α
),  4.81 (d, 1H
9β
, 
J=6.9Hz), 4.97-5.00 (m, 1H
7β
),  5.10 (d, 1H
8β
, J=5.0Hz), 5.18 (d, 1H
9α
, J=5.1Hz),  5.23 (d, 1H
8α
, 
J=4.7Hz), 5.56 (s, 1H
1β
), 5.57 (s, 1H
1α
), 6.55 (d, 1H
10β
, J=4.8Hz), 6.84 (d, 1H
10α
, J=6.6Hz), 7.36-
7.40 (m, 6H-Ar), 7.43-7.46 (m, 4H-Ar). 
 
13
C-NMR (400 MHz, DMSO-d6):  C = 62.4 (C-3β), 66.2 (C-3α), 68.5 (C-2α), 68.9 (C-2β), 70.1 
(C-5α), 73.3 (C-5β), 73.4 (C-6α), 76.2 (C-6β), 81.4 (C-4α), 82.2 (C-4β), 93.6 (C-7β), 98.1 (C-
7α), 101.1 (C-1α), 101.3 (C-1β),126.8 (CH-Ar), 126.8 (CH-Ar), 128.5 (CH-Ar), 129.3 (CH-Ar), 
138.3 (C-Ar), 138.4 (C-Ar).  
 
Note: missing 2 × CH-Ar due to overlapping peaks.  
 
IR vmax (neat) = 3314, 1386 cm
-1 
 
MS (ES+) m/z = 269 [M+H]
+
. 
HRMS (ES+) calculated 269.1025 for C13H17O6, observed 269.1035 [M+H]
+
. 
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1,3-Benzylidene-L-erythritol 198 
 
 
 
A mixture of glucopyranose 197 (7.0 g, 25.9 mmol), sodium metaperiodate (11.4 g, 53.1 mmol) 
and sodium bicarbonate (5.8 g, 84.0 mmol) in THF-H2O (1.0:2.3, 265 mL) was stirred at room 
temperature for 1 hour.  The reaction was then cooled to 0 
o
C, sodium borohydride (2.00 g, 53.1 
mmol) was added and the reaction mixture stirred for a further hour at 0 
o
C.  The precipitate was 
then filtered off, the filtrate extracted with ethyl acetate (2 x 200 mL), washed with saturated 
Na2SO4 (aq)-NaHCO3 (aq) (1:1, 2 × 200 mL) and dried over MgSO4.  The organic layer was 
concentrated in vacuo to yield the product (5.09 g, 94%) as a white solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, DMSO-d6): H = 3.46-3.58 (m, 4H
2,3,4,5
), 3.71-3.78 (m, 1H
5
), 4.07-4.13 (m, 
1H
2
), 4.64 (t, 1H
7
, J=5.7Hz), 5.17 (d, 1H
6
, J=5.0Hz), 5.50 (s, 1H
1
), 7.35-7.37 (m, 3H-Ar), 7.44-
7.46 (m, 2H-Ar). 
 
13
C-NMR (400 MHz, DMSO-d6): C = 61.3 (C-3, 5), 71.2 (C-2), 83.6 (C-4), 100.6 (C-1), 126.8 
(CH-Ar), 128.4 (CH-Ar), 129.0 (CH-Ar), 138.8 (C-8). 
 
IR vmax (neat) = 3282, 2947, 1454 cm
-1 
 
MS (CI) m/z = 211 [M+H]
+
, 228 [M+NH4]
+
. 
HRMS (CI+) calculated 228.1236 for C11H18O4N, observed 228.1241 [M+NH4]
+
. 
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(4S,5R)-4-((tert-Butyldimethylsilyloxy)methyl)-2-phenyl-1,3-dioxan-5-ol 185 
 
 
 
A solution of diol 198 (4.88 g, 23.2 mmol) and imidazole (1.74 g, 25.5 mmol) in anhydrous 
CH2Cl2 (430 mL) was stirred at 0 
o
C while TBSCl (4.37 g, 29.0 mmol) was added during 5 
minutes.  The resulting milky solution was stirred overnight at room temperature, then excess 
ethanol amine (2.5 mL) added and the mixture stirred for a further 30 minutes.  The reaction 
mixture was diluted with H2O (300 mL), extracted with CH2Cl2 (2 × 250 mL), the combined 
organic layers washed with brine (300 mL), dried over MgSO4 and concentrated in vacuo.  The 
crude product was purified using flash silica column chromatography (20% acetone in 40-60 
petroleum ether) to yield the product (6.10 g, 81%) as a colourless, viscous oil. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H =  0.12 (s, 3H
6/7
), 0.13 (s, 3H
6/7
), 0.92 (s, 9H
9
), 3.46 (d, 1H
10
, 
J=1.2Hz), 3.62-3.67 (m, 1H
5
), 3.74-3.77 (m, 1H
3
), 3.85 (dd, 1H
2
, J=9.6Hz, J=8.8Hz), 3.88-4.01 
(m, 1H
4
), 4.04 (dd, 1H
2
, J=9.7Hz, J=4.6Hz), 4.33 (dd, 1H
5
, J=10.9Hz, J=5.3Hz), 5.50 (s, 1H
1
), 
7.34-7.39 (m, 3H), 7.45-7.48 (m, 2H). 
 
13
C-NMR (400 MHz, CDCl3): C = -5.6 (C-6/7), -3.6 (C-6/7), 18.6 (C-8), 25.8 (C-9), 66.3 (C-
5), 66.6 (C-4), 70.5 (C-2), 78. 9 (C-3), 101.1 (C-1), 126.1 (CH-Ar), 128.3 (CH-Ar), 129.0 (CH-
Ar), 137.4 (C-11). 
 
 IR vmax (neat) = 3473, 2958, 2860, 1251 cm
-1
 
 
MS (ES+) m/z = 325 [M + H]
+
,
 
347 [M+Na]
+
, 388 [M+Na+MeCN]
+
. 
HRMS (ES+) calculated 325.1835 for C17H29O4Si, observed 325.1837 [M+H]
+
. 
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(4S,5S)-4-((tert-Butyldimethylsilyloxy)methyl)-2-phenyl-1,3-dioxan-5-yl benzoate 199 
 
 
 
To a 0 
o
C solution of alcohol 185 (100 mg, 0.31 mmol) in toluene (3.0 mL) was added 
triphenylphosphine (420 mg, 1.54 mmol) and benzoic acid (188 mg, 1.54 mmol).  To the 
resulting solution was then added DIAD (0.30 mL, 1.54 mmol), the reaction heated to reflux and 
stirred for 72 hours.  The reaction mixture was diluted with saturated NaHCO3 (aq) (7 mL), 
extracted with CH2Cl2 (3 × 6 mL), dried over magnesium sulphate and concentrated in vacuo.  
The crude product was purified using flash silica column chromatography (20% EtOAc in 40-60 
petroleum ether) to yield the product (40 mg, 29%) as a colourless oil. 
 
1
H-NMR (400 MHz, CDCl3): H = -0.09 (s, 3H
6/7
), -0.03 (s, 3H
6/7
), 0.81 (s, 9H
9
), 3.81-3.89 (m, 
2H
2
), 4.20 (dd, 1H
5
, J=13.0Hz, J=1.4Hz), 4.25 (ddd, 1H
3
, J=7.8Hz, J=6.0Hz, J=1.6Hz), 4.49 (dd, 
1H
5
, J=13.0Hz, J=1.3Hz), 5.12-5.14 (m, 1H
4
),  5.66 (s, 1H
1
),  7.36-7.42 (m, 3H-Ar), 7.44-7.48 
(m, 2H-Ar), 7.53-7.60 (m, 3H-Ar), 8.13-8.15 (m, 2H-Ar). 
 
13
C-NMR (400 MHz, CDCl3): C = -5.5 (C-6/7), -5.4 (C-6/7), 18.1 (C-8), 25.7 (C-9), 61.3 (C-
5), 65.4 (C-4), 69.6 (C-2), 78.2 (C-3), 101.3 (C-1), 126.2 (CH-Ar), 128.3 (CH-Ar), 128.4 (CH-
Ar), 129.1 (CH-Ar), 129.8 (CH-Ar), 130.1 (C-15), 133.1 (CH-Ar), 137.9 (C-10), 166.1 (C-14). 
 
IR vmax (neat) = 2930, 2857, 1722, 1271 cm
-1
 
 
MS (ESI) m/z: Did not provide spectra suitable for interpretation. 
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(2R,4S)-4-[[tert-Butyl(dimethyl)silyl]methyl]-2-phenyl-1,3-dioxan-5-one 201 
 
 
 
 
To a solution of oxalyl chloride (2.26 mL, 26.7 mmol) in CH2Cl2 (80 mL) at −78 
o
C was added 
DMSO (3.80 mL, 53.4 mmol).  After 5 minutes a solution of alcohol 185 (5.78 g, 17.8 mmol) in 
CH2Cl2 (25 mL) was added and the reaction mixture stirred at −78 
o
C for 1 hour.  The reaction 
mixture was then treated with NEt3 (11.2 mL, 80.1 mmol), before being slowly warmed to 0 
o
C 
and stirred for 15 minutes.  The solution was then poured into cold saturated NH4Cl (aq) (250 
mL), extracted with EtOAc (2 × 300 mL), dried over MgSO4 and concentrated in vacuo.  The 
crude product was purfied using flash silica column chromatography (15% EtOAc in 40-60 
petroleum ether) to yield the product (5.06 g, 88%) as a yellow oil. 
 
1
H-NMR (400 MHz, CDCl3): H = 0.06 (s, 3H
6/7
), 0.08 (s, 3H
6/7
), 0.89 (s, 9H
9
), 4.06-4.09 (m, 
2H
5
), 4.39-4.50 (m, 2H
2
), 4.52-4.54 (m, 1H
4
), 5.94 (s, 1H
1
), 7.39-7.44 (m, 3H-Ar), 7.54-7.58 (m, 
2H-Ar). 
 
13
C-NMR (400 MHz, CDCl3): C = -5.4 (C-6/7), -5.3 (C-6/7), 18.3 (C-8), 25.8 (C-9), 62.8 (C-
5), 72.6 (C-2), 84.1 (C-4), 99.2 (C-1), 126.2 (CH-Ar), 128.4 (CH-Ar), 129.2 (CH-Ar), 137.1 (C-
10), 205.2 (C-3). 
 
IR vmax (neat) = 2928, 2857, 1738, 1253 cm
-1
 
 
MS (ES+) m/z = 323 [M+H]
+
. 
HRMS (ES+) calculated 323.1679 for C17H27O4Si, observed 323.1669 [M+H]
+
. 
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(4S,5S)-4-[[tert-Butyl(dimethyl)silyl]oxymethyl]-2-phenyl-1,3-dioxan-5-ol 200 
 
 
 
To a −78 oC solution of ketone 201 (4.50 g, 14.0 mmol) in THF (26 mL) was added 1.0 M L-
selectride in THF (26.5 mL, 26.5 mmol) dropwise and the resulting solution stirred at −78 oC for 
3 hours.  The reaction mixture was then warmed to room temperature and treated with 10% 
NaOH (aq) (250 mL), the layers were separated and the aqueous layer was extracted with EtOAc 
(3 × 300 mL).  The combined organic layers were dried over MgSO4 and concentrated in vacuo 
to yield the crude product. The crude product was purified using flash silica column 
chromatography (15% EtOAc in 40-60 petroleum ether) to yield the product (3.82 g, 84%) as a 
colourless oil. 
 
1
H-NMR (400 MHz, CDCl3): H = 0.08 (s, 3H
6/7
), 0.09 (s, 3H
6/7
), 0.91 (s, 9H
9
), 2.83 (d, 1H
10
, 
J=10.2Hz), 3.70-3.74 (m, 1H
3
), 3.80 (dd, 1H
5
, J=10.1Hz, J=5.3Hz), 3.91 (dd, 1H
5
, J=10.1Hz, 
J=6.7Hz), 3.98 (ddd, 1H
4
, J=6.7Hz, J=5.3Hz, J=1.1Hz), 4.08 (dd, 1H
2
, J=11.9Hz, J=1.3Hz), 4.25 
(dd, 1H
2
, J=11.9Hz, J=1.9Hz), 5.59 (s, 1H
1
), 7.35-7.40 (m, 3H-Ar), 7.48-7.51 (m, 2H-Ar). 
 
13
C-NMR (400 MHz, CDCl3): C = -5.4 (C-6/7), -5.4 (C-6/7), 18.3 (C-8), 25.8 (C-9), 62.4 (C-
5), 63.7 (C-4), 72.7 (C-2), 79.8 (C-3), 101.4 (C-1), 126.0 (CH-Ar), 128.2 (CH-Ar), 129.0 (CH-
Ar), 137.4 (C-Ar). 
 
IR vmax (neat) = 3465, 2958, 2927, 1250 cm
-1
 
 
MS (ES+) m/z = 325 [M+H]
+
,
 
347 [M+Na]
+
. 
HRMS (ESI) calculated 325.1835 for C17H29O4Si, observed 325.1837 [M+H]
+
. 
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(4S,5S)-4-((tert-Butyldimethylsilyloxy)methyl)-2-phenyl-1,3-dioxan-5-yl 
trifluoromethanesulfonate 202 
 
 
 
To a stirred solution of alcohol 200 (300 mg, 0.92 mmol) and pyridine (0.33 mL, 4.07 mmol) in 
CH2Cl2 (6.0 mL) at −78 
o
C, was added trifluoromethanesulfonate anhydride (0.31 mL, 1.85 
mmol) dropwise.  The resulting solution was warmed to 0 
o
C and stirred for 2 hours.  The 
reaction was then diluted with CH2Cl2 (30 mL), washed with H2O (3 × 20 mL), dried over 
MgSO4 and concentrated in vacuo to yield the crude product as an orange residue which was 
used directly in the proceeding step with no further purification. 
 
 
tert-Butyl-dimethyl-[[(2R,4S,5R)-2-phenyl-5-phenylsulfanyl-1,3-dioxan-4-yl]methoxy]silane 
203 
 
 
 
To a stirred suspension of 1.0 M 
t
BuOK in THF (1.5 mL, 1.50 mmol) and 18-crown-6 (138 mg, 
0.52 mmol) in THF (1.0 mL) at −55 oC was added thiophenol (0. 16 mL, 1.50 mmol).  To this 
was added a solution of triflate 202 (470 mg, 1.03 mmol) in THF (1.2 mL).  The reaction mixture 
was stirred for 48 hours at −55 oC and then treated with saturated NaHCO3 (aq) (10 mL) and 
extracted into Et2O (25 mL).  The organic layer was washed with H2O (15 mL), brine (15 mL), 
dried over MgSO4 and concentrated in vacuo to yield the crude product.  The crude product was 
purified using flash silica column chromatography (40% CH2Cl2 in 40-60 petroleum ether) to 
yield the product (206 mg, 48%) as a colourless oil. 
 
 
1
H-NMR (400 MHz, CDCl3): H =  0.04 (s, 3H
6/7
), 0.06 (s, 3H
6/7
), 0.09 (s, 9H
9
), 3.51-3.57 (m, 
1H
3
), 3.76 (ddd, 1H
4
, J=10.6Hz, J=4.0Hz, J=1.9Hz), 3.79 (m, 1H
2
) 4.03 (dd, 1H
5
, J=11.5Hz, J= 
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1.9Hz), 4.10 (dd, 1H
5
, J= 11.5 Hz, J=4.0Hz), 4.34 (dd, 1H
2
, J=11.4Hz, J=5.1Hz), 5.20 (s, 1H
1
), 
7.24-7.36 (m, 6H-Ar), 7.46-7.52 (m, 4H-Ar). 
 
13
C-NMR (400 MHz, CDCl3): C = -5.3 (C-6/7), -5.1 (C-6/7), 18.4 (C-8), 25.9 (C-9), 41.7 (C-
3), 63.3 (C-5), 71.0 (C-2), 81.4 (C-4), 101.4 (C-1), 126.2 (CH-Ar), 127.5 (CH-Ar), 128.2 (CH-
Ar), 128.9 (CH-Ar), 129.1 (CH-Ar), 132.3 (C-Ar), 138.0 (C-Ar). 
 
Note: missing 1 × CH-Ar due to overlapping signals. 
 
IR vmax (neat) = 3031, 2956, 2927, 2855, 1252 cm
-1 
 
MS (EI+) m/z = 417 [M+H]
+
.   
HRMS (EI+) calculated 417.2051 for C23H33O3SSi, observed 417.2057 [M+H]
+
. 
 
 
[(4S,5R)-2-Phenyl-5-phenylsulfanyl-1,3-dioxan-4-yl]methanol 205  
 
 
 
1.0 M TBAF in THF (0.79 mL, 0.79 mmol) was added dropwise to a 0 
o
C solution of the 
protected alcohol 203 (300 mg, 0.72 mmol) in THF (1.2 mL).  The reaction mixture was then 
warmed to room temperature and stirred for a further 15 minutes at this temperature, before being 
poured into H2O (10 mL) and extracted into Et2O (2 × 30 mL).  The combined organic layers 
were dried over MgSO4 and concentrated in vacuo to yield the crude product.  The crude product 
was purified using flash silica column chromatography (15% EtOAc in 40-60 petroleum ether) to 
yield the product (173 mg, 79%) as an amorphous, white solid. 
 
1
H-NMR (400 MHz, CDCl3): H =  2.07 (t, 1H
6
, J=6.8Hz), 3.43-3.51 (m, 1H
3
), 3.81-3.87 (m, 
1H
2
),  3.85 (ddd, 1H
4
, J=10.5Hz, J= 5.0Hz, J= 2.6Hz), 3.98 (ddd, 1H
5
, J=12.0Hz, J=6.8Hz, 
J=5.1Hz)  4.11 (ddd, 1H
5
, J=12.0Hz, J=6.8Hz, J=2.6Hz), 4.38 (dd, 1H
2
, J=11.4Hz, J=5.1Hz) 
5.54 (s, 1H
1
), 7.33-7.42 (m, 6H-Ar), 7.48-7.53 (m, 4H-Ar). 
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13
C-NMR (400 MHz, CDCl3): C = 41.9 (C-3), 63.0 (C-5), 70.8 (C-2), 80.7 (C-4), 101.3 (C-1), 
126.1 (CH-Ar), 128.0 (CH-Ar), 128.4 (CH-Ar), 129.3 (CH-Ar), 132.2 (C-Ar), 132.7 (CH-Ar), 
137.5 (C-Ar). 
 
Note: missing 1 × CH-Ar due to overlapping signals. 
 
IR vmax (neat) = 3348, 3071, 2975, 2858, 1138 cm
-1
 
 
MS (EI+) m/z: 302 [M]
+
. 
HRMS (EI+) calculated 302.0977 for C17H18O3S, observed 302.0977 [M]
+
. 
 
 
(4R,5R)-4-(Iodomethyl)-2-phenyl-5-phenylsulfanyl-1,3-dioxane 206 
 
 
 
Triphenylphosphine (290 mg, 1.12 mmol), imidazole (284 mg, 1.12 mmol) and I2 (142 mg, 1.12 
mmol) were added to a solution of alcohol 205 (170 mg, 0.56 mmol) in CH2Cl2 (10 mL).  The 
reaction mixture was stirred for 3 hours at room temperature then concentrated in vacuo to yield 
the crude product, which was purified using flash silica column chromatography (2.5% EtOAc in 
40-60 petroleum ether) to yield  the product (147 mg, 64%) as a white solid. 
 
1
H-NMR (400 MHz, CDCl3): H = 3.31 (ddd, 1H
3
, J=11.2Hz, J=9.9Hz, J=5.0Hz), 3.56-3.66 (m, 
2H
4,5
), 3.81-3.90 (m, 2H
2,5
)  4.33 (dd, 1H
2
, J=11.5Hz, J=5.0Hz) 5.57 (s, 1H
1
) 7.37-7.46 (m, 6H-
Ar), 7.51-7.55 (m, 4H-Ar). 
 
13
C-NMR (400 MHz, CDCl3): C = 7.9 (C-5), 47.0 (C-3), 70.5 (C-2), 78.7 (C-4), 101.2 (C-1), 
126.1 (CH-Ar), 128.3 (CH-Ar), 129.1 (CH-Ar), 129.4 (CH-Ar), 131.5 (C-Ar), 133.3 (CH-Ar), 
137.4 (C-Ar). 
 
Note: missing 1 × CH-Ar due to overlapping signals. 
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IR vmax (neat) = 2982, 2855, 1215 cm
-1 
 
MS (EI+) m/z = 412 [M]
+
. 
HRMS (EI+) calculated 411.9994 for C17H17IO2S, observed 411.9989 [M]
+
.  
 
mp (CH2Cl2) = 62-66 
o
C. 
 
 
Ethyl 3-Bromopropionamidoacetate 195 
 
 
 
To a stirred solution of glycine-ethyl-ester hydrochloride (100 mg, 0.72 mmol) in H2O-THF (1:1, 
4.0 mL) at 0 
o
C, was added a solution of 3-bromopropionyl (80 µL, 0.72 mmol) chloride in THF 
(1.0 mL) during 10 minutes, maintaining a pH between 5.5-6.5 using 1.0 M NaOH (aq).  The 
reaction mixture was then stirred for 30 minutes, before being warmed to room temperature and 
stirred for a further hour.  The reaction mixture was then extracted into EtOAc (25 mL), washed 
with brine (2 × 30 mL), dried over MgSO4 and concentrated in vacuo.  The crude product was 
triturated twice with 40-60 petroleum ether (5.0 mL) to yield the product (141 mg, 83%) as a 
white solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.29 (t, 3H
1
, J=7.2Hz), 2.84 (t, 2H
7
, J=6.7Hz), 3.63 (t, 2H
8
, 
J=6.7Hz), 4.06 (d, 2H
4
, J=5.0Hz), 4.23 (q, 2H
2
, J=7.2Hz), 6.18 (d, 1H
5
, J=5.1Hz). 
 
13
C-NMR (400 MHz, CDCl3):  C = 14.1 (C-1), 26.8 (C-8), 39.3 (C-7), 41.5 (C-4), 61.7 (C-2), 
169.8 (C-3), 207.1 (C-6). 
 
IR vmax (neat) = 3286, 2986, 1741, 1647 cm
-1 
 
MS (ES+) m/z = 238 [M+H]
+
. 
HRMS (ES+) calculated 238.0079 for C7H13BrNO3, observed 238.0085 [M+H]
+
. 
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Ethyl-(2-oxoazetidin-1-yl)acetate 189 
 
 
 
Pulverised KOH (360 mg, 6.41 mmol) and tetrabutylammonium bromide (348 mg, 1.08 mmol) 
were suspended in a CH2Cl2-MeCN solution (19:1, 110 mL) and stirred vigorously at room 
temperature.  To this was added a solution of bromide 195 (1.22 g, 5.13 mmol) in CH2Cl2-MeCN 
(19:1, 110 mL) during 6 hours.  Additional KOH (360 mg, 6.41 mmol) and tetrabutylammonium 
bromide (348 mg, 1.08 mmol) were added and the reaction stirred overnight.  The reaction 
mixture was then filtered and the filtrate concentrated in vacuo to yield the crude product.  The 
crude product was purified using flash silica column chromatography (50% ethyl acetate in 40-60 
petroleum ether) to yield the product (314 mg, 39% yield) as a colourless oil. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.28 (t, 3H
1
, J=7.2Hz), 3.03 (t, 2H
6
, J=4.2Hz), 3.42 (t, 2H
5
, 
J=4.2Hz), 3.98 (s, 2H
4
), 4.20 (q, 2H
2
, J=7.1Hz). 
 
13
C-NMR (400 MHz, CDCl3): C = 14.1 (C-1), 37.7 (C-6), 40.0 (C-5), 41.5 (C-4), 61.7 (C-2), 
165.5 (C-7), 170.0 (C-3).  
 
IR vmax (neat) = 2986, 1729 cm
-1 
 
MS (ES+) m/z = 180 [M+Na]
+
. 
HRMS (ES+) calculated 180.0637 for C7H11NO3Na, observed 180.0652 [M+Na]
+
. 
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Results and Discussion Section 3. 
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1,2:5,6-Di-O-isopropylidene-D-mannitol 227 
 
 
 
ZnCl2 (40.3 g, 0.30 mol) was heated to a melt in vacuo (3 mbar) then cooled to room temperature 
under argon.  To this was added anhydrous acetone (390 mL) and D-mannitol (20.0 g, 0.11 mol) 
and the resulting suspension stirred for 16 hours at room temperature.  The reaction mixture was 
poured into 7.0 M K2CO3 (aq) (140 mL), stirred vigorously and the precipitated solid filtered and 
washed with acetone.  The filtrate was concentrated in vacuo to remove acetone and then 
extracted with Et2O (2 × 400 mL), the combined organic layers were dried over MgSO4 and 
concentrated in vacuo.  Hexane (400 mL) was then added, the resulting suspension stirred for 20 
minutes, stored at 0 
o
C for 1 hour and then filtered and washed with cold hexane to yield the 
product (21.1 g, 73%) as a white solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.36 (s, 6 H
1/2
), 1.42 (s, 6H
1/2
), 2.60 (d, 2H
7
, J=6.7Hz), 3.73-
3.77 (m, 2H
6
), 3.97 (dd, 2H
4
, J=8.5Hz, J=5.6Hz), 4.12 (dd, 2H
4
, J=8.5Hz, J=6.4Hz), 4.16-4.22 
(m, 2H
5
). 
 
13
C-NMR (100 MHz, CDCl3):  C = 25.2 (C-1/2), 26.7 (C-1/2), 66.7 (C-4), 71.2 (C-6), 76.3 (C-
5), 109.4 (C-3). 
 
IR vmax (neat) = 3309, 2982, 1371 cm
-1 
 
MS (ES+) m/z = 263 [M+H]
+
,
 
285 [M+Na]
+
. 
HRMS (ES+) calculated 263.1495 for C12H23O6, observed 263.1504 [M+H]
+
. 
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2,3-O-Isopropylidene-D-glyceraldehyde 225 
 
 
 
Silica supported sodium metaperiodate (NaIO4:SiO2):  
NaIO4 (25.7 g, 0.12 mol) was suspended in H2O (50 mL) and heated to 80 
o
C.   Silica gel (100 g) 
was then added followed by vigorous shaking and stirring. 
 
To a stirred suspension of NaIO4:SiO2 (115 g) in CH2Cl2 (190 mL) at 0 
o
C was added a solution 
of protected acetonide 227 (10.0 g, 38.2 mmol) in CH2Cl2 (190 mL).  The reaction mixture was 
then stirred for 30 minutes at 0 
o
C and then filtered.  The collected solids were washed with 
CH2Cl2 and the filtrate was concentrated in vacuo.  The crude product was purified by vacuum 
distillation (head temperature 50–54oC at 18 mbar) to give the product (6.27 g, 64%) as an 
unstable colourless liquid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.41 (s, 3H
1/2
), 1.48 (s, 3H
1/2
), 4.10 (dd, 1H
4
, J=8.6Hz, 
J=4.8Hz), 4.20 (dd
4
, 1H, J=8.6Hz, J=7.8Hz), 4.41 (m, 1H
5
), 9.72 (d, 1H
6
, J=1.8Hz). 
 
13
C-NMR (100 MHz, CDCl3):  C = 25.1 (C-1), 26.3 (C-2), 65.6 (C-4), 79.9 (C-5), 110.1 (C-3), 
201.9 (C-6). 
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Ethyl 3-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-difluoro-3-hydroxy-propanoate 229 
 
 
 
To a suspension of Zn dust (8.8 g, 140 mmol) and I2 (1.4 g, 0.31 mmol) in Et2O (45 mL) was 
added a mixture of aldehyde 225 (3.5 g, 27 mmol) and ethyl bromodifluoroacetate (4.5 mL, 35 
mmol) in THF (90 mL) and Et2O (45 mL).  The resulting solution was refluxed for 1 hour.  The 
reaction mixture was cooled and poured into cold 1.0 M HCl (aq) (150 mL), extracted into Et2O 
(2 × 300 mL), the combined organics were washed with brine (150 mL), saturated NaHCO3 (aq) 
(150 mL), dried over MgSO4 and concentrated in vacuo.  The crude product was purified using 
flash silica column chromatography (20% EtOAc in 40-60 petroleum ether) to yield the product 
as a colourless oil containing a 1.0:2.3 mixture of cis (B) and trans (A) diastereomers (5.2 g, 
76%). 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.36 (m, 18H
1,2,10A+B
), 2.69 (d, 1H
11A
, J=4.3Hz), 2.93 (d, 
1H
11B
, J=8.7Hz), 3.88-4.40 (m, 12H
4,5,6,9A+B
). 
 
13
C-NMR (100 MHz, CDCl3): C = 13.9 (C-10A+B), 25.0 (C-1A/B), 25.3 (C-1A/B), 26.2 (C-
2A+B), 63.2 (C-9A), 63.3 (C-9B), 65.5 (d, C-4A, 
4
JC-F=2.6 Hz), 66.4 (C-4B), 70.7-71.0 (m, C-
6B), 71.8 (dd, C-6A, 
2
JC-F=24.9Hz, 
2
JC-F=23.0Hz), 72.2 (C-5B), 73.4 (C-5A),  109.7 (C-3A), 
110.3 (C-3B), 113.9 (dd, C-7, JC-F=254.0, JC-F=254.8Hz), 163.0 (C-8A/B), 163.3 (C-8A/B). 
 
Note: assigning peaks for individual diastereomers was difficult due to overlapping peaks. 
 
IR vmax = 3456, 2995, 1763 cm
-1 
 
MS (ES+) m/z = 255 [M+H]
+
. 
HRMS (ES+) calculated 255.1044 for C10H17F2O5, observed 255.1038 [M+H]
+
. 
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Ethyl 3-(benzoyloxy)-3-[(4R)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-difluoropropanoate 230 
 
 
 
A solution of benzoyl chloride (0.27 mL, 2.36 mmol) in CH2Cl2 (2.5 mL) was added dropwise to 
a solution of alcohol 229 (500 mg, 1.97 mmol), 2,6-lutidine (0.45 mL, 3.93 mmol) and DMAP 
(151 mg, 1.24 mmol) in CH2Cl2 (2.5 mL) at 35 
o
C.  The reaction mixture was then stirred for 3 
hours, cooled to room temperature, diluted with CH2Cl2 (10 mL) and washed sequentially with 
1.0 M HCl (aq) (10 mL), saturated NaHCO3 (aq) (10 mL), H2O (10 mL), dried over MgSO4 and 
concentrated in vacuo.  The crude product was purified using flash silica column chromatography 
(10% EtOAc in 40-60 petroleum ether) to yield the product as a colourless oil containing a 
1.0:2.3 mixture of cis (B) and trans (A)  diastereomers (520 mg, 74%). 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.32 (m, 18H
1,2,10A+B
), 4.00 (dd, 1H
4B
, J=8.9Hz, J=5.9Hz), 
4.06 (dd, 1H
4A
, J=8.9Hz, J=5.8Hz), 4.12-4.19 (m, 2H
4A+B
), 4.23-4.26 (m, 4H
9A+B
), 4.50-4.54 (m, 
1H
5A
), 4.55-4.60 (m, 1H
5B
), 5.70 (ddd, 1H
6B
, J=13.8Hz, 
3
JH-F=7.6Hz, 
3
JH-F=5.8Hz), 5.83-5.91 (m, 
1H
6A
), 7.44-7.49 (m, 4H-Ar), 7.58-7.63 (m, 2H-Ar), 8.06-8.10 (m, 4H-Ar). 
 
13
C-NMR (100 MHz, CDCl3): C = 13.8 (C-10A+B), 25.1 (C-1A), 25.4 (C-1B), 26.0 (C-2B), 
26.1 (C-2A), 63.3 (C-9B), 63.4 (C-9A), 65.6 (C-4A), 65.8 (d, C-4B, 
4
JC-F=3.5Hz), 70.8 (dd, C-
6A, 
2
JC-F=25.4Hz, 
2
JC-F=22.8Hz), 71.1-71.7 (m, C-6B), 72.3 (C-5B), 72.5 (C-5A), 110.1 (C-3A), 
110.2 (C-3B), 112.80 (t, C-7A, JC-F=258.5Hz), 128.6 (CH-Ar), 128.7 (CH-Ar), 130.1 (CH-Ar), 
130.1 (CH-Ar), 133.7 (CH-Ar), 133.9 (CH-Ar), 161.8 (C=O), 162.3 (C=O), 164.6 (C=O), 164.8 
(C=O). 
 
Note: assigning peaks for individual diastereomers was difficult, missing 2 × C-Ar and C-7B due 
to overlapping peaks assigning peaks. 
 
IR vmax = 2988, 1767, 1736 cm
-1 
 
MS (CI+) m/z = 359 [M+H]
+
.  
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HRMS (CI+) calculated 359.1306 for C17H21F2O3, observed 359.1299 [M+H]
+
. 
 
 
2-Deoxy-2,2-difluoro-D-pentofuranos-1-ulose-3-benzoate 231 
 
 
 
A mixture of the propionate 230 (0.58 g, 1.63 mmol), H2O (0.17 mL, 9.13 mmol) and 
trifluoroacetic acid (0.03 mL, 0.39 mmol) in MeCN (3.3 mL) was refluxed at 80 
o
C for 3 hours. 
Using azeotoropic distillation the MeCN was removed and replaced by dry toluene and the 
reaction heated at 100 
o
C for a further hour.  The mixture was then cooled to room temperature 
and concentrated in vacuo to yield the crude oil (0.39 g, 89%) as a 1.0:2.3 mixture of xylo (B) 
and ribo (A) epimers which were used directly in the next step without further purification. 
The data were in agreement with the published data.
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Data for ribo epimer.  
 
1
H-NMR (400 MHz, CDCl3): H = 3.96 (dd, 1H
5
, J=13.0Hz, J=3.3Hz) 4.11 (dd, 1H
5
, J=13.0Hz, 
J=2.7Hz) 4.90 (m, 1H
4
) 5.79 (ddd, 1H
1
, J=11.5Hz, 
3
JH-F=9.3Hz, 
3
JH-F=5.7Hz) 7.48 (m, 2H-Ar) 
7.63 (m, 1H-Ar), 8.06 (m, 2H-Ar). 
 
IR vmax = 3457, 2948, 1815, 1724 cm
-1 
 
MS (ES+) m/z = 273 [M+H]
+
.  
HRMS (ES+) calculated 273.0575 for C12H11F2O5, observed 273.0577 [M+H]
+
. 
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2-Deoxy-2,2-difluoro-D-ribo-pentofuranose-1-ulose-3,5-dibenzoate 228 
 
 
 
To a solution of lactone 231 (250 mg, 0.92 mmol) in EtOAc (1.6 mL) was added pyridine (0.16 
mL. 1.84 mmol) and DMAP (14 mg, 0.10 mmol) and the resulting mixture heated to 65 
o
C. A 
solution of benzoyl chloride (0.12 mL, 1.10 mmol) in EtOAc (1.6 mL) was then added and the 
solution stirred for 2 hours.  The reaction mixture was cooled to 5 
o
C, filtered through a celite 
padded frit and concentrated in vacuo to give the crude product as a mixture of epimers (225 mg, 
65%). Recrystallisation from CH2Cl2-Heptane yielded the desired product (70 mg, 20%) as a 
white solid. 
The data were in agreement with the published data.
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[α]D
25
 (c = 1.0, CHCl3) +49.6 
 
1
H-NMR (400 MHz, CDCl3): H = 4.71 (dd, 1H
5
, J=12.7Hz, J=4.4Hz), 4.78 (dd, 1H
5
, 
J=12.7Hz, J=3.9Hz), 5.00 (m, 1H
4
), 5.75 (ddd, 1H
1
, 
3
JH-F=12.2Hz, 
3
JH-F=5.9Hz, J=4.6Hz), 7.45-
7.53 (m, 4H-Ar), 7.59-7.70 (m, 2H-Ar), 8.03-8.10 (m, 4H-Ar). 
 
13
C-NMR (100 MHz, CDCl3): C = 62.2 (C-5), 69.5 (dd, C-1, 
2
JC-F=31.0Hz, 
2
JC-F=15.7Hz), 78.4 
(d, C-4, 
3
JC-F=5.9Hz), 111.48 (dd, C-2, JC-F =262.6Hz, JC-F=257.9Hz), 127.4 (C-Ar), 128.6 (CH-
Ar), 128.7 (C-Ar), 128.8 (CH-Ar), 129.8 (CH-Ar), 130.2 (CH-Ar), 133.7 (CH-Ar), 134.5 (CH-
Ar), 162.5 (C=O), 164.6 (C=O), 165.7 (C=O). 
 
IR vmax = 3070, 1817, 1805, 1725, 1711 cm
-1 
 
Anal. calculated for C19H14F2O6: C, 60.64; H, 3.75. Found: C, 60.51; H, 3.65.  
 
mp (CH2Cl2-Heptane) = 107-108 
o
C 
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2-Deoxy-2, 2-difluoro-D-ribofuranos-1-ulose-3,5-dibenzoate 232 
 
 
 
To a 0 
o
C solution of furanose 228 (10.0 g, 26.6 mmol) in Et2O-THF (1:1, 110 mL) was added 
LiAlH(O
t
Bu)3 (10.2 g, 40.0 mmol) portion-wise during 40 minutes and the resulting suspension 
warmed to room temperature and stirred for 1.5 hours.  The reaction mixture was quenched by 
dropwise addition of MeOH (20 mL), then diluted with Et2O (200 mL) and washed sequentially 
with 1.0 M HCl (aq) (200 mL), saturated NaHCO3 (aq) (150 mL), saturated Rochelle’s salt (aq) 
(2 × 200 mL) and H2O (200 mL).  The organic layer was then dried over MgSO4 and 
concentrated in vacuo to yield the product (10.0 g, 99.8%) as colourless oil in a 1.0:1.5 mixture 
of β and α anomers.  This was used directly in the next step with no further purification. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 4.45-4.49 (m, 1H
4β
), 4.60 (dd, 1H
5α
, J=12.0Hz, J=4.3Hz), 
4.67-5.69 (m, 2H
5β
), 4.71-4.80 (m, 2H
4α,5α
), 5.33-5.36 (m, 1H
3β
), 5.47-5.52 (m, 2H
1+3α
), 5.73 (td, 
1H
1β
, 
3
JH-F=10.1Hz, J=6.2Hz), 7.38-7.50 (m, 8H-Ar), 7.54-7.66 (m, 4H-Ar), 8.04-8.10 (m, 8H-
Ar). 
 
13
C-NMR (100 MHz, CDCl3): C = 63.2 (C-5α), 64.3 (C-5β), 71.3 (dd, C-1α, 
2
JC-F=29.0Hz, 
2
JC-
F =16.0Hz), 72.0 (dd, C-1β, 
2
JC-F=36.4Hz, 
2
JC-F=17.6Hz), 77.2 (C-4α), 79.5 (C-4β), 95.5-96.4 (m, 
C-3α+β), 121.5 (t, C-2α/β, JC-F=261.0Hz), 122.3 (t, C-2α/β, JC-F=256.1Hz), 128.0 (C-Ar), 128.5 
(CH-Ar), 128.6 (CH-Ar), 129.6 (CH-Ar), 129.8 (CH-Ar), 129.9 (CH-Ar), 130.1 (CH-Ar), 133.0 
(CH-Ar), 133.4 (CH-Ar), 133.5 (CH-Ar), 133.9 (CH-Ar), 134.0 (CH-Ar). 165.2 (C=O), 165.3 
(C=O), 166.3 (C=O), 166.5 (C=O). 
 
Note: missing 3 × C-Ar and 1 × CH-Ar due to overlapping peaks. 
 
IR vmax (neat) = 3453, 2955, 1719 cm
-1 
 
MS (ES+) m/z = 379 [M+H]
+
.  
HRMS (ES+) calculated 379.0993 for C19H17F2O6, observed 379.0974 [M+H]
+
. 
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2-Deoxy-2, 2-difluoro-D-ribofuranos-1-ulose-3,5-dibenzoate-1-methanesulfonate 233 
 
 
 
To a solution of hemiacetal 232 (20.0 g, 52.9 mmol) in CH2Cl2 (210 mL) at 0 
o
C was added NEt3 
(13.9 mL, 100 mmol) and methanesulfonyl chloride (7.0 mL, 90.0 mmol).  The resulting solution 
was warmed to room temperature and stirred for 2 hours.  The reaction mixture was then diluted 
with CH2Cl2 (500 mL) and washed sequentially with 1.0 M HCl (aq) (500 mL), saturated 
NaHCO3 (aq) (300 mL), H2O (500 mL), dried over MgSO4 and concentrated in vacuo to yield 
the product as orange oil (21.3 g, 88%) in a 1.0:1.5 mixture of β and α anomers.   
The data were in agreement with the published data.
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1
H-NMR (500 MHz, CDCl3): H = 3.02 (s, 3H
6β
), 3.18 (s, 3H
6α
), 4.60 (dd, 1H
5β
, J=12.3Hz, 
J=4.4Hz), 4.64-4.69 (m, 2H
4β,5β
), 4.72-4.78 (m, 2H
5α
), 4.84 (dd, 1H
4α
, J=7.9Hz, J=4.0Hz), 5.57 
(dd, 1H
1α
, 
3
JH-F=16.4Hz J=4.2Hz), 5.94 (dt, 1H
1β
, J=15.3Hz, 
3
JH-F=7.1Hz), 6.03-6.05 (m, 1H
3β
),  
6.14 (dd, 1H
3α
, 
3
JH-F=6.0Hz, 
3
JH-F=1.1Hz), 7.42-7.51 (m, 8H-Ar), 7.58-7.67 (m, 4H-Ar), 8.03-
8.09 (m, 8H-Ar). 
 
13
C-NMR (125 MHz, CDCl3):  C = 40.2 (C-6α), 40.3 (C-6β), 62.5 (C-5α), 63.0 (C-5β), 69.4 
(dd, C-1β, 2JC-F=26.0Hz, 
2
JC-F=15.6Hz), 71.0 (dd, C-1α, 
2
JC-F=36.8Hz, 
2
JC-F=17.4Hz), 79.72 (d, 
C-4β, 3JC-F=7.7Hz), 82.7 (C-4α), 98.8 (dd, C-3β, 
2
JC-F=42.0Hz, 
2
JC-F=25.0Hz), 99.6 (dd, C-3α, 
2
JC-F=46.2Hz, 
2
JC-F=25.0Hz), 118.3-122.9 (m, C-2α+β), 127.9 (C-Ar), 128.0 (C-Ar), 128.9 (C-
Ar), 129.1 (CH-Ar), 128.5 (CH-Ar), 128.7 (CH-Ar), 128.7 (CH-Ar), 128.8 (CH-Ar), 129.8 (CH-
Ar), 130.1 (CH-Ar), 130.2 (CH-Ar), 133.5 (CH-Ar), 133.7 (CH-Ar), 134.2 (CH-Ar), 134.2 (CH-
Ar), 164.9 (C=O), 165.0 (C=O), 165.8 (C=O), 165.9 (C=O). 
 
Note: missing 1 × C-Ar due overlapping peaks. 
 
IR: vmax = 3030, 1724 cm
-1 
HRMS: Did not provide spectra suitable for interpretation. 
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2’-Deoxy-2’,2’-difluoruridine-3’,5’-dibenzoate 221β 
 
 
 
Uracil (8.9 g, 79.3 mmol) and (NH4)2SO4 (628 mg, 4.76 mmol) were refluxed in HMDS (220 
mL) for 12 hours, then cooled to room temperature and concentrated in vacuo.  The resulting 
residue was dissolved in DCE (150 mL), treated with TMSOTf (14.4 mL, 79.3 mmol) and a 
solution of mesylates 233 (21.3 g, 46.7 mmol) in DCE (80 mL) added.  The mixture was heated 
to reflux and stirred for 24 hours, then cooled to room temperature and the solvent removed in 
vacuo.  The resulting gum was dissolved in EtOAc (800 mL) then washed sequentially with H2O 
(2 × 600 mL), saturated NaHCO3 (aq) (600 mL) and brine (600 mL) dried over MgSO4 and 
concentrated in vacuo to yield the crude product (3.92 g, 66%) as a 1.0:1.4 mixture of β and α-
anomers.  Recrystallisation of the crude material, once from EtOAc and once from CH2Cl2 
yielded exclusively the β-anomer (4.65 g, 21%) as a white solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 4.57-4.60 (m, 1H
4
), 4.69 (dd, 1H
5
, J=12.5Hz, J=4.3Hz), 4.83 
(dd, 1H
5
, J=12.5Hz, J=3.1Hz), 5.62-5.68 (m, 1H
1
), 5.67 (dd, 1H
7
, J=8.2Hz, J=2.1Hz), 6.39 (dd, 
1H
3
, 
3
JH-F=11.8Hz, 
3
JH-F=6.3Hz),7.39 (dd, 1H
6
, J=8.2Hz, J=2.1Hz), 7.49 (m, 4H-Ar), 7.65 (m, 
2H-Ar), 8.07 (m, 4H-Ar), 8.23 (s, 1H
10
). 
 
13
C-NMR (100 MHz, CDCl3):  C = 62.4 (C-5) 71.3 (dd, C-1, 
2
JC-F=16.8Hz, 
2
JC-F= 4.7Hz) 78.5 
(C-4) 83.1 (dd, C-3, 
2
JC-F=37.5Hz, 
2
JC-F=21.0Hz) 103.2 (C-7) 120.77 (dd, C-2, JC-F =259.1Hz, JC-
F =266.6Hz) 127.7 (C-Ar) 128.7 (CH-Ar) 128.8 (CH-Ar) 129.0 (C-Ar) 129.6 (CH-Ar) 130.1 
(CH-Ar) 133.7 (CH-Ar) 134.3 (CH-Ar)  139.6 (d, C-6, 
4
JC-F=3.2Hz) 149.7 (C=O) 161.8 (C=O) 
164.8 (C=O) 165.9 (C=O). 
 
IR: vmax = 3189, 3060, 2970, 1723, 1689 cm
-1 
 
MS (ES+) m/z = 473 [M+H]
+
.  
HRMS (ES+) calculated 473.1160 for C23H19N2F2O7, observed 473.1150 [M+H]
+
. 
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2’-Deoxy-2’,2’-difluorouridine 260 
 
 
 
To a solution of the protected nucleoside 221β (390 mg, 0.42 mmol) in MeOH (83 mL) at 0 oC 
was added 7.0 M NH3 in MeOH (17 mL, 116 mmol).  The resulting solution was warmed to room 
temperature and stirred for 16 hours.  The solvents were removed in vacuo and the resultant 
residue partitioned between H2O (80 mL) and EtOAc (80 mL). The organic layer was re-
extracted with H2O (80 mL) and the combined aqueous layers concentrated in vacuo to yield the 
product (197 mg, 90%) as a colourless amorphous solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, D2O): H = 3.75 (dd, 1H
5
, J=13.1Hz, J=4.4Hz), 3.90 (dd, 1H
5
, J=13.1Hz, 
J=2.0Hz), 3.96 (m, 1H
4
), 4.26 (td, 1H
1
, 
3
JH-F=11.8Hz, J=8.5Hz), 5.80 (d, 1H
7
, J=8.1Hz), 6.09 (m, 
1H
3
), 7.67 (d, 1H
6
, J=8.1Hz). 
 
13
C-NMR (100 MHz, D2O):  C = 59.3 (C-5), 69.2 (dd, C-1, 
2
JC-F=25.6Hz, 20.7Hz) 80.46 (d, C-
4, 
3
JC-F=7.8Hz) 84.13 (dd, C-3, 
2
JC-F=39.3Hz, 25.3Hz), 102.5 (C-7),  122.1 (dd, C-2, JC-F= 
260.6Hz, 259.5Hz), 141.4 (C-6), 151.4 (C-9), 165.9 (C-8). 
 
IR vmax (neat) = 3266, 1686 cm
-1 
 
MS (ES+) m/z = 265 [M+H]
+
. 
HRMS (ES+) calculated 265.0636 for C9H11N2F2O5, observed 265.0635 [M+H]
+
. 
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(2R,3R,5R)-2-[(Benzoyloxy)methyl]-4,4-difluoro-5-(5-iodo-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl)oxolan-3-yl benzoate 235 
 
 
 
A mixture of the protected nucleoside 221β (300 mg, 0.64 mmol), I2 (102 mg, 0.40 mmol) and 
ceric ammonium nitrate (175 mg, 0.32 mmol) in MeCN (6.4 mL) were refluxed at 80 
o
C for 4 
hours, then cooled to room temperature and stirred for 16 hours.  The solvent was removed in 
vacuo and the resulting residue dissolved in cold EtOAc (20 mL) and washed with brine (10 mL) 
and 5% NaHSO3 (aq) (5 mL). The aqueous layers were extracted with EtOAc (20 mL) and the 
combined organic layers were washed sequentially with 5% NaHSO3 (aq) (5 mL), brine (15 mL) 
and H2O (10 mL) dried over MgSO4 and concentrated in vacuo.  The crude product was purified 
using flash silica column chromatography (4% acetone in CHCl3) to yield the product (290 mg, 
76%) as a white powder. 
 
1
H-NMR (500 MHz, CDCl3): H = 4.59-4.62 (m, 1H
4
), 4.76 (dd, 1H
5
, J=12.6Hz, J=3.8Hz), 4.84 
(dd, 1H
5
, J=12.6Hz, J=2.9Hz), 5.65 (ddd, 1H
1
, 
3
JH-F=14.9Hz, 
3
JH-F=4.9Hz, J=1.7Hz), 6.37 (dd, 
1H
3
, 
3
JH-F=12.4Hz, 
3
JH-F=5.7Hz), 7.48-7.52 (m, 4H-Ar), 7.60-7.67 (m, 2H-Ar), 7.81 (d, 1H
6
, 
4
JH-
F=2.3Hz), 8.08-8.10 (m, 4H-Ar), 8.28 (s, 1H
10
). 
 
13
C-NMR (125 MHz, CDCl3):  C = 62.3 (C-5), 69.2 (C-7), 71.4 (dd, C-1, 
2
JC-F=35.4Hz, 
2
JC-
F=16.5Hz), 79.0 (C-4), 83.2 (dd, C-3, 
2
JC-F=36.0Hz, 
2
JC-F=21.1Hz), 120.44 (dd, C-2, JC-F= 
259.1Hz, 258.5Hz), 127.7 (C-Ar), 128.7 (CH-Ar), 128.8 (CH-Ar), 128.9 (C-Ar), 129.8 (CH-Ar), 
130.1 (CH-Ar), 133.7 (CH-Ar), 134.4 (CH-Ar), 144.1 (C-6), 149.3 (C=O), 158.8 (C=O), 164.8 
(C=O), 166.0 (C=O).   
 
IR vmax (neat) = 3252, 3049, 1729, 1723, 1694 cm
-1 
 
MS (ES+) m/z = 599 [M+H]
+
. 
HRMS (ES+) calculated 599.0127 for C23H18N2F2O7I, observed 599.0102 [M+H]
+
. 
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1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2,3,4-
tetrahydropyrimidine-2,4-dione 223 
 
 
 
To a solution of iodide 235 (280 mg, 0.47 mmol) in MeOH (95 mL) at 0 
o
C was added 7.0 M 
NH3 in MeOH (9.4 mL, 59.3 mmol) and the resulting solution warmed to room temperature and 
stirred for 16 hours.  The solvents were removed in vacuo and the resultant residue partitioned 
between CH2Cl2 (50 mL) and H2O (50 mL).  The organic layer was extracted with water (2 × 50 
mL) and the combined aqueous layers then concentrated under reduced pressure to yield the 
product (182 mg, 99%) as an off white amorphous solid. 
 
1
H-NMR (400 MHz, MeOD-d4): H = 3.78 (dd, 1H
5
, J=12.6Hz, J=2.5Hz), 3.90 (dt, 1H
4
, 
J=8.4Hz, J=2.4), 3.93-3.97 (m, 1H
5
), 4.32 (td, 1H
1
, 
3
JH-F=12.4Hz, J=8.5Hz), 6.09-6.13 (m, 1H
3
), 
8.44 (s, 1H
6
). 
 
13
C-NMR (100 MHz, MeOD-d4):  C = 59.9 (C-5) 69.1 (C-7) 69.6-70.0 (m, C-1) 82.8 (d, C-4, 
3
JC-F=8.1Hz) 85.0-86.0 (m, C-3) 122.60 (dd, C-2, JC-F=261.1Hz, JC-F=258.6) 146.1 (C-6) 151.8 
(C-9) 162.4 (C-8). 
 
IR vmax (neat) = 3400, 3059, 1700, 1671 cm
-1 
 
MS (ES+) m/z = 391 [M+H]
+
. 
HRMS (ES+) calculated 390.9603for C9H10N2F2O5I, observed 390.9605 [M+H]
+
. 
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1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trimethylstannyl)-
1,2,3,4-tetrahydropyrimidine-2,4-dione 224 
 
 
 
Iodide 223 (75 mg, 0.19 mmol) was dissolved in 1,4-dioxane (3 mL) at 50 
o
C, then cooled to 
room temperature and hexamethylditin (90 µL, 0.42 mmol) and Pd(PPh3)4 (5 mg, 5 µmol) added.  
The reaction mixture was then stirred at reflux for 20 hours, cooled to room temperature and 
concentrated in vacuo.  The crude product was purified using flash silica column chromatography 
(25% acetone in CH2Cl2) to yield the product (67 mg, 83%) as a white solid. 
 
1
H-NMR (400 MHz, CD3OD): H = 0.25 (s, 9H
13
), [d, 
2
JH-
119
Sn=58.8Hz, d, 
2
JH-
117
Sn=56.3Hz] 
3.75 (dd, 1H
5
, J=12.6Hz, J=2.5Hz), 3.87 (dt, 1H
4
, J=8.6Hz, J=2.5Hz), 3.92-3.95 (m, 1H
5
), 4.31 
(td, 1H
1
, 
3
JH-F=12.5Hz , J=8.6Hz,), 6.16 (t, 1H
3
, 
3
JH-F=7.8Hz), 7.62 (s, 1H
6
), [d, 
3
J119Sn-
H=37.5Hz]. 
 
13
C-NMR (100 MHz, CD3OD):  C = -9.5 (C13), [d, JC-
117
Sn=365.5Hz, d, JC-
119
Sn=382.4Hz] 59.8 
(C-5), 70.03 (t, C-1, 
2
JC-F=22.6Hz), 82.22 (t, C-4, 
3
JC-F=4.0Hz), 85.1-85.6 (m, C-3), 113.8 (C-7), 
124.21 (t, C-2, 
1
JC-F=258.0Hz), 145.3 (C-6), 152.7 (C-9), 168.6 (C-8). 
 
IR vmax (neat) = 3269, 1697, 1648, 1601 cm
-1 
 
HRMS Did not provide spectra suitable for interpretation. 
 
mp (acetone) = 73-76 
o
C.  
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2’-Deoxy-2’,2’-difluorothymidine 90 
 
 
 
A mixture of Pd2(dba)3 (124 mg, 0.12 mmol), tri(o-tolyl)phosphine (143 mg, 0.47 mmol) and 
stannane 224 (100mg, 0.23 mmol) in DMF (30 mL) was purged with argon for 10 minutes, then 
treated with a solution of methyl iodide (40 mg, 0.28 mmol) in DMF (3mL).  The resulting 
mixture was heated at 130 
o
C for 10 minutes then cooled to room temperature, the catalyst 
removed by filtration and the filtrate concentrated in vacuo.  The crude product was purified 
using flash silica column chromatography (7% MeOH in CHCl3) to yield the product (39 mg, 
61%) as a colourless oil. 
 
1
H-NMR (500 MHz, MeOD-d4): H = 1.87 (s, 3H
13
), 3.78 (dd, 1H
5
, J=12.7Hz, J=3.1Hz), 3.87 
(dt, 1H
4
, J=8.4Hz, J=2.7Hz), 3.94 (m, 1H
5
), 4.30 (td, 1H
1
, 
3
JH-F=12.2Hz, J=8.4Hz), 6.12 (dd, 
1H
3
, 
3
JH-F=9.1Hz, 
3
JH-F=6.8Hz), 7.71 (s, 1H
6
).  
 
13
C-NMR (125 MHz, MeOD-d4):  C = 12.4 (C-13) 60.4 (C-5) 70.30 (dd, C-1, 
2
JC-F=25.6Hz, 
2
JC-F =20.4Hz), 82.5 (d, C-4, 
3
JC-F=8.4Hz), 85.18 (dd, C-3, 
2
JC-F =40.1Hz, 
2
JC-F =25.2Hz), 111.7 
(C-7), 124.01 (dd, C-2, JC-F =253.1Hz, JC-F =263.1Hz), 137.4 (C-6), 152.2 (C-9), 166.0 (C-8). 
 
IR vmax (neat) = 3374, 1692 cm
-1 
 
MS (ES+) m/z = 279 [M+H]
+
. 
HRMS (ES+) calculated 279.0793 for C10H13N2F2O5, observed 279.0790 [M+H]
+
. 
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2’,2’-Difluoro-2’-deoxycytidine-3’,5’-dibenzoate 222β 
 
 
 
Cytosine (4.82g, 43.4 mmol) and (NH4)2SO4 (0.34 g, 2.60 mmol) in HMDS (100 mL) were 
refluxed for 16 hours, then cooled to room temperature and concentrated in vacuo.  The resulting 
residue was dissolved DCE (80 mL), treated with TMSOTf (7.9 mL, 43.4 mmol) and then a 
solution of mesylates 233 (11.8 g, 25.9 mmol) in DCE (50 mL) added.  The resulting solution 
was heated at reflux for 48 hours then cooled to room temperature and concentrated in vacuo.  
The resultant residue taken up in EtOAc (150 mL), washed with H2O (2 × 150 mL), saturated 
NaHCO3 (aq) (150 mL) and then concentrated to approximately one third volume resulting in the 
precipitation of a white solid. This was collected by filtration, washed with cold EtOAc and then 
vacuum dried to give the product (4.91 g, 40%) in a 1.0:1.0 mixture of β and α-anomers.  
Trituration with hot MeOH allowed isolation of the insoluble β-product (1.99 g, 16%) as a white 
solid.    
The data were in agreement with the published data.
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1
H-NMR (500 MHz, DMSO-d6): H = 4.67-4.77 (m, 3H
4,5
), 5.79 (d, 1H
8
, J=7.5Hz), 5.80-5.84 
(m, 1H
1
), 6.38 (br, s, 1H
3
), 7.46-7.49 (m, 2H-Ar/2H
10
), 7.56-7.59 (m 2H-Ar), 7.62-7.67 (m, 2H-
Ar), 7.72-7.75 (m 1H-Ar), 7.94-7.96 (m, 2H-Ar), 8.04-8.06 (m, 2H-Ar). 
 
13
C-NMR (125 MHz, DMSO-d6):  C = 63.4 (C-5), 71.7 (dd, C-1, 
2
JC-F=26.3Hz, 
2
JC-F=22.3Hz), 
75.6 (C-4) 78.8 (t, C-3, 
2
JC-F=33.4Hz) 94.99 (C-8), 121.72 (dd, C-2, JC-F=268.8Hz, JC-
F=254.4Hz), 128.0 (C-Ar), 128.7 (CH-Ar), 128.9 (CH-Ar), 129.1 (CH-Ar), 129.2 (CH-Ar), 129.6 
(CH-Ar), 133.6 (CH-Ar), 134.2 (CH-Ar), 141.8 (C-Ar), 154.3 (C=O), 164.3 (C=O), 165.3 
(C=O), 165.7 (C-7).  
 
IR vmax (neat) = 3366, 3176, 1719, 1631 cm
-1 
 
MS (ES+) m/z = 472 [M+H]
+
. 
HRMS (ES+) calculated 472.1320 for C23H20N3F2O6, observed 472.1331 [M+H]
 +
. 
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2’-Deoxy-2’,2’-difluorocytidine 84 
 
 
 
To a solution of protected nucleoside 222β (600 mg, 1.27 mmol) in MeOH (120 mL) at 0 oC was 
added 7.0 M NH3 in MeOH (25 mL, 178 mmol) and the resulting solution warmed to room 
temperature and stirred for 16 hours.  The solvents were removed in vacuo and the resultant 
residue partitioned between EtOAc (125 mL) and H2O (125 mL).  The organic layer was 
extracted with H2O (2 × 125 mL) and the combined aqueous layers concentrated under reduced 
pressure to yield the product (335 mg, 100%) as an amorphous white solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, D2O): H = 3.75 (dd, 1H
5
, J=13.1Hz, J=4.3Hz), 3.90 (dd, 1H
5
, J=13.1Hz, 
J=2.2Hz), 3.92-3.96 (m, 1H
4
), 4.23 (td, 1H
1
, 
3
JH-F=12.0Hz, J=8.7Hz), 5.96 (d, 1H
8
, J=7.6Hz), 
6.10 (t, 1H
3
, 
3
JH-F=7.9Hz), 7.64 (d, 1H
9
, J=7.6Hz). 
 
13
C-NMR (100 MHz, D2O):  C = 59.3 (C-5), 69.20 (t, C-1, 
2
JC-F=23.3Hz), 80.02 (t, C-4, 
3
JC-F 
=4.2Hz), 84.90 (t, C-3, 
2
JC-F=31.2Hz), 96.4 (C-8), 123.5 (d, C-2, JC-F=257.9Hz), 141.2 (C-9), 
157.2 (C-6), 166.3 (C-7). 
 
IR: vmax (neat) = 3232, 3206, 1666, 1639 cm
-1 
 
MS (ES+) m/z = 264 [M+H]
+
, 286 [M+Na]
+
. 
HRMS (ES+) calculated 263.0796 for C9H12N3F2O4, observed 264.0800 [M+H]
+
. 
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4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1,2-
dihydropyrimidin-2-one 238 
 
 
 
A mixture of gemcitabine 84 (123 mg, 0.47 mmol), I2 (119 mg, 0.47 mmol) and iodic acid (83 
mg, 0.47 mmol) in AcOH-H2O-CCl4 (8:3:2, 23 mL) was heated at 45 
o
C for 4 hours.  The 
reaction mixture was then concentrated in vacuo and recrystallized from H2O to yield the product 
(111 mg, 61%) as a white solid.   
 
1
H-NMR (500 MHz, MeOD-d4): H = 3.78 (dd, 1H
5
, J=12.7Hz, J=2.7Hz), 3.90 (td, 1H
4
, 
J=8.5Hz, J=2.5Hz), 3.95 (dd, 1H
5
, J=13.0Hz, J=2.5Hz), 4.28 (dt, 1H
1
, 
3
JH-F=12.3Hz, J=8.6Hz), 
6.14-6.17 (m, 1H
3
), 8.38 (s, 1H
9
). 
 
13
C-NMR (125 MHz, MeOD-d4):  C = 57.6 (C-8), 60.0 (C-5), 69.7-70.1 (m, C-1), 82.5-82.6 
(m, C-4), 85.7-86.2 (m, C-3), 123.89 (t, C-2, JC-F=258.6Hz), 148.6 (C-9), 156.9 (C-6), 166.0 (C-
7). 
 
IR vmax (neat) = 3321, 3211, 1623 cm
-1 
 
MS (ES+) m/z = 389 [M+H]
+
, 452 [M+MeCN+Na]
+
. 
HRMS (ES+) calculated 389.9762 for C9H11N3F2O4I, observed 389.9768 [M+H]
+
. 
 
 
 
 
 
 
 
 
 
186 
 
(2R,3R,5R)-5-(4-Acetamido-5-iodo-2-oxopyrimidin-1(2H)-yl)-2-(acetoxymethyl)-4,4-
difluorotetrahydrofuran-3-yl acetate 244 
 
 
 
To a solution of iodide 238 (190 mg, 0.49 mmol) and DMAP (6.1 mg, 0.05 mmol) in pyridine 
(3.0 mL) was added acetic anhydride (0.41 mL, 4.40 mmol) and the resulting solution stirred for 
16 hours.  The reaction mixture was quenched with saturated NaHCO3 (aq) (20 mL), extracted 
into EtOAc (2 × 30 mL), the combined organic layers washed with H2O (30 mL), dried over 
MgSO4 and concentrated in vacuo.  The crude material was purified using flash silica column 
chromatography (3% acetone in CHCl3) to yield the product (138 mg, 59%) as an amorphous 
solid. 
 
1
H-NMR (500 MHz, CDCl3): H = 2.17 (s, 3H-Ac), 2.19 (s, 3H-Ac), 2.21 (s, 3H-Ac), 4.35 (dd, 
1H
4
, J=8.9Hz, J=3.8Hz), 4.42-4.45 (m, 2H
5
), 5.26-5.31 (m, 1H
1
), 6.36-6.40 (m, 1H
3
), 7.93 (s, 
1H
9
). 
 
13
C-NMR (125 MHz, CDCl3):  C = 20.4 (C-Ac), 20.8 (C-Ac), 40.4 (C-8), 61.8 (C-5), 70.53 
(dd, C-3, 
2
JC-F=33.6Hz, 
2
JC-F=18.4Hz), 78.4 (C-4), 83.3-84.5 (br, s, C-1), 149.0 (C-9), 159.1 
(C=O), 168.9 (C=O), 170.2 (C=O). 
 
Note: missing C-7, 1× C-Ac and C-2 due to a weak signal and overlapping peaks. 
 
IR vmax (neat) = 3347, 1746, 1711, 1668 cm
-1 
 
MS (ES+) m/z = 516 [M+H]
+
, 538 [M+Na]
+
. 
HRMS (ES+) calculated 516.0079 for C15H17N3F2O7I, observed 516.0062 [M+H]
+
. 
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Results and Discussion Section 4. 
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2’-Deoxy-2’,2’-difluorouridine 260 
 
 
 
To a solution of the protected nucleoside 221β (390 mg, 0.42 mmol) in MeOH at 0 oC (83 mL) 
was added 7.0 M NH3 in MeOH (17 mL, 116 mmol).  The resulting solution was warmed to 
room temperature and stirred for 16 hours.  The solvents were removed in vacuo and the resultant 
residue partitioned between H2O (80 mL) and EtOAc (80 mL). The organic layer was re-
extracted with H2O (80 mL) and the combined aqueous layers concentrated in vacuo to yield the 
product (197 mg, 90%) as a colourless amorphous solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, D2O): H = 3.75 (dd, 1H
5
, J=13.1Hz, J=4.4Hz), 3.90 (dd, 1H
5
, J=13.1Hz, 
J=2.0Hz), 3.96 (m, 1H
4
), 4.26 (td, 1H
1
, 
3
JH-F=11.8Hz, J=8.5Hz), 5.80 (d, 1H
7
, J=8.1Hz), 6.09 (m, 
1H
3
), 7.67 (d, 1H
6
, J=8.1Hz). 
 
13
C-NMR (100 MHz, D2O):  C = 59.3 (C-5), 69.2 (dd, C-1, 
2
JC-F=25.6Hz, 20.7Hz) 80.46 (d, C-
4, 
3
JC-F=7.8Hz) 84.13 (dd, C-3, 
2
JC-F=39.3Hz, 25.3Hz), 102.5 (C-7),  122.1 (dd, C-2, JC-F= 
260.6Hz, 259.5Hz), 141.4 (C-6), 151.4 (C-9), 165.9 (C-8). 
 
IR vmax (neat) = 3266, 1686 cm
-1 
 
MS (ES+) m/z = 265 [M+H]
+
. 
HRMS (ES+) calculated 265.0636 for C9H11N2F2O5, observed 265.0635 [M+H]
+
. 
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1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(hydroxymethyl)-
1,2,3,4-tetrahydropyrimidine-2,4-dione 261 
 
 
 
To a solution of nucleoside 260 (280 mg, 1.06 mmol), in H2O:MeCN (7:3, 3.75 mL) was added 
para-formaldehyde (302 mg, 10.6 mmol) and NEt3 (1.05 mL, 7.42 mmol) and the resulting 
solution stirred for 3 days at 60 
o
C.  The reaction mixture was concentrated in vacuo and the 
crude residue purified using (15% MeOH in CH2Cl2) to yield the product (71 mg, 23%) as a 
colourless gum. 
 
1
H-NMR (400 MHz, MeOD-d4): H = 3.79 (dd, 1H
5
, J=12.5Hz, J=3.1Hz), 3.88-3.97 (m, 2H
4+5
), 
4.30-4.36 (m, 3H
1+10
), 6.15-6.19 (m, 1H
3
), 7.87 (s, 1H
6
). 
 
13
C-NMR (100 MHz, MeOD-d4): C = 57.9 (C-10), 60.5 (C-5), 70.4 (dd, C-1, 
2
JC-F 24.9Hz, 
2
JC-F 
=20.6Hz), 82.6 (d, C-4, 
3
JC-F =8.0Hz), 85.3 (dd, C-3, 
2
JC-F =40.2Hz, 
2
JC-F =24.8Hz), 115.6 (C-7), 
125.4 (t, C-2, JC-F=258.6.3Hz), 138.8 (C-6), 152.0 (C-9), 164.8 (C-8).   
 
IR vmax (neat) =3344, 2927, 1677 cm
-1 
 
MS (ES-) m/z = 293 [M-H]
-
.
 
HRMS (ES-) calculated 293.0585 for C10H11N2F2O6, observed 293.0579 [M-H]
-
.   
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1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-[(methoxymethoxy)methyl]oxolan-2-yl]-4-
(methoxymethoxy)-1,2-dihydropyrimidin-2-one 262 
 
 
 
To a solution of the nucleoside 260 (90 mg, 0.34 mmol) in DMF (2.8 mL) at 0 
o
C was added 
DIPEA (0.24 mL, 1.42 mmol) followed by dropwise addition of chloromethyl methyl ether (0.1 
mL, 1.36 mmol).  The resulting solution was warmed to room temperature and stirred for 16 
hours.  The reaction was quenched by the addition of H2O (10 mL), then extracted into EtOAc (2 
× 10 mL), washed with 1.0 M HCl (aq) (10 mL) and then a mixture of H2O:brine (1:1, 2 × 20 
mL).  The organic layers were dried over MgSO4, concentrated in vacuo and purified using flash 
silica column chromatography (4% MeOH in CHCl3) to yield the product as a colourless oil (76 
mg, 63%). 
 
1
H-NMR (400 MHz, CDCl3): H = 2.68 (dd, 1H
10
, J=6.2Hz, J=1.5Hz), 3.40 (s, 3H (CH3)), 3.44 
(s, 3H (CH3)), 3.83 (dd, 1H
5
, J=11.5Hz, J=3.5Hz), 3.93 (dd, 1H
5
, J=11.6Hz, J=1.8Hz), 4.09 (m, 
1H
4
), 4.36 (m, 1H
1
), 4.71 (s, 2H (CH2)), 5.37 (d, 1H, J=9.6Hz (CH2)), 5.40 (d, 1H, J=9.6Hz 
(CH2)),  5.81 (d, 1H
7
, J=8.2Hz), 6.26 (dd, 1H
3
, 
3
JH-F=8.7Hz, 
3
JH-F =7.1Hz), 7.53 (d, 1H
6
, 
J=8.2Hz). 
 
13
C-NMR (100 MHz, CDCl3):  C = 55.6 (CH3, MOM), 57.9 (CH3, MOM), 64.9 (C-5), 70.5 (dd, 
C-1, 
2
JC-F=28.5Hz, 
2
JC-F =19.2Hz), 72.1 (CH2, MOM), 80.1 (d, C-4, 
3
JC-F=7.6Hz), 84.2 (dd, C-3, 
2
JC-F=41.0Hz, 
2
JC-F=22.4Hz), 96.8 (CH2, MOM), 102.5 (C-7), 121.9 (dd, C-2, 
1
JC-F=261.8Hz, 
1
JC-
F=258.0Hz), 138.1 (C-6), 151.0 (C-8), 162.2 (C-9). 
 
IR vmax (neat) = 3385, 2931, 1719, 1665 cm
-1 
 
MS (CI+) m/z = 353 [M+H]
+
, 370 [M+NH4]
+
.
 
HRMS (CI+) calculated 353.1160 C13H19F2N2O7, observed 353.1165 [M+H]
+
. 
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1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-[(methoxymethoxy)methyl]oxolan-2-yl]-5-
(hydroxymethyl)-4-(methoxymethoxy)-1,2-dihydropyrimidin-2-one 263 
 
 
 
A suspension of protected nucleoside 262 (92 mg, 0.26 mmol) and para-formaldehyde (20 mg, 
0.63 mmol) in 0.5 N KOH (aq) (0.5 mL) was stirred at 60 
o
C for 3 days.  The reaction mixture 
was then concentrated in vacuo and purified using flash silica column chromatography (4% 
MeOH in CHCl3) to yield the starting material (25 mg, 27%) and a mixture of the product and an 
inseparable, unidentifiable side-product (29 mg, 29%) as a gum, which was used directly in the 
next step with no further purification. 
 
1
H-NMR (500 MHz, CDCl3): H = 3.41 (s, 3H (CH3)), 3.45 (s, 3H (CH3)), 3.84 (dd, 1H
5
, 
J=11.6Hz, J=3.1Hz), 3.95 (br, d, 1H
5
, J=11.6Hz), 4.09 (dt, 1H
4
, J=7.7Hz, J=3.0Hz), 4.37-4.46 
(m, 3H
1+10
), 4.73 (s, 2H (CH2)), 5.38 (d, 1H, J=9.6Hz (CH2)), 5.41 (d, 1H, J=9.6Hz (CH2)), 6.27 
(dd, 1H
3
, 
3
JH-F=9.6Hz, 
3
JH-F=5.4Hz), 7.70 (s, 1H
6
). 
 
13
C-NMR (125 MHz, CDCl3): C = 55.7 (CH3, MOM) 58.1 (CH3, MOM) 59.4 (C-10) 64.7 (C-
5) 70.0 (dd, C-1, 
2
JC-F =27.4Hz, 
2
JC-F =19.6Hz) 72.2 (CH2, MOM) 80.0 (d, C-4, 
3
JC-F =7.9Hz) 
83.9-84.6 (m, C-3) 96.7 (CH2, MOM) 113.6 (C-7) 124.6 (t, C-2, 
1
JC-F=261.2Hz) 135.2 (C-6) 
150.7 (C-8) 162.7 (C-9). 
 
IR vmax (neat) = 3274, 2950, 1708, 1656 cm
-1 
 
MS (ES+) m/z = 383 [M+H]
+
.
 
HRMS (ES+) calculated 383.1226 for C14H21N2F2O8, observed 383.1257 [M+H]
+
. 
 
 
 
 
 
192 
 
{1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-[(methoxymethoxy)methyl]oxolan-2-yl]-4-
(methoxymethoxy)-2-oxo-1,2-dihydropyrimidin-5-yl}methyl 5-(dimethylamino)-
naphthalene-1-sulfonate 264 
 
 
 
To a solution of the hydroxymethylated nucleoside 263 (60 mg, 0.17 mmol) and triethylamine 
(70 μL, 0.52 mmol) in CH2Cl2 (3 mL) was added dansyl chloride (86 mg, 0.35 mmol).  After 
stirring for 24 hours additional equivalents of triethylamine (70 μL, 0.52 mmol) and dansyl 
chloride (86 mg, 0.35 mmol) were added and reaction continued for a further 12 hours.  The 
mixture was then concentrated in vacuo and purified using flash silica column chromatography 
(100% CHCl3) to yield the product as yellow gum (18 mg, 17%).  
 
1
H-NMR (400 MHz, CDCl3): H = 2.55-2.58 (m, 1H
22
),  2.92 (s, 6H
21
),  3.36 (s, 3H(CH3)),  3.43 
(s, 3H (CH3)),  3.51 (dd, 1H
5
, J=11.8Hz, J=2.4Hz),  3.82 (br, d, 1H
5
, J=11.6Hz),  4.25 (dt, 1H
4
, 
J=7.8Hz, J=2.1Hz),  4.41 (br s, 2H (CH2)), 4.47 (d, 1H
10
, J=6.6Hz),  4.58 (d, 1H
10
, J=6.5Hz),  
5.10-5.17 (m, 1H
1
),  5.34 (d, 1H, J=9.6Hz (CH2)),  5.38 (d, 1H, J=9.6Hz (CH2)), 6.19 (t, 1H
3
, 
3
JH-F=7.7Hz),  7.25 (d, 1H
19
, J=7.5Hz),  7.62 (m, 3H
6, 15, 18
),  8.25 (d, 1H
16
, J=8.6Hz),  8.33 (dd, 
1H
17
, J=7.3Hz, J=0.8Hz),  8.68 (d, 1H
14
, J=8.6Hz). 
 
13
C-NMR (100 MHz, CDCl3): C = 45.42 (C-21),  55.74 (CH3, MOM),  58.03 (CH3, MOM),  
59.31 (CH2, MOM),  63.63 (C-5),  72.17 (CH2, MOM),  73.71  (t, C-1, 
2
JC-F =24.0Hz),  77.80 (C-
4),  84.0-84.9 (br, s, C-3),  96.67 (C-10),  113.28 (C-7),  115.89 (C-19), 119.00 (C-16),  122.92 
(C-18),  129.22 (C-15), 129.81 (C-12/13), 129.86 (C-11), 130.44 (C-12/13),  130.94 (C-17),  
132.72 (C-14), 134.92 (C-6),  150.55 (C-20),  152.00 (C-8),  162.51 (C-9). 
 
Note: missing C-2 due to overlapping signals. 
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IR vmax (neat) = 3478, 2928, 1718, 1675 cm
-1 
 
MS (ES+) m/z = 616 [M+H]
+
, 638 [M+Na]
+
.
 
HRMS (ES+) calculated 616.1776 for C26H32F2N3O10S, observed 616.1767 [M+H]
+
. 
 
 
1-((6aR,8R,9aR)-9,9-Difluoro-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin-8-yl)-5-iodopyrimidine-2,4(1H,3H)-dione 265 
 
 
 
To a solution of iodide 223 (210 mg, 0.54 mmol) and imidazole (165 mg, 2.42 mmol) in DMF 
(1.1 mL) at 0 
o
C was added 1,3-dichloro-1,1,3,3-tetraisopropyl disiloxane (0.19 mL, 0.59 mmol) 
dropwise and the resulting solution warmed to room temperature and stirred for 16 hours.  The 
reaction mixture was then diluted with EtOAc (20 mL), washed sequentially with brine (15 mL) 
and H2O (15 mL), dried over MgSO4 and concentrated in vacuo.  The crude product was purified 
using flash silica column chromatography (100% CH2Cl2) to yield the product (302 mg, 88%) as 
colourless oil.  
 
1
H-NMR (400 MHz, DMSO-d6): H = 1.12 (m, 28H
11-22
), 3.96 (ddd, 1H
4
, J=9.8Hz, J=2.5Hz, 
J=1.4Hz), 4.06 (dd, 1H
5
, J=13.6Hz, J=2.5Hz), 4.23 (d, 1H
5
, J=13.4Hz), 4.34 (td, 1H
1
, J=13.6Hz, 
J=9.6Hz), 6.10 (m, 1H
3
), 7.86 (s, 1H
6
), 8.28 (s, 1H
10
). 
 
13
C-NMR (100 MHz, DMSO-d6):  C = 12.4 (C-11-14), 12.6 (C-11-14), 12.9 (C-11-14), 13.5 
(C-11-14), 16.7 (C-15-22), 16.8 (C-15-22), 16.9 (C-15-22), 17.1 (C-15-22), 17.2 (C-15-22), 17.4 
(C-15-22), 17.6 (C-15-22), 17.7 (C-15-22), 59.1 (C-5), 69.0 (C-1), 79.4 (C-4), 84.4 (C-3), 142.6 
(C-6), 149.2 (C-9), 164.6 (C-8). 
 
Note: missing C-2 and C-7 due to weak signals.  
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IR vmax (neat) = 2947, 2868, 1702, 1612 cm
-1 
 
MS (ES+) m/z =633 [M+H]
+
. 
HRMS (ES+) calculated 633.1125 for C21H36N2O6F2Si2I, observed 633.1130 [M+H]
+
. 
 
 
5-Hydroxymethyluracil 259 
 
 
 
A suspension of uracil (2.5 g, 22.3 mmol) and para-formaldehyde (2.0 g, 66.9 mmol) in H2O (75 
mL) was treated with NEt3 (4.6 mL, 33.4 mmol), then heated to 60 
o
C and stirred for 16 hours.  
The reaction mixture was then concentrated in vacuo, triturated with H2O and EtOH (1:1, 20 
mL), stirred for 1 hour at 0 
o
C, filtered and washed with cold EtOH to yield the product (2.3 g, 73 
%) as a white solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, DMSO-d6): H = 4.10 (d, 2H
7
, J=5.3Hz) 4.85 (t, 1H
8
, J=5.3Hz) 7.24 (s, 
1H
2
) 10.73 (s, br, 1H
3
) 11.05 (s, br, 1H
5
). 
 
13
C-NMR (100 MHz, DMSO-d6):  C = 56.2 (C-7), 113.2 (C-1), 138.6 (C-2), 151.8 (C-6), 164.2 
(C-4). 
 
IR vmax (neat) = 3010, 1737, 1662 cm
-1 
 
MS (CI+) m/z =160 [M+NH4]
+
. 
HRMS (CI+) calculated 160.0722 for C5H10N3O3, observed 160.0715 [M+NH4]
+
. 
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5-{[(tert-Butyldiphenylsilyl)oxy]methyl}-uracil 267 
 
 
 
To a solution of 5-hydroxymethyl uracil 259 (2.3 g, 16.2 mmol) and imidazole (1.4 g, 21.1 
mmol) in DMF (23 mL) was added TBDPSCl (5.0 mL, 19.4 mmol) and the resulting solution 
stirred for 24 hours at room temperature.  The reaction mixture was then concentrated in vacuo 
and re-crystallised twice from MeOH:CHCl3 (7:3) to yield the product as a white solid (5.0 g, 
81%). 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.00 (s, 9H
9
), 4.36 (s, 2H
7
), 7.27 (d, 1H
2
, J=5.4Hz), 7.41-
7.48 (m, 6H
11+13
), 7.63-7.66 (m, 4H
12
), 10.76 (d, 1H
3
, J=5.4Hz,) 11.13 (s, br, 1H
5
). 
 
13
C-NMR (400 MHz, CDCl3):  C = 19.2 (C-8), 27.1 (C-9), 59.3 (C-7), 114.6 (C-1) 128.4 (C-
12), 130.4 (C-13), 133.2 (C-10) 135.5 (C-11), 138.6 (C-2), 151.6 (C-6), 163.9 (C-4). 
 
IR vmax (neat) = 2939, 1720, 1680 cm
-1 
 
MS (ES+) m/z = 381 [M+H]
+
. 
HRMS (ES+) calculated 381.1634 for C21H25N2O3Si, observed 381.1639 [M+H]
+
.
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(2R,3R)-2-[(Benzoyloxy)methyl]-5-(5-{[(tert-butyldiphenylsilyl)oxy]methyl}-2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-1-yl)-4,4-difluorooxolan-3-yl benzoate 269 
 
 
 
Protected uracil 267 (1.98 g, 5.21 mmol) and (NH4)2SO4 (41 mg, 0.30 mmol) were refluxed in 
HMDS (26 mL) for 16 hours, then cooled to room temperature and concentrated in vacuo.  The 
resulting residue was dissolved in DCE (8 mL), TMSOTf (0.94 mL, 5.21 mmol) was added and 
the mixture treated with a solution of mesylates 233 (1.40 g, 3.07 mmol) in DCE (22 mL).  After 
refluxing for 16 hours, the reaction mixture was cooled to room temperature and the solvent 
removed in vacuo.  The resulting gum was dissolved in CH2Cl2 (100 mL) then washed 
sequentially with H2O (2 ×100 mL), saturated NaHCO3 (aq) (100 mL) and brine (100 mL) then 
dried over MgSO4 and concentrated in vacuo to yield the crude product.  The crude product was 
purified using flash silica column chromatography (100% CH2Cl2) to yield the product (2.27 g, 
63%) as a colourless solid in a 1.5:1.0 mixture of anomers. 
 
1
H-NMR (400 MHz, CDCl3): H = 1.03 (s, 9H
12α
), 1.05 (s, 9H
12β
), 4.53-4.72 (m, 10H
4,5, 10α+β
), 
5.56-5.60 (m, 1H
1β
), 5.82 (dt, 1H
1α
, 
3
JH-F=10.4Hz, J=5.2Hz), 6.37 (dd, 1H
3β
, 
3
JH-F=11.6Hz, 
3
JH-F 
=6.5Hz), 6.53 (t, 1H
3α
, 
3
JH-F=7.0Hz), 7.34-7.64 (m, 34H-Ar), 7.98-8.09 (m, 8H-Ar), 8.37 (s, 
2H
17α+β
).  
 
13
C-NMR (100 MHz, CDCl3): C = 19.2 (C-11), 19.2 (C-11), 26.7 (C-12), 26.7 (C-12), 58.7 (C-
10), 58.8 (C-10), 63.1 (C-5), 63.3 (C-5) 71.6-71.9 (m, C-1α+β), 77.8 (C-4β), 81.2 (C-4α), 83.4 
(C-3β), 85.1 (C-3α), 114.5 (C-7), 115.1 (C-7), 127.7-128.9 (m, C-2α+β), 127.9 (CH-Ar), 128.5 
(CH-Ar), 128.6 (CH-Ar), 128.7 (CH-Ar), 129.7 (CH-Ar), 129.8 (CH-Ar), 130.0 (C-Ar), 130.1 
(CH-Ar), 132.5 (C-Ar), 132.6 (C-Ar), 133.5 (CH-Ar), 133.6 (CH-Ar), 134.2 (CH-Ar), 134.3 
(CH-Ar), 134.7 (C-Ar), 135.3 (C-Ar) 135.4 (CH-Ar), 135.4 (CH-Ar), 149.7 (C=O), 149.7 (C=O), 
161.1 (C=O), 161.2 (C=O), 164.6 (C=O), 164.6 (C=O), 165.8 (C=O), 165.9 (C=O). 
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Note: missing multiple CH-Ar and C-Ar due to overlapping peaks. At this point the identity of 
the anomers could not be ascertained α and β were arbitrarily assigned to allow easier analysis of 
the NMR data.  
 
IR vmax (neat) = 1721, 1689 cm
-1 
 
MS (ES+) m/z = 741 [M+H]
+
. 
HRMS (ES+) calculated 741.2444 for C40H39F2N2O8Si, observed 741.2426 [M+H]
+
. 
 
 
(2R,3R,5R)-2-[(Benzoyloxy)methyl]-4,4-difluoro-5-[5-(hydroxymethyl)-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl]oxolan-3-yl benzoate 270β 
 
 
 
To a solution of protected nucleoside 269 (380 mg, 0.51 mmol) in THF (51 mL) at 0 
o
C was 
added 1.0 M TBAF in THF (0.64 mL, 0.64 mmol) dropwise and the resulting solution warmed to 
room temperature and stirred for 16 hours.  The reaction mixture was then concentrated in vacuo 
and purified using flash silica column chromatography (3% MeOH in CHCl3) to yield the 
product (207 mg, 81%) as a 1:1 mixture of anomers.  Recrystallisation from CHCl3 yielded pure 
β-anomer (207 mg, 40%) as colourless needles.  
 
1
H-NMR (500 MHz, DMSO-d6): H = 4.15 (d, 2H
10
, J=5.2Hz), 4.72 (qd, 2H
5
, J=12.4Hz, 
J=4.1Hz), 4.82 (m, 1H
4
), 5.11 (t, 1H
11
, J=5.3Hz), 5.74-5.80 (m, 1H
1
), 6.43 (t, 1H
3
, 
3
JH-F=9.4Hz), 
7.47-7.51 (m, 2H-Ar), 7.56-7.60 (m, 2H-Ar), 7.61 (s, 1H
6
), 7.63-7.74 (m, 2H-Ar), 7.97-7.98 (m, 
2H-Ar) ,8.05-8.07 (m, 2H-Ar), 11.74 (s, 1H
12
). 
 
13
C-NMR (125 MHz, DMSO-d6): C = 55.7 (C-10), 62.9 (C-5), 71.1-71.4 (m, C-1), 75.7 (C-4), 
83.4-84.4 (br, s, C-3), 115.0 (C-7), 121.54 (t, C-2, JC-F=261.7Hz), 127.9 (C-Ar), 128.8 (CH-Ar), 
128.9 (CH-Ar), 129.0 (C-Ar), 129.2 (CH-Ar), 129.7 (CH-Ar), 133.6 (CH-Ar), 134.2 (CH-Ar), 
136.5 (C-6), 150.0 (C=O), 162.2 (C=O), 164.3 (C=O). 165.4 (C=O). 
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IR vmax (neat) = 3431, 1713, 1697 cm
-1 
 
MS (ES+) m/z = 503 [M+H]
+
. 
HRMS (ES+) calculated 503.1266 for C24H21N2F2O8, observed 503.1283 [M+H]
+
. 
 
mp (CHCl3)= 160-162 
o
C. 
 
 
1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(hydroxymethyl)-
1,2,3,4-tetrahydropyrimidine-2,4-dione 261 
 
 
 
To a solution of nucleoside 270β (50 mg, 0.1 mmol) in MeOH (2.0 mL) at 0 oC was added 7.0 M 
NH3 in MeOH (1.1 mL, 8.0 mmol) and the resulting solution warmed to room temperature and 
stirred for 16 hours.  The solvents were removed in vacuo and the resultant residue partitioned 
between H2O (10 mL) and EtOAc (10 mL). The organic layer was re-extracted with H2O (2 × 10 
mL) and the combined aqueous layers concentrated under reduced pressure to yield the product 
(28 mg, 95%) as a colourless amorphous solid. 
 
1
H-NMR (400 MHz, MeOD-d4): H = 3.79 (dd, 1H
5
, J=12.5Hz, J=3.1Hz), 3.88-3.97 (m, 2H
4+5,
) 
4.30-4.36 (m, 3H
1+10,
) 6.15-6.19 (m, 1H
3
), 7.87 (s, 1H
6
). 
 
13
C-NMR (100 MHz, MeOD-d4): C = 57.9 (C-10), 60.5 (C-5), 70.42 (dd, C-1, 
2
JC-F 24.9Hz, 
2
JC-F =20.6Hz), 82.62 (d, C-4, 
3
JC-F =8.0Hz), 85.29 (dd, C-3, 
2
JC-F =40.2Hz, 
2
JC-F =24.8Hz), 115.6 
(C-7), 125.39 (t, C-2, JC-F=258.6.3Hz), 138.8 (C-6), 152.0 (C-9), 164.8 (C-8).   
 
IR vmax (neat) =3344, 2927, 1677 cm
-1 
 
MS (ES-) m/z = 293 [M-H]
-
.
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HRMS (ES-) calculated 293.0585 for C10H11N2F2O6, observed 293.0579 [M-H]
-
.   
 
 
(2R,3R,5R)-2-[(Benzoyloxy)methyl]-4,4-difluoro-5-[5-(fluoromethyl)-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl]oxolan-3-yl benzoate 271  
 
 
 
A solution of the nucleoside 270β (100 mg, 0.20 mmol) in THF (0.70 mL) was added dropwise 
to a −15 oC solution of DAST (28 µl, 0.21 mmol) in THF (0.55 mL), stirred at this temperature 
for 30 minutes and then warmed to room temperature and stirred for a further hour.  The reaction 
mixture was then poured into cold H2O (10 mL), extracted into CH2Cl2 (10 mL), washed with 
H2O (10 mL), dried with MgSO4 and concentrated in vacuo.  The crude product was purified 
using flash silica column chromatography (2% MeOH in CH2Cl2) to yield the product (25 mg, 
25%) as a white solid. 
 
1
H-NMR (500 MHz, DMSO-d6): H = 4.70-4.84 (m, 3H
5+4
), 5.02 (d, 2H
10
, 
2
JH-F=48.6Hz), 5.76-
5.91 (m, 1H
1
), 6.42 (t, 1H
3
, 
3
JH-F=7.8Hz),  7.47 (t, 2H-Ar, J=7.4Hz), 7.58 (t, 2H-Ar, J=7.3Hz), 
7.63-7.75 (m, 2H-Ar), 7.93-7.96 (m, 2H-Ar), 8.02-88.06 (m, 2H-Ar), 8.07-8.09 (m, 1H
6
), 11.96 
(s, 1H
11
). 
 
13
C-NMR (125 MHz, DMSO-d6): C = 63.3 (C-5), 71.46 (dd, C-1, 
2
JC-F=25.3Hz, 
2
JC-F=22.1Hz), 
75.7 (C-4), 77.15 (d, C-10, JC-F=162.6Hz) 83.4-84.5 (br, s, C-3), 109.68 (d, C-7, 
2
JC-F =18.3Hz), 
121.53 (t, C-2, JC-F=261.4Hz), 127.9 (C-Ar), 128.7 (CH-Ar), 128.9 (CH-Ar), 129.0 (C-Ar), 129.2 
(CH-Ar), 129.7 (CH-Ar), 133.6 (CH-Ar), 134.3 (CH-Ar), 142.3 (d, C-6, 
3
JC-F =6.9Hz), 149.8 
(C=O), 161.9 (C=O), 164.3 (C=O), 165.3 (C=O). 
 
IR vmax (neat) = 1724, 1700 cm
-1 
 
MS (ES-) m/z = 503 [M-H]
-
. 
HRMS (ES-) calculated 503.1066 for C24H18N2F3O7, observed 503.1084 [M-H]
-
. 
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mp (THF) = 152-156 
o
C. 
 
 
1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(methoxymethyl)-
1,2,3,4-tetrahydropyrimidine-2,4-dione 273  
 
 
 
To a suspension of fluoride 271 (18 mg, 0.04 mmol) in MeOH (1.0 mL) at room temperature was 
added K2CO3 (7 mg, 0.05 mmol).  The reaction mixture was stirred for 30 minutes, then 
concentrated in vacuo and purified using flash silica column chromatography (7 % MeOH in 
CH2Cl2) to yield the product (9 mg, 76%) as a colourless gum. 
 
1
H-NMR (400 MHz, MeOD-d4): H = 3.37 (s, 3H
11
), 3.80 (dd, 1H
5
, J=12.6Hz, J=2.9Hz), 3.92 
(dt, 1H
4
, J=8.4Hz, J=2.6Hz), 3.97 (br d, 1H
5
, J=12.8Hz), 4.14 (d, 1H
10
, J=12.4Hz), 4.20 (d, 1H
10
, 
J=11.6Hz), 4.32 (td, 1H
1
, 
3
JH-F=12.2Hz, J=8.4Hz), 6.15-6.19 (m, 1H
3
), 7.98 (s, 1H
6
). 
 
13
C-NMR (100 MHz, MeOD-d4): C = 58.4 (C-11), 60.3 (C-5), 67.8 (C-10), 70.2 (dd, C-1, 
2
JC-
F=25.9Hz, 
2
JC-F=19.9Hz), 82.6 (d, C-4, 
3
JC-F=8.4Hz), 85.2 (dd, C-3, 
2
JC-F=40.3Hz, 
2
JC-F=24.5Hz), 
112.4 (C-7), 124.0 (dd, C-2, JC-F =259.0Hz, JC-F =258.1Hz), 140.3 (C-6), 151.9 (C-9), 164.7 (C-
8). 
 
IR vmax (neat) = 3363, 3072, 1682 cm
-1 
 
MS (ES+) m/z = 309 [M+H]
+
. 
HRMS (ES+) calculated 309.0898 for C11H15N2F2O6, observed 309.0916 [M+H]
+
. 
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(2R,3R,5R)-5-[5-(Azidomethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl]-2-
[(benzoyloxy)methyl]-4,4-difluorooxolan-3-yl benzoate 276 
 
 
 
To a solution of nucleoside 270β (400 mg, 0.80 mmol) in 1,4-dioxane (8 mL) was added TMSCl 
(0.50 mL, 4.00 mmol).  After 5 hours at 65 
o
C additional TMSCl was added (0.5 mL, 4.00 mmol) 
and the reaction stirred for 16 hours at this temperature.  The mixture was then concentrated in 
vacuo, the residue re-dissolved in DMF (8 mL), sodium azide (312 mg, 4.80 mmol) added and 
the solution stirred for 5 hours at 65 
o
C.  The solvents were then removed under reduced pressure 
and the resulting solid partitioned between EtOAc (60 mL) and brine (60 mL).  The organic layer 
was dried using MgSO4, concentrated in vacuo and the crude material purified using flash silica 
column chromatography (2% MeOH in CH2Cl2, dry loaded using 1,4-dioxane) to yield the 
product as a white solid (288 mg, 68% over 2 steps).  
  
1
H-NMR (500 MHz, DMSO-d6): H = 4.01 (d, 1H
10
, J=13.6Hz), 4.05 (d, 1H
10
, J=13.6Hz), 4.68-
4.71 (m, 1H
4
), 4.76-4.82 (m, 2H
5
), 5.81 (m, 1H
1
), 6.40 (t, 1H
3
, 
3
JH-F=8.9Hz), 7.47 (t, 2H-Ar, 
J=7.8Hz), 7.57 (t, 2H-Ar, J=7.8Hz), 7.63-7.74 (m, 2H-Ar), 7.88 (s, 1H
6
), 7.95 (dd, 2H-Ar, 
J=8.2Hz, J=1.1Hz), 8.04 (dd, 2H-Ar, J=8.2Hz, J=1.1Hz), 11.92 (s, 1H
11
). 
 
13
C-NMR (125 MHz, DMSO-d6): C = 46.5 (C-10), 63.3 (C-5), 71.3-71.7 (m, C-1), 75.7 (C-4), 
83.2-84.4 (br, s, C-3), 109.31 (C-7), 121.59 (t, C-2, JC-F =261.6Hz), 127.9 (C-Ar), 128.7(CH-Ar), 
128.9 (CH-Ar), 129.0 (C-Ar), 129.2 (CH-Ar), 129.7 (CH-Ar), 133.6 (CH-Ar), 134.3 (CH-Ar), 
139.9 (C-6), 149.8 (C=O), 162.4 (C=O), 164.3 (C=O), 165.4 (C=O). 
 
IR vmax (neat) = 3279, 2096, 1722, 1689 cm
-1 
 
HRMS: Did not provide spectra suitable for interpretation. 
 
mp (acetone) = 170-176 
o
C. 
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5-(Azidomethyl)-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-
1,2,3,4-tetrahydropyrimidine-2,4-dione 249 
 
 
 
To a solution of the benzoyl protected azide 276 (30 mg, 60 µmol) in MeOH (3.0 mL) at 0 
o
C 
was added 7.0 M NH3 in MeOH (0.7 mL, 4.80 mmol) and the resulting solution warmed to room 
temperature and stirred for 16 hours.  The solvents were removed in vacuo and the resultant 
residue purified using flash silica column chromatography (5% MeOH in CH2Cl2) to yield the 
product (18 mg, 94%) as an amorphous colourless solid. 
 
1
H-NMR (500 MHz, MeOD-d4): H = 3.80 (dd, 1H
5
, J=12.6Hz, J=2.9Hz), 3.90-3.93 (m, 1H
4
), 
3.96 (br, d, 1H
5
, J=12.9Hz), 4.08 (s, 2H
10
), 4.32 (td, 1H
1
, 
3
JH-F=12.2Hz, J=8.4Hz), 6.13-6.17 (m, 
1H
3
), 8.05 (s, 1H
6
). 
 
13
C-NMR (125 MHz, MeOD-d4): C = 48.2 (C-10), 60.3 (C-5), 70.18 (dd, C-1, 
2
JC-F =26.5Hz, 
2
JC-F J=19.4Hz) 82.77 (d, C-4, 
3
JC-F =8.4Hz) 85.30 (dd, C-3, 
2
JC-F =40.8Hz, 
2
JC-F =23.9Hz) 
110.79 (C-7) 123.96 (t, C-2, JC-F=255.1Hz) 140.6 (C-6), 151.8 (C-9), 164.7 (C-8). 
 
IR vmax (neat) = 3311, 2109, 1707, 1680 cm
-1 
 
Anal. calculated for C10H11F2N5O5: C, 37.63; H, 3.47; N, 21.94. Found: C, 37.51; H, 3.39; N, 
21.87.  
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(2R,3R,5R)-5-[5-(Aminomethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl]-2-
[(benzoyloxy)methyl]-4,4-difluorooxolan-3-yl benzoate 282 
 
 
 
To a solution of the azide 276 (100 mg, 0.19 mmol) in THF:H2O (10:1, 3.8 mL) was added 
triphenylphosphine (296 mg, 1.14 mmol) and the reaction mixture stirred for 16 hours at room 
temperature.  The solvents were removed in vacuo and the crude material purified using flash 
silica column chromatography (5-10% MeOH in CH2Cl2) to yield the product (70 mg, 74%) as 
an amorphous white solid. 
 
1
H-NMR (500 MHz, THF-d8): H = 3.38 (s, 2H
10
), 4.12 (br s, 2H
12
), 4.72 (m, 3H
4+5
), 5.78-5.83 
(m, 1H
1
), 6.38 (t, 1H
3
, 
3
JH-F=9.1Hz), 7.42-7.66 (m, 7H-Ar), 8.00-8.14 (m, 4H-Ar). 
 
13
C-NMR (125 MHz, THF-d8): C = 36.8 (C-10), 61.1 (C-5) 69.90 (dd, C-1, 
2
JC-F =28.5Hz, 
2
JC-F 
=20.5Hz), 75.3 (C-4), 82.2-82.9 (br, s, C-3), 114.7 (C-7), 122.10 (t, C-2, JC-F=259.3Hz) 126.5 
(CH-Ar), 126.6 (CH-Ar), 126.8 (C-Ar), 127.6 (CH-Ar), 127.9 (C-Ar), 127.9 (CH-Ar), 131.2 
(CH-Ar), 131.8 (CH-Ar), 131.6 (CH-Ar), 148.3 (C=O), 160.6 (C=O), 162.4 (C=O), 163.5 (C=O). 
 
IR vmax (neat) = 2960, 1728, 1720 1673 cm
-1 
 
MS (ES+) m/z = 502 [M+H]
+
. 
HRMS (ES+) calculated 502.1420 for C24H22N3F2O7, observed 502.1426 [M+H]
+
. 
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(2R,3R,5R)-2-[(Benzoyloxy)methyl]-5-{5-[5-(dimethylamino)naphthalene-1-
sulfonamidomethyl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl}-4,4-difluorooxolan-3-yl 
benzoate 283 
 
 
 
A room temperature solution of amine 282 (30 mg, 60 µmol) and NEt3 (11 µl, 80 µmol) in THF 
(1.2 mL) was treated with dansyl chloride (19 mg, 70 µmol) and stirred for 16 hours.  The 
reaction mixture was then concentrated in vacuo dissolved in CH2Cl2 (15 mL), washed with H2O 
(10 mL), dried over MgSO4 and the solvents removed in vacuo.  The crude material was purified 
using flash silica column chromatography (2% MeOH in CH2Cl2) to yield the product (35 mg, 
79%) as a pale green fluorescent solid.    
 
1
H-NMR (400 MHz, CDCl3): H = 2.82 (s, 6H
23+24
), 3.60 (dd, 1H
10
, J=15.4Hz, J=6.5Hz), 3.78 
(dd, 1H
10
, J=15.4Hz, J=6.5Hz), 4.57-4.61 (m, 1H
4
), 4.77 (dd, 1H
5
, J=12.5Hz, J=4.6Hz), 4.87 
(dd, 1H
5
, J=12.5Hz, J=3.1Hz), 5.58-5.63 (m, 1H
1
), 5.88 (t, 1H
12
, J=6.5Hz), 6.20 (dd, 1H
3
, 
3
JH-
F=12.0Hz, 
3
JH-F=6.1Hz), 7.11 (d, 2H-Ar, J=8.1Hz), 7.40 (dd, 1H-Ar, J=8.3Hz, J=7.5Hz),7.47-
7.52 (m, 5H-Ar), 7.59-7.67 (m, 2H-Ar), 8.06-8.14 (m, 6H-Ar), 8.44 (d, 1H-Ar, J=8.5Hz), 8.64 (s, 
1H
11
). 
 
13
C-NMR (100 MHz, CDCl3): C = 40.7 (C-10), 45.3 (C-23+24), 62.5 (C-5), 71.5 (dd, C-1, 
2
JC-F 
=34.8Hz, 
2
JC-F =16.9Hz), 78.9 (C-4), 82.6-83.4 (br, s, C-3), 110.3 (C-7), 115.2 (CH-Ar), 118.7 
(CH-Ar), 123.3 (CH-Ar), 127.8 (C-Ar), 128.5 (CH-Ar), 128.8 (CH-Ar), 128.9 (CH-Ar), 128.9 
(C-Ar), 129.2 (C-Ar), 129.5 (CH-Ar), 129.6 (C-Ar), 129.8 (CH-Ar), 130.2 (CH-Ar), 130.3 (CH-
Ar), 133.9 (CH-Ar), 134.3 (CH-Ar), 135.5 (C-Ar), 137.3 (CH-Ar), 149.0 (C=O), 151.9 (C-Ar), 
162.0 (C=O), 164.8 (C=O), 166.0 (C=O). 
 
Note: missing C-2 due to multiple overlapping peaks. 
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IR vmax (neat) = 3058, 1720, 1680 cm
-1
 
 
MS (ES+) m/z = 735 [M+H]
+
. 
HRMS (ES+) calculated 735.1936 for C36H33N4F2O9S, observed 735.1907 [M+H]
+
. 
 
mp (CH2Cl2) = 102-107 
o
C. 
 
 
N-({1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl}methyl)-5-(dimethylamino)naphthalene-1-sulfonamide 284 
 
 
 
To solution of the dansylated nucleoside 283 (30 mg, 40 µmol) in MeOH (2.0 mL) at 0 
o
C was 
added 7.0 M NH3 in MeOH (0.5 mL, 3.2 mmol) and the resulting solution warmed to room 
temperature and stirred for 16 hours.  The solvents were removed in vacuo and the resultant 
residue purified using flash silica column chromatography (4% MeOH in CH2Cl2) to yield the 
product (16 mg, 76%) as a pale green fluorescent solid. 
 
1
H-NMR (500MHz, MeOD-d4): H = 2.85 (s, 6H
23+24
), 3.83 (m, 4H
4,5+10
), 3.95-3.99 (m, 1H
5
), 
4.22 (td, 1H
1
, 
3
JH-F=12.1Hz, J=8.3Hz), 5.90 (m, 1H
3
), 7.23 (dd, 1H-Ar, J=7.6Hz, J=0.7Hz), 7.53 
(ddd, 2H-Ar, J=8.6Hz, J=7.5Hz, J=2.8Hz), 7.59 (s, 1H
6
), 8.16 (dd, 1H-Ar, J=7.3Hz, J=1.2Hz), 
8.21 (td, 1H-Ar, J=8.6Hz, J=0.8Hz), 8.50 (dt, 1H-Ar, J=8.6Hz, J=1.0Hz). 
 
13
C-NMR (125 MHz, MeOD-d4): C = 40.6 (C-10), 45.8 (C23+24), 60.5 (C-5), 68.8-70.3 (m, C-
1), 82.66 (d, C-4, 
3
JC-F =7.9Hz), 85.04 (dd, C-3, 
2
JC-F =39.2Hz, 
2
JC-F =25.5Hz), 111.2 (C-7), 
116.4 (CH-Ar), 120.4 (CH-Ar), 123.76 (t, C-2, JC-F =252.8Hz) 124.6 (CH-Ar), 129.3 (CH-Ar), 
130.6 (CH-Ar), 130.7 (C-Ar), 131.0 (C-Ar), 131.2 (CH-Ar), 137.3 (C-Ar), 139.2 (C-6), 151.3 (C-
9), 153.1 (C-Ar), 164.2 (C-8).  
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IR vmax (neat) =3338, 1677 cm
-1 
 
MS (ES+) m/z = 527 [M+H]
+
. 
HRMS (ES+) calculated 527.1412 for C22H25N4F2O7S, observed 527.1408 [M+H]
+
. 
 
mp (MeOH-CH2Cl2) = 118-124 
o
C. 
 
 
[(2R,3R)-3-(Benzoyloxy)-5-[5-({[({1-[(4R,5R)-4-(benzoyloxy)-5-[(benzoyloxy)methyl]-3,3-
difluorooxolan-2-yl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-
yl}methyl)carbamoyl]amino}methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl]-4,4-
difluorooxolan-2-yl]methyl benzoate 285 
 
 
 
CDI (2.3 mg, 14 µmol) was added to a solution of amine 282 (15 mg, 28 µmol) in DMF (0.3 mL) 
and the resulting solution stirred at room temperature for 16 hours.  The reaction mixture was 
concentrated in vacuo and the crude material purified using flash silica column chromatography 
(5-10% MeOH in CH2Cl2) to yield the product (12 mg, 80%) as a white solid. 
 
1
H-NMR (500 MHz, THF-d8): H = 3.84-3.92 (m, 4H
10
), 4.63-4.67 (m, 2H
4
), 4.71-4.79 (m, 
4H
5
), 5.87 (m, 4H
1+12
), 6.32 (br, s, 2H
3
), 7.40-7.43 (m, 4H-Ar), 7.46-7.49 (m, 4H-Ar), 7.53 (tt, 
2H-Ar, J=7.4, J=1.3Hz), 7.62 (tt, 2H-Ar, J=7.5, J=1.3Hz), 7.69 (s, 2H
6
), 8.03-8.09 (m, 8H-Ar), 
10.71 (s, 2H
11
). 
 
13
C-NMR (125 MHz, THF-d8): C = 37.3 (C-10), 64.1 (C-5), 72.6-73.0 (m, C-1), 78.0 (C-4), 
85.6-86.1 (br, s, C-3), 114.0 (C-7), 122.64 (t, C-2, JC-F=261.5Hz), 129.2 (CH-Ar), 129.3 (CH-
Ar), 129.6 (C-Ar), 130.4 (CH-Ar), 130.6 (C-Ar), 130.6 (CH-Ar), 133.8 (CH-Ar), 134.5 (CH-Ar), 
139.1 (C-6), 151.0 (C-9), 158.6 (C-13), 163.8 (C=O), 165.1 (C=O), 166.3 (C=O). 
 
IR vmax (neat) = 1725, 1693 cm
-1 
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MS (ES+) m/z = 1029 [M+H]
+
. 
HRMS (ES+) calculated 1029.2566 for C49H41F4N6O15, observed 1029.2566 [M+H]
+
. 
 
 
1,3-bis({1-[(4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxo-
1,2,3,4-tetrahydropyrimidin-5-yl}methyl)urea 286 
 
 
 
To a solution of dimeric nucleoside 285 (10 mg, 9.7 µmol) in MeOH (1.0 mL) at 0 
o
C was added 
7.0 M NH3 in MeOH (0.2 mL, 0.81 mmol) and the resulting solution warmed to room 
temperature and stirred for 16 hours.  The reaction mixture was then concentrated in vacuo and 
partitioned between H2O (5 mL) and EtOAc (5 mL). The organic layer was re-extracted with 
H2O (5 mL) and the combined aqueous layers concentrated in vacuo to yield the crude product.  
Purification of the crude material using flash silica column chromatography (15% MeOH in 
CH2Cl2) gave the product (3 mg, 51%) as a white solid. 
 
1
H-NMR (500 MHz, MeOD-d4): H = 3.79 (dd, 2H
5
, J=12.6Hz, J=3.4Hz) 3.87-3.90 (m, 2H
4
) 
3.93-3.96 (m, 6H
5+10
) 4.30 (td, 2H
1
, 
3
JH-F =12.1Hz, J=8.3Hz) 6.11-6.13 (m, 2H
3
) 7.80 (s, 2H
6
). 
 
13
C-NMR (125 MHz, MeOD-d4): C = 37.8 (C-10), 60.6 (C-5), 70.37 (dd, C-1, 
2
JC-F=25.0Hz, 
2
JC-F=20.8Hz), 82.70 (d, C-4, 
3
JC-F =7.1Hz), 85.34 (dd, C-3, 
2
JC-F=36.3Hz, 
2
JC-F=28.5Hz), 113.9 
(C-7), 123.92 (t, C-2, JC-F=252.5Hz), 138.9 (C-6), 151.9 (C-9), 160.5 (C-13), 165.1 (C-8). 
 
IR vmax (neat) = 3350, 1683 cm
-1 
 
MS (ES-) m/z = 611 [M-H]
-
. 
HRMS (ES-) calculated 611.1361 for C21H23F4N6O11, observed 611.1346 [M-H]
-
. 
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But-3-ynyl-p-toluenesulfonate 280 
 
 
 
To a solution of 3-butyn-1-ol (0.22 mL, 2.85 mmol), NEt3 (0.5 mL, 3.70 mmol) and 4-
(dimethylamino)pyridine (34 mg, 0.28 mmol) in CH2Cl2 (11.5 mL) at 0 
o
C was added p-
toluenesulfonyl chloride (598 mg, 3.14 mmol) and the resulting solution warmed to room 
temperature and stirred for 16 hours.  1.0 M NaOH (aq) (10 mL) was then added and the mixture 
stirred for a further 15 minutes.  The phases were then separated and the organic layer diluted 
with CH2Cl2 (20 mL), washed sequentially with brine (20 mL) and H2O (20 mL), then dried over 
MgSO4 and concentrated in vacuo.  The crude material was purified using flash silica column 
chromatography (30% EtOAc in 50-60 petroleum ether) to yield the product as a clear colourless 
oil (564 mg, 88%).  
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 1.97 (t, 1H
1
, J=2.6Hz), 2.45 (s, 3H
9
), 2.56 (td, 2H
3
, J=7.1Hz, 
J=2.6Hz), 4.10 (t, 2H
4
, J=7.1Hz), 7.35 (d, 2H
7
, J=8.1Hz), 7.81 (d, 2H
6
, J=8.2Hz). 
 
13
C-NMR (100 MHz, CDCl3): C = 19.4 (C-3), 21.6 (C-9), 67.4 (C-4), 70.7 (C-1), 78.3 (C-2), 
128.0 (C-6), 129.9 (C-7), 132.8 (C-8), 145.0 (C-5). 
 
MS (CI+) m/z = 242 [M+NH4]
+
. 
HRMS (CI+) calculated 242.0851 for C11H16NSO3, observed 242.0850 [M+NH4]
+
. 
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(2R,3R,5R)-2-[(Benzoyloxy)methyl]-4,4-difluoro-5-(5-{[4-(2-{[(4-
methylbenzene)sulfonyl]oxy}ethyl)-1H-1,2,3-triazol-1-yl]methyl}-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-1-yl)oxolan-3-yl benzoate 281 
 
 
 
A solution of the azide 276 (90 mg, 0.17 mmol), ascorbic acid (30 mg, 0.17 mmol), CuSO4.5H2O 
(21 mg, 90 µmol) and alkyne 280 (46 mg, 0.20 mmol) in DMF-H2O (9:1, 3.7 mL) was stirred for 
16 hours at room temperature.  The reaction mixture was concentrated in vacuo, partitioned 
between CH2Cl2 (15 mL) and H2O (15 mL), the organic layer dried over MgSO4 and the solvent 
removed under reduced pressure.  The crude product was purified using flash silica column 
chromatography (1-2% MeOH in CH2Cl2) to yield the product (85 mg, 67%) as a white solid. 
 
1
H-NMR (400 MHz, CDCl3): H = 2.42 (s, 3H-Tos), 3.05 (t, 2H
14
, J=6.8Hz), 4.27 (t, 2H
15
, 
J=6.8Hz), 4.62 (dd, 1H
4
, J=9.2Hz, J=4.6Hz), 4.75-4.83 (m, 2H
5
), 5.00 (d, 1H
10
, J=14.6Hz), 5.06 
(d, 1H
10
, J=14.6Hz), 5.66 (dd, 1H
1
, 
3
JH-F=16.3Hz, J=4.6Hz), 6.38 (dd, 1H
3
, 
3
JH-F=10.7Hz, 
3
JH-
F=7.1Hz), 7.32 (d, 2H-Ar, J=8.3Hz), 7.44-7.51 (m, 4H-Ar), 7.57-7.66 (m, 3H-Ar), 7.72 (s, 1H
12
) 
7.75 (d, 2H-Ar, J=8.3Hz), 8.06-8.09 (m, 4H-Ar), 9.70 (s, 1H
11
). 
 
13
C-NMR (100 MHz, CDCl3): C = 21.6 (CH3-Tos), 25.8 (C-14), 46.0 (C-10), 62.6 (C-5), 68.9 
(C-15), 71.5 (dd, C-1, 
2
JC-F=34.4Hz, 
2
JC-F=17.0Hz), 78.8 (C-4), 83.7 (br, s, C-3), 109.6 (C-7), 
120.8 (dd, C-2, JC-F=266.4Hz, JC-F=260.0Hz), 123.1 (CH-Ar), 127.8 (C-Ar), 127.9 (CH-Ar), 
128.7 (CH-Ar), 128.8 (CH-Ar), 129.1 (C-Ar), 129.7 (CH-Ar), 129.9 (CH-Ar), 130.1 (CH-Ar), 
132.8 (C-Ar), 133.7 (CH-Ar), 134.3 (CH-Ar), 140.5 (CH-Ar), 142.7 (C-Ar), 144.9 (C-Ar), 149.5 
(C-Ar), 162.0 (C=O), 162.6 (C=O), 164.7 (C=O), 166.0 (C=O). 
 
IR vmax (neat) = 3068, 1723, 1693 cm
-1 
 
MS (ES+) m/z = 752 [M+H]
+
, 774 [M+Na]
+
. 
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HRMS (ES+) calculated 752.1838 for C35H32N2F5O10S, observed 752.1846 [M+H]
+
. 
 
mp (CH2Cl2) = 162-167 
o
C. 
 
 
(2R,3R,5R)-2-[(Benzoyloxy)methyl]-4,4-difluoro-5-(5-{[4-(2-hydroxyethyl)-1H-1,2,3-triazol-
1-yl]methyl}-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-3-yl benzoate 277 
 
 
 
A solution of azide 276 (80 mg, 0.15 mmol), ascorbic acid (26 mg, 0.15 mmol), CuSO4.5H2O (19 
mg, 76 µmol) and 3-butyn-1-ol (13 µl, 0.17 mmol) in DMF-H2O (9:1, 3.0 mL) was stirred for 16 
hours at room temperature.  The reaction mixture was then concentrated in vacuo, partitioned 
between CH2Cl2 (15 mL) and H2O (15 mL), the organic layer dried over MgSO4 and the solvent 
removed in vacuo.  The crude product was purified using flash silica column chromatography 
(5% MeOH in CH2Cl2) to yield the product (48 mg, 54%) as a white solid. 
 
1
H-NMR (500 MHz, DMSO-d6): H = 2.73 (t, 2H
14
, J=6.9Hz), 3.59 (td, 2H
15
, J=6.9Hz, 
J=5.3Hz), 4.65 (t, 1H
16
, J=5.3Hz), 4.64-4.82 (m, 3H
4+5
), 5.07-5.13 (m, 2H
10
), 5.79-5.88 (m, 1H
1
), 
6.40 (t, 1H
3
, 
3
JH-F=8.4Hz), 7.44 (m, 2H-Ar), 7.57 (m, 2H-Ar), 7.62 (m, 1H-Ar), 7.73 (m, 1H-Ar), 
7.76 (s, 1H
6
), 7.94 (m, 2H-Ar), 8.04 (m, 2H-Ar), 8.09 (s, 1H
12
), 11.91 (s, 1H
11
). 
 
13
C-NMR (125 MHz, DMSO-d6): C = 29.2 (C-14), 45.7 (C-10), 60.4 (C-15), 63.5 (C-5), 71.4-
71.8 (m, C-1), 75.8 (C-4), 83.9-85.2 (br, s, C-3), 109.0 (C-7), 121.7 (t, C-2, JC-F=260.9Hz), 122.5 
(C-12), 128.0 (C-Ar), 128.8 (CH-Ar), 129.0 (CH-Ar), 129.1 (C-Ar), 129.3 (CH-Ar), 129.8 (CH-
Ar), 133.7 (CH-Ar), 134.4 (CH-Ar), 141.5 (C-6), 144.4 (C-13), 149.9 (C=O), 162.3 (C=O), 164.4 
(C=O), 165.5 (C=O). 
IR vmax (neat) = 3281, 1728, 1676 cm
-1 
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MS (ES+) m/z = 598 [M+H]
+
, 620 [M+Na]
+
. 
HRMS (ES+) calculated 598.1749 for C28H26F2N5O8, observed 598.1731 [M+H]
+
. 
 
mp (THF-Hexane) = 173-178 
o
C. 
 
 
(2R,3R,5R)-2-[(Benzoyloxy)methyl]-4,4-difluoro-5-(5-{[4-(2-fluoroethyl)-1H-1,2,3-triazol-1-
yl]methyl}-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-3-yl benzoate 278 
 
 
 
To a −78 oC solution of alcohol 277 (40 mg, 70 µmol) in THF (1.4 mL) was added 
diethylaminosulfur trifluoride (17 µl, 0.13 mmol) and stirring continued at this temperature for 
30 minutes, before being warmed to room temperature and stirred for a further hour.  Cold H2O 
(5 mL) was then added to the reaction and the mixture extracted into CH2Cl2 (2 ×10 mL).  The 
combined organic layers were then dried over MgSO4 and concentrated in vacuo to yield the 
crude product. The crude material was purified using flash silica column chromatography (4% 
MeOH in CH2Cl2) to yield the product (9 mg, 21%) as a white solid. 
 
1
H-NMR (500 MHz, THF-d8): H = 3.02 (dt, 2H
14
, 
3
JH-F=22.4Hz, J=6.6Hz), 4.61 (dt, 2H
15
, 
2
JH-
F=47.2Hz, J=6.6Hz), 4.69-4.76 (m, 3H
4+5
), 5.12 (s, 2H
10
), 5.78-5.83 (m, 1H
1
), 6.36 (t, 1H
3
, 
3
JH-
F=7.6Hz), 7.44-7.52 (m, 4H-Ar), 7.54-7.57 (m, 1H-Ar), 7.63-7.67 (m, 1H-Ar), 7.71 (s, 1H
6/12
), 
7.87 (s, 1H
6/12
), 8.05-8.10 (m, 4H-Ar), 11.00 (s, 1H
11
). 
 
13
C-NMR (125 MHz, THF-d8): C = 28.00 (d, C-14, 
2
JC-F=21.8Hz), 46.5 (C-5), 63.9 (C-10), 
72.5-72.9 (m, C-1), 78.4 (C-4), 83.11 (d, C-15, JC-F=167.8Hz), 84.9-85.7 (br, s, C-3), 110.6 (C-
7), 123.2 (C-12), 129.3 (CH-Ar), 129.4 (CH-Ar), 129.5 (C-Ar), 130.3 (CH-Ar), 130.5 (C-Ar), 
130.6 (CH-Ar), 133.9 (CH-Ar), 134.6 (CH-Ar), 141.4 (C-6), 143.42 (d, C-13, 
3
JC-F=7.5Hz), 
150.7 (C-9), 163.0 (C=O), 165.1 (C=O), 166.3 (C=O). 
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Note: missing C-2 due to multiple overlapping signals. 
 
IR vmax (neat) = 2923, 1724, 1695 cm
-1 
 
MS (ES+) m/z = 600 [M+H]
+
. 
HRMS (ES+) calculated 600.1706 for C28H25F3N5O7, observed 600.1712 [M+H]
+
. 
 
mp (THF) = 168-172 
o
C. 
 
 
1-[(2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-{[4-(2-fluoroethyl)-
1H-1,2,3-triazol-1-yl]methyl}-1,2,3,4-tetrahydropyrimidine-2,4-dione 252 
 
 
 
To a solution of the protected nucleoside 278 (9 mg, 15 µmol) in MeOH (1.5 mL) at 0 
o
C was 
added 7.0 M NH3 in MeOH (0.2 mL, 1.2 mmol) and the resulting mixture warmed to room 
temperature and stirred for 16 hours.  The reaction mixture was then concentrated in vacuo and 
purified using flash silica column chromatography (5% MeOH in CH2Cl2) to yield the product (2 
mg, 34%) as a white solid.  
 
1
H-NMR (400 MHz, MeOD-d4): H = 3.07 (dt, 2H
14
, 
3
JH-F=24.6Hz, J=6.1Hz), 3.79 (dd, 1H
5
, 
J=12.6Hz, J=3.1Hz), 3.89-3.97 (m, 2H
4+5
), 4.30 (td, 1H
1
, 
3
JH-F=12.2Hz, J=8.3Hz), 4.63 (dt, 1H
15
, 
2
JH-F=47.0Hz, J=6.2Hz), 5.20-5.28 (m, 2H
10
), 6.14 (dd, 1H
3
, 
3
JH-F=9.1Hz, J=6.2Hz), 7.85 (s, 
1H
6
), 8.18 (s, 1H
12
). 
 
13
C-NMR (100 MHz, MeOD-d4): C = 28.0 (d, C-14, 
2
JC-F=21.6Hz), 47.6 (C-10), 60.4 (C-5), 
70.3 (dd, C-1, 
2
JC-F =26.6Hz, 
2
JC-F=19.4Hz), 82.9 (d, C-4, 
3
JC-F=8.3Hz), 83.3 (d, C-15, JC-
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F=167.4Hz), 85.3 (dd, C-3, 
2
JC-F=41.2Hz, 
2
JC-F=24.7Hz), 110.0 (C-7), 124.6 (C-6), 125.17 (t, C-
2, JC-F=259.1Hz), 142.0 (C-12), 144.85 (d, C-13, 
3
JC-F=5.6Hz), 151.7 (C-9), 164.3 (C-8). 
 
IR vmax (neat) = 3222, 2924, 1688 cm
-1 
 
MS (ES+) m/z = 392 [M+H]
+
. 
HRMS (ES+) calculated 392.1182  for C14H17N5F3O5, observed 392.1201 [M+H]
+
. 
 
 
2,3,4,6-Tetra-O-benzoyl-α-D-glucopyranosyl benzoate 287 
 
 
 
Benzoyl chloride (3.9 mL, 33.3 mmol) was added dropwise to a 0 
o
C solution of D-glucose (1.0 
g, 5.6 mmol) and DMAP (136 mg, 1.11 mmol) in pyridine (28 mL) and the resulting solution 
allowed to warm to room temperature and stirred for 16 hours.  Cold H2O (50 mL) was then 
added to quench the reaction and the mixture extracted into EtOAc (2 × 100 mL).  The combined 
organic layers were washed with 1.0 M HCl (aq) (2 × 100 mL), brine (50 mL), dried over MgSO4 
and concentrated in vacuo to give the crude product.  The crude product was re-crystallised from 
EtOAc-Hexanes to yield the product (2.46 g, 63%) as a white solid.    
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 4.49-4.53 (m, 1H
6
), 4.63-4.66 (m, 2H
5+6
), 5.71 (dd, 1H
2
, 
J=10.3Hz, J=3.6Hz), 5.89 (t, 1H
4
, J=9.8Hz), 6.35 (t, 1H
3
, J=10.0Hz), 6.88 (d, 1H
1
, J=3.7Hz), 
7.31-7.59 (m, 13H-Ar), 7.62-7.69 (m, 1H-Ar), 7.90-7.92 (m, 4H-Ar), 7.96-7.98 (m, 2H-Ar), 
8.04-8.06 (m, 2H-Ar), 8.13-8.16 (m, 1H-Ar), 8.18-8.20 (m, 2H-Ar). 
 
13
C-NMR (100 MHz, CDCl3): C = 62.5 (C-6), 68.8 (C-4), 70.4 (C-5), 70.4 (C-2), 70.5 (C-3), 
90.0 (C-1), 128.4 (CH-Ar), 128.4 (CH-Ar), 128.7 (C-Ar), 128.8 (CH-Ar), 129.0 (C-Ar), 129.5 
(C-Ar), 129.8 (CH-Ar), 129.8 (CH-Ar), 129.9 (CH-Ar), 129.9 (CH-Ar), 130.0 (CH-Ar), 130.2 
(CH-Ar), 130.6 (C-Ar), 133.2 (CH-Ar), 133.4 (CH-Ar), 133.5 (CH-Ar), 133.6 (CH-Ar), 133.7 
(CH-Ar), 134.0 (CH-Ar), 164.4 (C=O), 165.1 (C=O), 165.4 (C=O), 165.9 (C=O), 166.1 (C=O). 
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Note: missing 1 × C-Ar due overlapping peaks. 
 
IR vmax (neat) =2959, 1719 cm
-1 
 
MS (ES+) m/z = 723 [M+Na]
+
, 764 [M+Na+MeCN]
+
. 
HRMS (ES+) calculated 764.2108 for C43H35O11NaN, observed 764.2137 [M+Na+MeCN]
+
. 
 
 
2,3,4,6-Tetra-O-benzoyl-α/β-D-glucopyranose 289 
 
 
 
A solution of 2.0 M methylamine in THF (5.2 mL, 10.2 mmol) was added to a solution of the 
protected glucose 287 (1.3 g, 1.86 mmol) in THF:MeOH (5:1, 6 mL) and the mixture stirred for 6 
hours at room temperature.  The reaction mixture was concentrated in vacuo and the crude 
residue purified using flash silica column chromatography (30% EtOAc in 40-60 petroleum 
ether) to yield the product (0.76 g, 68%) as a colourless solid in a 4:1 mixture of α and β 
anomers. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 3.31 (dd, 1H
7α
, J=3.9Hz, J=1.1Hz), 4.47 (dd, 1H
6α
, 
J=12.4Hz, J=4.6Hz), 4.51-4.55 (m, 1H
6β
), 4.62-4.73 (m, 4H
5+6, α+β
), 5.35 (ddd, 1H
2α
, J=10.3Hz, 
J=3.6Hz, J=1.0Hz), 5.38-5.40 (m, 1H
2β
), 5.74-5.80 (m, 4H
1+4, α+β
), 5.95-6.02 (m, 1H
3β
), 6.28 (t, 
1H
3α
, J=9.9Hz), 7.29-7.58 (m, 16H-Ar), 7.88-7.93 (m, 8H-Ar), 7.94-8.03 (m, 8H-Ar), 8.06-8.10 
(m, 8H-Ar). 
 
13
C-NMR (100 MHz, CDCl3): C = 62.8 (C-6), 67.9 (C-5), 69.4 (C-4), 70.1 (C-3), 72.2 (C-2), 
90.5 (C-1), 128.3 (CH-Ar), 128.4 (CH-Ar), 128.5 (CH-Ar), 128.9 (CH-Ar), 128.9 (C-Ar), 129.0 
(C-Ar), 129.2 (C-Ar), 129.2 (C-Ar), 129.7 (CH-Ar), 129.8 (CH-Ar), 129.9 (CH-Ar), 129.9 (CH-
Ar), 130.0 (CH-Ar), 133.1 (CH-Ar), 133.4 (CH-Ar), 133.5 (CH-Ar) 
165.3 (C=O), 165.5 (C=O), 165.5 (C=O), 166.3 (C=O). 
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Note: missing 1 × C-Ar due to overlapping peaks. 
13C data for α-anomer only. 
 
IR vmax (neat) = 3429, 2947, 1721 cm
-1 
 
MS (ES-) m/z = 595 [M-H]
-
. 
HRMS (ES-) calculated 595.1604 for C34H27O10, observed 595.1602 [M-H]
-
. 
 
 
O-(2,3,4,6-Tetra-O-benzoyl-α-D-glucopyranosyl) trichloroacetimidate 290 
 
 
 
1,8-Diazabicyclo[5.4.0]undec-7-ene (38 µl, 0.25 mmol) was added to a 0 
o
C solution of the 
alcohol 289 (150 mg, 0.25 mmol) and trichloroacetontirile (0.25 mL, 2.5 mmol) in CH2Cl2 (1.25 
mL) and the resulting solution warmed to room temperature and stirred for 1.5 hours.  The 
reaction mixture was then concentrated in vacuo and the crude material purified using (20% 
EtOAc in 40-60 petroleum ether) to yield the product (136 mg, 73%) as a white foam. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 4.51 (dd, 1H
6
, J=12.8Hz, J=5.4Hz), 4.64-4.69 (m, 2H
5+6
), 
5.65 (dd, 1H
2
, J=10.1Hz, J=3.7Hz), 5.84 (t, 1H
4
, J=9.8Hz), 6.30 (t, 1H
3
, J=10.1Hz), 6.86 (d, 1H
1
, 
J=3.7Hz), 7.46 (m, 12H-Ar), 7.89 (m, 2H-Ar), 7.98 (m, 4H-Ar), 8.07 (m, 2H-Ar), 8.66 (s, 1H
8
). 
 
13
C-NMR (100 MHz, CDCl3): C = 62.5 (C-6), 68.7 (C-4), 70.2 (C-3), 70.7 (C-5). 70.7 (C-2), 
88.7 (C-9) 93.1 (C-1), 128.4 (CH-Ar), 128.4 (CH-Ar), 128.5 (CH-Ar), 128.5 (CH-Ar), 128.8 
(CH-Ar), 128.9 (C-Ar), 129.6 (C-Ar), 129.7 (CH-Ar), 129.8 (CH-Ar), 129.9 (CH-Ar), 130.1 (C-
Ar), 133.2 (CH-Ar), 133.3 (CH-Ar), 133.6 (CH-Ar), 160.5 (C-7), 165.2 (C=O), 165.4 (C=O), 
165.7 (C=O), 166.1 (C=O). 
 
Note: missing 1 × C-Ar and 1 × CH-Ar due to overlapping peaks. 
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IR vmax (neat) = 2959, 1726, 1676 cm
-1 
 
MS (ES+) m/z = 740 [M+H]
+
. 
HRMS (ES+) calculated 740.0857 for C36H29Cl3NO10, observed 740.0889 [M+H]
+
. 
 
 
2,3,4,6-Tetra-O-benzoyl-α-D-glucopyranosyl bromide 288 
 
 
 
To a solution of protected glucose 287 (1.13 g, 1.6 mmol) in acetic anhydride-acetic acid 
(1.0:2.7, 18 mL) was added 33% HBr in AcOH (12.7 mL, 72.4 mmol) and the resulting solution 
heated to 50 
o
C and stirred for 4 hours.  The reaction mixture was then cooled to room 
temperature, diluted with CH2Cl2 (150 mL), washed with H2O (150 mL), brine (150 mL) and the 
organic layer dried over MgSO4 and concentrated in vacuo.  The crude product was purified 
using (20% EtOAc in 40-60 petroleum ether) to yield the product (0.81 g, 76%) as a white solid. 
The data were in agreement with the published data.
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1
H-NMR (400 MHz, CDCl3): H = 4.54 (dd, 1H
6
, J=12.5Hz, J=4.5Hz), 4.70 (dd, 1H
6
, 
J=12.5Hz, J=2.6Hz), 4.76 (ddd, 1H
5
, J=10.2Hz, J=4.3Hz, J=2.7Hz), 5.36 (dd, 1H
2
, J=10.0Hz, 
J=4.1Hz), 5.85 (t, 1H
4
, J=10.0Hz), 6.29 (t, 1H
3
, J=9.8Hz), 6.89 (d, 1H
1
, J=4.0Hz), 7.31-7.60 (m, 
12H), 7.88-7.92 (m, 2H), 7.98-8.04 (m, 4H), 8.08-8.11 (m, 2H). 
 
13
C-NMR (100 MHz, CDCl3): C = 62.0 (C-6), 68.0 (C-5), 70.6 (C-4), 71.5 (C-3), 72.7 (C-2), 
86.9 (C-1), 128.4 (CH-Ar), 128.5 (CH-Ar), 128.5 (CH-Ar), 128.6 (CH-Ar), 128.8 (C-Ar), 129.5 
(C-Ar), 129.8 (CH-Ar), 129.8 (CH-Ar), 129.9 (CH-Ar), 130.1 (CH-Ar), 133.3 (CH-Ar), 133.4 
(CH-Ar), 133.6 (CH-Ar), 133.8 (CH-Ar), 165.1 (C=O), 165.3 (C=O), 165.6 (C=O), 166.0 (C=O). 
 
Note: missing 2 × C-Ar due to overlapping peaks. 
 
IR vmax (neat) = 2959, 1721 cm
-1 
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MS (ES+) m/z = 580 [M-Br]
+
, 659 [M+H]
 +
. 
HRMS (ES+) calculated 659.0917 for C34H28BrO9, observed 659.0938 [M+H]
 +
. 
 
 
4,5-Bis(benzoyloxy)-2-({1-[(2R,4R,5R)-4-(benzoyloxy)-5-[(benzoyloxy)methyl]-3,3-
difluorooxolan-2-yl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl}methoxy)-6-
[(benzoyloxy)methyl]oxan-3-yl benzoate 291 
 
 
 
A solution of nucleoside 270β (104 mg, 0.21 mmol) and glycosyl donor 290 (200 mg, 0.27 
mmol) in MeCN (3 mL) was added to a flask containing 4Å molecular sieves and the suspension 
stirred for 15 minutes at room temperature, before being cooled to 0 
o
C and treated with 
TMSOTf (58µl, 0.27 mmol).  The mixture was then warmed to room temperature and stirred for 
16 hours.  The reaction was quenched by addition of NEt3 (0.1 mL), then filtered through a celite 
padded frit and concentrated in vacuo  to give the crude product.  The crude product was purified 
using flash silica column chromatography (40% EtOAc in 40-60 petroleum ether) to yield the 
product (125 mg, 55%) as a white solid. 
  
1
H-NMR (400 MHz, CDCl3): H = 4.14 (ddd, 1H
16
, J=9.8Hz, J=4.9Hz, J=3.3Hz), 4.38 (dd, 1H
5
, 
J=13.1Hz, J=0.6Hz), 4.46-4.54 (m, 2H
5+17
), 4.57-4.59 (m, 1H
4
), 4.63 (dd, 1H
17
, J=12.2Hz, 
J=3.2Hz), 4.76-4.79 (m, 2H
10
), 4.97 (d, 1H
12
, J=7.9Hz), 5.30 (dd, 1H
13
, J=9.8Hz, J=7.9Hz), 5.59 
(t, 1H
15
, J=9.8Hz), 5.64-5.67 (m, 1H
1
), 5.89 (t, 1H
14
, J=9.7Hz), 6.25-6.29 (m, 1H
3
), 7.29-7.65 
(m, 19H-Ar), 7.81-7.83 (m, 2H-Ar), 7.89-7.92 (m, 4H-Ar), 8.01-8.03 (m, 2H-Ar), 8.06-8.09 (m, 
4H-Ar), 8.70 (s, 1H
11
). 
 
13
C-NMR (100 MHz, CDCl3): C = 62.8 (C-10), 63.0 (C-17), 64.3 (C-5), 69.6 (C-15), 71.4-71.8 
(m, C-1), 71.8 (C-13), 72.3 (C-16), 72.7 (C-14), 78.5 (C-4), 83.5-84.3 (br, s, C-3), 101.5 (C-12), 
111.8 (C-7), 127.9 (C-Ar), 128.3 (CH-Ar), 128.3 (CH-Ar), 128.4 (CH-Ar), 128.7 (CH-Ar), 128.8 
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(C-Ar), 129.3 (C-Ar), 129.6 (C-Ar), 129.7 (CH-Ar), 129.8 (CH-Ar), 130.1 (CH-Ar), 133.2 (CH-
Ar), 133.2 (CH-Ar), 133.2 (CH-Ar), 133.4 (CH-Ar), 133.6 (CH-Ar), 134.2 (CH-Ar), 138.0 (CH-
Ar), 149.5 (C=O), 161.5 (C=O), 164.7 (C=O), 165.0 (C=O), 165.2 (C=O), 165.7 (C=O), 166.0 
(C=O), 166.1 (C=O). 
 
Note: missing 2 × C-Ar, 5 × CH-Ar and C-2 due to overlapping peaks. 
 
IR vmax (neat) = 3261, 1721 cm
-1 
 
MS (ES+) m/z = 1103 [M+Na]
+
, 1081 [M+H]
+
. 
HRMS (ES+) calculated 1080.2843 for C58H47F2N2O17, observed 1081.2866 [M+H]
+
. 
 
 
1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-({[3,4,5-trihydroxy-
6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-1,2,3,4-tetrahydropyrimidine-2,4-dione 253 
 
 
 
Protected nucleoside 291 (53 mg, 0.05 mmol) was dissolved in 7.0 M NH3 in MeOH (3.3 mL) 
and allowed to stir for 16 hours at room temperature.  The reaction mixture was then 
concentrated in vacuo and partitioned between EtOAc (10 mL) and H2O (10 mL), the organic 
layer extracted with H2O (10 mL) and the combined organic layers concentrated in vacuo.  The 
crude material was triturated using MeOH-CH2Cl2 to yield the product (15 mg, 66%) as an 
amorphous white solid.   
 
1
H-NMR (500 MHz, D2O): H = 3.20 (dd, 1H
13
, J=9.3Hz, J=8.0Hz), 3.28-3.36 (m, 2H
15+16
), 
3.40 (t, 1H
14
, J=9.0Hz), 3.64 (dd, 1H
17
, J=12.3Hz, J=5.5Hz), 3.81 (dd, 1H
5
, J=13.1Hz, J=4.1Hz), 
3.82 (dd, 1H
17
, J=12.3Hz, J=3.3Hz), 3.95 (dd, 1H
5
, J=13.2Hz, J=2.3Hz), 4.01 (ddd, 1H
4
, 
J=8.4Hz, J=4.0Hz, J=2.6Hz), 4.33 (td, 1H
1
, 
2
JH-F=11.8Hz, J=8.5Hz), 4.43 (d, 1H
12
, J=8.0Hz), 
4.45 (d, 1H
10
, J=12.7Hz), 4.55 (d, 1H
10
, J=12.7Hz), 6.14-6.17 (m, 1H
3
), 7.88 (s, 1H
6
). 
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13
C-NMR (125 MHz, D2O): C = 59.2 (C-5), 60.7 (C-17), 64.0 (C-10), 69.1 (dd, C-1, 
2
JC-
F=24.6Hz, 
2
JC-F=21.7Hz), 69.5 (C-14/15/16), 72.9 (C-13), 75.7 (C-14/15/16), 76.0 (C-14/15/16), 
80.5 (d, C-4, 
3
JC-F =7.2Hz), 84.1 (dd, C-3, 
2
JC-F =25.3Hz, 
2
JC-F =38.5Hz), 101.4 (C-12), 110.9 (C-
7), 122.1 (dd, C-2, JC-F=259.7Hz, JC-F =258.6Hz), 140.7 (C-6), 151.5 (C-9), 165.0 (C-8). 
 
IR vmax (neat) =3356, 1678 cm
-1 
 
MS (ES-) m/z = 595 [M+CO2H]
-
. 
HRMS (ES-) calculated 501.1168 for C17H23F2N2O13, observed 501.1187 [M+CO2H]
-
. 
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RADIOCHEMISTRY  
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Experimental Radiochemistry 
 
Radiosynthesis was performed on a GE TRACERlab FXc
®
 synthesis module at the Wolfson 
Brain Imaging Centre (WBIC), University of Cambridge under the supervision of Dr Patrick 
Riss.  Set-up of the synthesis module was performed by Dr Patrick Riss and Dr Valentina Ferrari.   
 
Analytical radio-HPLC was performed on an Agilent 1100 series HPLC system (Agilent 
Technologies UK Ltd, Wokingham, UK), consisting of a G1312 A gradient pump and a G1314 
variable wavelength UV detector. A Bioscan (Bioscan Inc., Washington DC, USA) thallium 
doped sodium iodide NaI(Tl) detector with Flow Count B FC 4000 analogue/digital interface 
were used for radioactivity detection. Lablogic Laura 4 software (LablogicSystems Ltd, 
Sheffield, UK) was used for data analysis and acquisition.  For quality control a Chromolith RP-
18e endcapped column (5 µm, 100 mm × 4.6 mm, Merck KGaA, Darmstadt, Germany) was 
used. The column was eluted at a flow rate of 1 mL/min using 6% EtOH in H2O (v/v) as the 
mobile phase.  
 
Semi-preparative radio-HPLC was performed using a Sykam S1122 isocratic pump, a UV 
detector (K2001, Knauer) and a radiodetector (built-in TRACERlab FXc
®
).  A Phenomenex 
Luna RP18(2) column (10 µm, 250 mm × 10 mm), was fitted to the module.  The column was 
eluted at a flow rate of 4.5 mL/min using 6% EtOH in H2O (v/v) as the mobile phase.  UV and 
radioactive traces were monitored with the TRACERlab (GE Medical Systems) software. 
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5-[Methyl-
11
C]- 2’-deoxy-2’,2’-difluorothymidine 90* 
 
 
 
[
11
C] CO2 was produced by the 
14N(p,α)11C nuclear reaction on an aluminium target filled with 
[
14
N] N2 containing 2% oxygen, using a GE PETtrace cyclotron.  Proton energy was 13 MeV 
with a beam current of 40 µA and the duration of irradiation was 15-30 minutes.  At EOB, the 
target gas was delivered and trapped in the GE MeI Microlab synthesiser (Figure 22 Section 
3.2.1).  [
11
C] CH3I was released into the reaction vessel under a stream of helium.   
 
A mixture of Pd2(dba)3 (0.6 mg, 0.6 µmol), tri(o-tolyl)phosphine (0.7 mg, 2.4 µmol) and 
stannane 224 (0.5 mg, 1.2 µmol) in DMF (0.17 mL) was prepared in an oven-dried, septum-
equipped-vial at room temperature.  The solution was purged with helium gas for 10 minutes and 
[
11
C] CH3I trapped in the solution at room temperature.  The resulting mixture was heated at 130 
o
C for 5 minutes then cooled to room temperature and diluted with H2O (250 µL).  The mixture 
was filtered (13 mm, 0.22 µm PTFE filter) and injected onto the HPLC with a semi-preparative 
column.  At a flow rate of 4.5 mL/min using 6% EtOH in H2O (v/v) as the mobile phase a 
fraction corresponding to radiolabelled 90 was eluted at 19.5 minutes in a decay-corrected 
radiochemical yield of 5% (n=3).   
 
The product was assayed for radiochemical purity by analytical HPLC.  The column was eluted 
at 1 mL/min using 6% EtOH in H2O (v/v), the retention time for 90 was 4.5 minutes with a 
radiochemical purity of 97%. 
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Supporting Data: NOESY Spectrum for 270β 
 
 
 
 
 
 
Figure 32- Nucleoside 270β. Bond lengths exaggerated for clarity. H-5 corresponds to CH2 next 
to benzoyl protected alcohol. 
 
A key correlation between protons H-3 and H-4 indicates both protons occupy the same face of 
the molecule confirming assignment as the β-anomer.  Furthermore there is no correlation 
apparent between protons H-3 and H-1, which would be expected in the α-anomer.  
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